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ABSTRACT OF DISSERTATION 
 
 
 
 
INFLAMMATION AND INSULIN DYSREGULATION IN THE HORSE 
 
Insulin dysregulation (ID) in the horse is receiving increasing attention as a serious 
health concern, in particular due to its association with the potentially career or life ending 
condition, laminitis. The role of inflammation and the immune system in ID as well as its 
associated health concerns has also been raised. However, the involvement of inflammation 
in and mechanisms behind ID in the horse remain unclear. Therefore, our overall 
hypothesis was that due in part to changes in their gut microbiota and plasma lipidome, 
horses with ID have changes in circulating proinflammatory markers, in particular in 
response to glycemic challenge, that further drive metabolic dysfunction. This work 
focuses on 7 potential associations between ID and inflammation to test this hypothesis; 
(H1) horses with ID will have an abnormal inflammatory response to glycemic challenge, 
(H2) ID horses will have differences in their gut microbiota compared to metabolically 
normal controls, (H3) these horses will likewise have differences in their plasma lipidome, 
(H4) response to routine vaccination will be reduced in horses with ID compared to 
metabolically normal controls, (H5) circulating endotoxin concentrations will be elevated 
in horses with ID, in particular in response to glycemic challenge, and their inflammatory 
and metabolic responses will be improved following supplementation with a gut 
modulating mannan rich fraction of the yeast cell wall, (H6) whole blood stimulation with 
endotoxin will induce TLR4 mediated inflammatory gene expression, and (H7) changing 
circulating lipid concentrations will improve both glycemic and inflammatory parameters 
in ID horses. Overall this work provides insight into contributing factors to ID in the horse, 
in particularly as they relate to inflammation. 
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 1 
CHAPTER 1 REVIEW OF THE LITERATURE 
 
1.1. Phenotype 
The percentage of adults in the United States considered to be overweight or obese 
(as measured by body mass index, or BMI) continues to increase, with some stating that 
up to 68.8% of the population falls into one these categories [1, 2]. The percentage of 
overweight or obese horses is likewise increasing, with reports ranging from 20.6-51% of 
U.S. or abroad populations affected [3-7]. There are many negative health concerns that 
have been associated with obesity in various species, including the horse. While it is 
unclear if obesity precedes these health concerns or if it is a resulting side effect, it is often 
considered a risk factor for many conditions. In particular, it is associated with insulin 
dysregulation and other endocrinopathic disorders in the horse [8-11].  
The term insulin dysregulation (ID) [12] has recently been used in the literature to 
describe most forms of abnormal insulin concentrations or signaling in the horse, whether 
that be high resting insulin concentrations (hyperinsulinemia), an abnormal response to 
glycemic or insulinemic challenge (such as the oral sugar test, or OST [13]), or tissue 
insulin insensitivity (insulin resistance, or IR). Arguably of greatest concern is its 
association with the potentially fatal condition, laminitis [14-16]. While the mechanisms 
behind laminitis remain unclear, it is ultimately a failure of the hoof lamellar structures that 
can lead to rotation or sinking of the distal phalanx [17]. This failure typically involves 
inflammation, impedes mechanical function, and is extremely painful for the animal [18]. 
Further support of the connection between ID and laminitis has been demonstrated as 
laminitis can be induced with administration of exogenous insulin [19, 20]. While the 
prevalence of endocrine associated laminitis (or endocrinopathic laminitis) is not well 
known, incidence of laminitis in the equine population has been reported from as little as 
1.5% to as much as 34% [21]. Additionally, one study reported that over a period of 16 mo 
in an equine referral hospital, 89% of laminitic cases had underlying endocrinopathies [22]. 
 A history of or predisposition to laminitis, increased general or regional adiposity 
(fatty deposits around the neck, tail head, behind the shoulder, or in the mammary gland 
region), and the presence of ID are the three main defining characteristics of Equine 
Metabolic Syndrome (EMS) [23]. Other proposed characteristics for diagnosis of EMS 
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include lipid dysregulation such as hypertriglyceridemia or dyslipidemia, hyperleptinemia, 
arterial hypertension, and systemic inflammation [23]. EMS is considered to be similar to 
metabolic syndrome (MetS) [24, 25] in humans [26]. An individual will qualify as MetS if 
he or she exhibits 3 out of the 5 following risk factors: elevated fasting glucose, elevated 
systolic and/or diastolic blood pressure, hypertriglyceridemia, low high-density lipoprotein 
cholesterol (HDL) levels, and increased central adiposity [25]. Also, individuals with MetS 
often have increases in both circulating and adipose tissue levels of inflammation [27]. 
 
1.2. Inflammation 
Research regarding EMS has concentrated on a better definition of the phenotype 
as well as potential underlying mechanisms [23, 28-31]. However, there have been 
conflicting results, particularly regarding inflammation. This may be due to several factors. 
Often, studies compare ponies rather than horses, or induce hyperinsulinemia with models 
such as dexamethasone administration [32] or diet-induced weight gain [33], rather than 
utilizing horses with naturally occurring ID. In many instances horses were not tested for 
potentially confounding factors, such as pituitary pars intermedia dysfunction (PPID), 
which can influence insulin and glucose dynamics [10, 11]. In addition, data regarding 
fasted versus fed states is in some instances not reported, assays used to determine insulin 
concentrations vary, and cut-off values used for diagnosis of ID are not established for 
these different assays in the horse [34-36].  
 Data concerning fed versus fasted states becomes important not only concerning 
insulin and glucose dynamics [37, 38], but also in regards to other parameters such as 
markers of inflammation. When indicated, much of the work in the horse has focused on 
fasting circulating or fasting tissue markers of inflammation. These results has been 
somewhat contradictory, with some reporting that horses with ID have an increase in 
inflammatory markers such as circulating tumor necrosis factor alpha (TNF-α) protein and 
TNF-α gene expression in adipose tissue [28, 39], as well as positive correlations between  
plasma concentrations of serum amyloid A and insulin [40]. Others have seen differences 
in inflammatory cytokine gene expression in nuchal adipose tissue between EMS horses 
and controls, with EMS horses having increases in IL-1β and IL-6 [41]. However, others 
found no differences or lower IL-1 and IL-6 peripheral blood mononuclear cell (PBMC) 
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gene expression and a trend for lower TNF-α plasma concentrations in obese horses, and a 
trend for a decrease in EMS horses PBMC TNF-α and IL-1β gene expression compared to 
metabolically normal controls [31, 42]. These contradicting results may be partly explained 
as humans and mice with or without metabolic dysfunction have been observed to have 
postprandial increases in inflammatory markers. TNF-α, IL-6, and IL-1β as well as 
increases in systemic soluble adhesion molecules, such as Intercellular Adhesion 
Molecule-1 (ICAM-1), have been observed in response to a high fat or combination high 
fat, high sugar/starch meal [43-45]. There are indications that this may be true in horses as 
well, with postprandial increases seen in IL-1β, TNF-α, IFN-γ, and IL-6 in response to oral 
feeding or oral administration of sugar/starch [46, 47].  
Horses are as hind-gut fermenters able to utilize sugars and starches as an energy 
source [48] and easily break down these structural carbohydrates into digestible volatile 
fatty acids. Diets rich in these energy sources, particularly in large quantities, have been 
shown to promote insulin insensitivity in the horse [49], further associating the role of the 
gut in inflammation and ID. In fact, in equine induction models of laminitis utilizing a 
carbohydrate polymer made up of inulin-type fructans (oligo-fructose) given orally [50], 
horses had an increase in whole blood cytokine gene expression of IL-1β, IL-8, and IL-10 
8 h post laminitis induction [51] as well as increases in lamellar IL-2, IL-6, IL-8, and IFN-
γ at the onset of laminitis [18].  
 Postprandial increases in inflammatory markers have several possible explanations. 
They may be due in part to proposed differences in oxidative stress in humans, mice, and 
horses with metabolic dysfunction [31, 52-55].  Similar to inflammation, it has been 
suggested that oxidative stress increases postprandially, in particular in individuals with 
hyperglycemia and hypertriglyceridemia [56-58]. Increases in inflammatory markers 
following administration of a meal may also be due to increases in bacterial endotoxin 
concentrations that have been observed in humans in response to dietary fat [59, 60]. 
Likewise in high fat fed mice, endotoxemia has been shown to induce inflammation and 
insulin resistance [61]. Indeed, postprandial changes in bacterial endotoxin concentrations 
are not surprising due to the suspected involvement of the gut and its associated microbiota 
in both metabolic and inflammatory mechanisms [62, 63].  
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1.3. Microbiota 
In horses and humans, the gut microbiota is both highly diverse and variable. 
Variation can be affected by, among other factors: genetics, age, diet, and disease states 
[64-66]. For example, in the healthy horse, the predominant gut bacterial phyla is 
Firmicutes [64, 67] and bacteria from the Clostridiales order, in particular the butyrate 
producing bacteria Ruminococcaceae and Lachnospiraceae, are positively correlated with 
intestinal health [68, 69]. However, following feeding of a high starch diet, horses have 
been shown to have an increase in the abundance of the one of the taxa from the Firmicutes 
phyla, Veillonellaceae [70]. Veillonellaceae, a gram-negative propionate/acetate producer, 
has been positively correlated with markers of metabolic dysfunction in high fat fed rats 
[71]. Horses with a history of laminitis have also been shown to have alterations in their 
gut microbiota, with previously laminitic horses having increased abundance of two 
unassigned members of the Clostridiales genera as well as differences in community 
structure, notably having a lower representation of Firmicutes and greater representation 
of Verrucomicrobia compared to controls [72]. Changes in bacterial abundance have 
likewise been shown in the horse at the onset of laminitis [73, 74]. In addition, decreases 
in Clostridiales have been documented in horses with colitis and in mares prior to the onset 
of colic [75, 76]. Metabolic dysfunction and obesity have also been associated with 
intestinal microbiota changes [77]. For example, an overabundance of the phyla 
Verrucomicrobia was observed in diet-induced obese minipigs [78]. Additionally, obesity 
has been linked with an overall decrease in microbial diversity in humans [79] and in dogs 
[80]. In horses, a decrease in diversity has been observed following antimicrobial 
administration [81] and in response to a change in diet [69], as well as in horses with EMS 
compared to metabolically normal controls [82]. These same EMS horses were also found 
to have differences in overall community structure, suggesting changes in composition due 
to overgrowth or decreased growth of specific community members. Given that in mice 
changes in the gut microbiota related to age have increased circulating concentrations of a 
component gram-negative bacteria cell wall, lipopolysaccharide (LPS), which 
subsequently resulted in an increase of inflammatory markers [83], these and other studies 
highlight the potential influence of the gut microbiota on metabolic dysfunction and its role 
in the induction of systemic, low grade inflammation.  
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 In humans, diets or supplements that reduce the population of bacteria that produce 
LPS, for example the so called Mediterranean diet [84], supplementation with polyphenols 
[85], or probiotics [86], are suggested as possible therapeutic targets for individuals with 
metabolic dysfunction. Supplementation with pre or probiotics is thought to be particularly 
beneficial as they positively influence intestinal health by improving the balance of the 
microbiota population by the addition of live favorable bacteria (typically lactic acid 
producers) in the case of probiotics, or by promoting the growth of specific members of 
the existing bacterial community in the case of prebiotics [87]. One suggested method to 
influence the gut microbiota in the horse has been supplementation with the prebiotic, 
fructooligosaccharides [88, 89]. Fructooligosaccharides (FOS) exhibit prebiotic properties 
as they promote growth of certain intestinal bacteria. They are converted to short chain 
fatty acids following fermentation by the gut microbiota [90] and subsequently serve as a 
source of energy for intestinal epithelial cells, have a major role in communication between 
the gut microbiota and the host, and are thought to have beneficial effects on host 
metabolism and even inflammation [91, 92]. Indeed, supplementation with FOS has been 
shown to positively impact metabolic parameters in horses [93] as well as in obese dogs 
[94]. In addition, it has been shown that utilizing another dietary prebiotic, in the form of 
yeast or yeast cell wall, can likewise effect inflammation in dairy cows [95], poultry [96], 
humans [97-99], and horses [100, 101]. Yeast cell wall supplementation has in cattle been 
shown to influence glucose and insulin concentrations following supplementation and LPS 
challenge [102], and reduced circulating triglyceride and cholesterol levels in poultry post 
supplementation [103, 104]. Mannan oligosaccharides, thought to be one of the main 
effectors found in the yeast cell wall, reduced circulating LPS concentrations in pigs [105], 
primarily mediated by positive changes in the gut microbiota.  
 
1.4. Lipids 
Not only have increases in LPS been associated with changes in the gut microbiota, 
but they have also been associated with inflammation and alterations in lipid metabolism 
[106]. EMS and ID horses have abnormal metabolic function [23, 29, 107] as well as 
abnormal circulating lipid concentrations [40, 42, 107]. Lipidomic analysis has allowed for 
further exploration of lipids and lipid profiles (or lipidome) as well as their relationship to 
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metabolism and inflammatory processes [108]. Lipids, in particular the sphingolipid 
sphingomyelin as well as the glycerophospholipids ethanolamine or choline plasmalogens, 
have a major role in mammalian cellular membrane health [109]. Therefore, they have a 
direct impact on cellular function, including cell signaling [110, 111]. Cell signaling, such 
as activation of inflammatory pathways in multiple cell types (in particular macrophages, 
adipocytes, and hepatocytes) and gene expression of metabolic and inflammatory proteins 
(for example SOCS-3 and MCP-1) can be influenced in many species by changes in 
circulating lipid concentrations [112-114]. In particular, changes in ceramide 
concentrations [113, 115-117] strongly impact cell signaling and metabolism. Bioactive 
lipids, such as ceramide, in addition to their influence on inflammatory and insulin 
signaling, are able to act as chemoattractants and second messengers for multiple cell types, 
including immune cells [118-120]. Further evidence of the role of the lipidome in 
metabolic dysfunction is demonstrated considering that changes in nutrition and nutritional 
supplementation are able to effect change in the plasma lipidome, resulting in the decrease 
of inflammatory markers and an increase in insulin sensitivity in humans [121, 122]. In 
one study, phosphatidylcholine and sphingomyelin containing linoleic and 
docosahexaenoic acid (thought to be anti-inflammatory lipids [123]) were found to be 
increased in exercised rats whereas phosphatidylcholines, phosphatidylethanolamine, and 
phosphatidylinositol containing arachidonic acid (thought to be a pro-inflammatory lipid 
[124]) were increased in rats with metabolic dysfunction following feeding of a high fat 
diet [125].  
Lipids not only influence cell signaling and impact cellular membrane health and 
function, but in humans and in mice there is evidence that they also play a role in the 
immune response. For example, the immune system can recognize both foreign lipids (for 
example KOD2-lipid A from Escherichia coli) [126], and self-lipids (such as gangliosides 
and glycosphingolipids) [127-129] as antigens. Lipids are also, as stated previously, able 
to act as lymphocyte chemoattractants [118]. Given associations between obesity, insulin 
resistance, systemic inflammation, and the immune response [31, 130, 131], questions have 
been raised as to the response to vaccination of those with metabolic dysfunction or obesity.  
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1.5. Immune responses 
Following vaccination, the immune system initially mounts the rapid non-specific 
innate immune response [132]. This innate response involves the release of cytokines and 
chemokines which promote the activation of the second arm of the immune response, the 
adaptive immune response [133], which provides the host with long lasting specific 
protection from disease. There have been indications that in response to influenza 
vaccination, diet-induced obese mice have a decrease in both their antibody response and 
neutralizing capacity compared to metabolically normal controls [134]. Diet-induced obese 
mice have likewise been shown to have a decrease in hepatitis specific antibody and T cell 
activation, but an increase in T and B cell proliferation as well as increases in levels of 
IFN-γ and TNF-α in response to a hepatitis B vaccine [135]. Humans with type 1 diabetes 
are considered to be at risk for non-responsiveness to vaccination [136], and in a group of 
245 hospital employees >3 yrs post hepatitis vaccination there was a correlation between 
increased adiposity and lower levels of circulating antibody [137]. Further, although body 
mass index was positively associated with an initially higher IgG antibody response, 12 
months following influenza vaccination individuals with a higher body mass index 
exhibited a greater decline in antibody titers [138]. In the same study, obese individuals’ 
virally challenged PBMCs displayed a lower functional protein expression and decreased 
CD8+ T-cell activation ex vivo. There is however, no published work to date on the 
response to vaccination in the ID or obese horse. 
 
1.6. Inflammatory mechanisms and signaling 
While multiple studies have shown probable links between the immune system, 
inflammation, lipids, and metabolic dysfunction [127, 139, 140], the underlying 
mechanisms of ID and contributing factors to laminitis in the horse remain unclear. 
Genetics appear to influence the prevalence of ID in the horse as certain breeds, such as 
ponies and Andalusians, are predisposed to its development [23, 141]. Additionally 
environmental factors, including nutrition and exercise, play a role in the development of 
metabolic dysfunction [142]. There has also been recent discussion as to the role of 
corticosteroids in the pathogenesis or severity of ID and laminitis, although at present 
supporting evidence is weak [143, 144].  In obese or insulin resistant humans and mice, 
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there has been data showing that adipose tissue macrophages, as opposed to adipose tissue, 
are the primary producers of inflammatory cytokines, in particular TNF-α [145, 146]. In 
the adipose tissue of individuals with obesity and ID, macrophages accumulate in greater 
numbers and size, and favor M1 (thought to be pro-inflammatory) macrophages as opposed 
to M2 (thought to be anti-inflammatory) macrophages [131, 147]. Macrophages recognize 
pathogens principally through pattern recognition receptors (PRR), in particular toll-like 
receptors (TLRs) such as TLR-4. TLR-4 has been implicated in ID and obesity as the 
primary receptor for recognition of LPS [148]. LPS stimulated signaling through TLR-4 
and its co-receptors, CD14 (cluster of differentiation 14) and MD-2 (Lymphocyte antigen 
96), activate signaling cascades which ultimately result in activation of NF-κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells), which in turn promotes pro-
inflammatory gene expression [149]. This receptor complex has also been shown to 
recognize free fatty acids (FFA) as antigens similarly resulting in the production of 
inflammatory cytokines, such as TNF-α and IL-6 [148, 150]. There is cross talk between 
the TLR-4 and insulin signaling cascades, and it appears that humans with type 2 diabetes 
have additional insulin signaling intermediates within their insulin signaling cascade [151]. 
However, underlying mechanisms of abnormal inflammatory signaling remain unclear. In 
particular, it remains to be seen if changes in inflammatory responses or concentrations, 
possibly due to increases in circulating LPS concentrations, initiates abnormal insulin 
signaling or if the reverse is true. 
 
1.7. Treatment and therapeutic strategies 
Considering the large number of horses affected by obesity or ID, there have been 
an increasing number of studies examining potential therapies for metabolic dysfunction 
in the horse. Classically, horses with ID are treated with exercise and dietary restriction, 
which have been shown to decrease insulin resistance as well as markers of inflammation 
[29]. However, these changes often over a period of several months and may not be a viable 
treatment option in horses with complicating health concerns, such as chronic laminitis.  
There are two off-label pharmaceutical drugs commonly administered to horses with ID. 
One of which, (Metformin) works in the liver by suppressing glucose production [152], 
and the other (levothyroxine sodium) as a synthetic thyroid hormone (T4) upregulates 
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metabolic processes by stimulation of the thyroid [153]. However, as stated prior, 
metformin and levothyroxine sodium are used off label in the horse and their mechanism 
of action is not well established. In addition, published results in the horse are conflicting 
regarding their efficacy and long term safety [9, 154-156].   
In humans and in other species, omega-3 fatty acid supplementation has been 
proposed as a treatment strategy for individuals with metabolic dysfunction [157]. Much 
of the research has focused on supplementation with the long-chain polyunsaturated 
omega-3 fatty acids docosahexaenoic acid (DHA) and/or eicosapentaenoic acid (EPA). 
Supplementation with these fatty acids appear to be dose responsive, as demonstrated in 
people and in horses [158, 159]. These fatty acids are readily incorporated and absorbed as 
increased concentrations have not only been observed in circulation following 
supplementation but in tissue as well; for example in skeletal muscle in horses [160] and 
adipose tissue in humans [161]. Supplementation with omega-3 fatty acids is thought to be 
beneficial for several reasons. Insulin sensitivity has been shown to be improved in rats, 
pigs, and humans [162-166]. In humans it has also been shown to promote body fat 
oxidation and reduce lipogenesis [167, 168] and has a positive effect on the plasma 
lipidome [169, 170]. In metabolically normal horses, supplementation with omega-3 fatty 
acids has indicated a positive effect on glucose clearance [171], improvement in markers 
of insulin sensitivity [172], and following dexamethasone administration has reduced 
baseline glucose and insulin concentrations and improved the modified insulin to glucose 
ratio [173]. It has also been shown in metabolically normal horses to reduce inflammatory 
mediators [174-176] and has an effect on circulating DHA, triglyceride, and phospholipid 
concentrations [159, 177, 178]. However, no work to date has been carried out regarding 
omega-3 fatty acid supplementation in the ID horse. 
 
1.8. Overall hypothesis and specific aims 
 Overall, data is still limited regarding the pathophysiology of ID in the equine. It 
does appear that many biological processes are influenced in horses affected by ID, in 
particular the inflammatory process. However, more work needs to be done regarding the 
underlying mechanisms of this common and potentially career or life ending disorder. 
Therefore, we proposed with this work to investigate the role of inflammation in the horse 
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with ID with the hypothesis that due in part to changes in their gut microbiota and plasma 
lipidome, horses with ID have changes in circulating proinflammatory markers, in 
particular in response to glycemic challenge, which further drive metabolic dysfunction. In 
order to assess this overall hypothesis, 7 specific hypotheses (H) were examined. 
(H1) Horses with ID will have an abnormal inflammatory response to glycemic challenge. 
This hypothesis was generated to investigate the inflammatory and metabolic 
responses of the ID horse to an oral glycemic challenge utilizing a high sugar/starch 
challenge as well as a commonly used glycoside. 
(H2) ID horses will have differences in their gut microbiota compared to metabolically 
normal controls. 
Fecal DNA was used to determine differences in the composition of the gut 
microbiota in a group of ID horses compared to metabolically normal controls for 
this hypothesis. 
(H3) These horses will likewise have differences in their plasma lipidome. 
Differences in circulating plasma lipid concentration in ID horses for this 
hypothesis were determined by lipidomics analysis, as well as an analysis of 
baseline inflammatory markers. 
(H4) Response to routine vaccination will be reduced in horses with ID compared to 
metabolically normal controls.  
This hypothesis was tested by administration of routine influenza vaccination in a 
group of ID as well as metabolically normal control horses to examine humoral and 
cell mediated immune responses to vaccination. 
(H5) Circulating endotoxin concentrations will be elevated in horses with ID, in particular 
in response to glycemic challenge, and their inflammatory and metabolic responses will be 
improved following supplementation with a gut modulating mannan rich fraction of the 
yeast cell wall.  
Markers of inflammation, circulating endotoxin concentrations, and metabolic 
parameters and responses were measured in horses both with and without ID prior 
to and following supplementation with a gut modulating yeast cell wall product to 
test this hypothesis. 
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(H6) Inflammatory gene expression in response to a TLR4 agonist, LPS as well as in 
response to an oral sugar test will be different in horses with ID.  
Whole blood was stimulated with endotoxin in ID and metabolically normal horses 
as baseline and following OST to determine inflammatory responses for this 
hypothesis. 
(H7) Changing circulating lipid concentrations will improve both glycemic and 
inflammatory parameters in ID horses. 
To test this hypothesis, ID horses were utilized for inflammatory, metabolic, and 
lipid concentrations and responses which were assessed both prior to and following 
supplementation with omega 3 fatty acids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Sarah E. Elzinga 2017  
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CHAPTER 2 METABOLIC AND INFLAMMATORY RESPONSES TO THE 
COMMON SWEETENER STEVIOSIDE AND A GLYCEMIC CHALLENGE IN 
HORSES WITH EQUINE METABOLIC SYNDROME 
Domestic Animal Endocrinology, 2017: 60, 1-8 
 
Extracts derived from the leaves of the stevia plant (stevioside) are commonly used 
as sweeteners for humans and horses. Stevioside appears to be safe for human 
consumption, including for individuals with insulin dysregulation. In the horse, the safety 
or metabolic effects of stevioside on normal animals or on those with metabolic 
dysfunction are unknown. Furthermore, the inflammatory response to a glycemic challenge 
or to stevioside in horses is not well defined. Therefore, the objective of this study was to 
measure the effects of stevioside and a glycemic challenge on insulin, glucose, and 
inflammatory responses in horses with a common metabolic dysfunction (equine metabolic 
syndrome or EMS) compared with non-EMS controls. To accomplish this, 15 horses were 
selected; 8 EMS and 7 age-matched controls. An oral sugar test was performed using Karo 
corn syrup (karo) or stevioside in a random crossover design. Horses were given 0.15 
mL/kg body weight of karo or its equivalent grams of sugar in stevia dissolved in water. 
Blood samples were collected by jugular venipuncture before administration of either 
stevia or karo and at 60 and 240 min after administration. Serum was used for glucose and 
insulin determination and plasma for isolation of peripheral blood mononuclear cells 
(PBMCs) for inflammatory cytokine analysis via flow cytometry and reverse transcription 
PCR (RT-PCR). Stevia appeared to stimulate lower glycemic and insulinemic responses 
when compared to karo, in particular in EMS horses. EMS and control horses had inverse 
inflammatory responses to administration of either stevia or karo with EMS horses having 
a proinflammatory response (P < 0.05). These data provide evidence as to why horses with 
EMS may be predisposed to developing laminitis, potentially as a result of an exaggerated 
inflammatory response to glycemic and insulinemic responses. Furthermore, the data 
provide new avenues for exploring mechanisms behind the syndrome, in particular when 
using a glycemic challenge. 
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2.1. Introduction 
Stevioside, a glycoside derived from the leaves of the stevia plant, has been 
increasingly used as a sweetener for both horses and humans [179]. It appears in a range 
of equine products, such as veterinary pastes, supplements, and anthelmintics. Stevioside 
can even be found in equine products intended for use in the insulin resistant animal. 
However, the safety and efficacy of stevioside in the metabolically normal or metabolically 
dysfunctional animal is unknown. For humans, stevioside is primarily used as a non-
glycemic sugar replacer and is classified as Generally Recognized as Safe by the United 
States food and drug administration (Generally Recognized as Safe). Research indicates 
that stevioside is safe for human consumption, including for individuals with hypertension 
and metabolic dysfunction [180]. Stevioside may even be metabolically beneficial in 
individuals with metabolic disorders as it has been shown to increase insulin sensitivity in 
insulin resistant rats [181] and to positively influence glucose and insulin dynamics in 
people [182-185]. Humans with metabolic dysfunction typically suffer from 
hyperglycemia and hyperinsulinemia. Considering that stevioside stimulates insulin 
release from the pancreas [184], it can therefore have a potentially positive effect in humans 
by lowering circulating glucose concentrations. However, horses with metabolic 
dysfunction, unlike humans with metabolic syndrome, typically have circulating glucose 
concentrations within the normal range, but are hyperinsulinemic. Thus, increasing the 
amount of circulating insulin in the horse may actually exacerbate existing insulin 
dysregulation (ID) [12] in the horse with metabolic syndrome (equine metabolic syndrome, 
or EMS). Even with the increasing use of stevia in equine products, the effects of stevioside 
on glucose and insulin metabolism in the horse have yet to be determined. The oral sugar 
test (OST), a common dynamic test used to determine glycemic and insulinemic responses 
to a simulated high carbohydrate meal, is typically carried out using a bolus of Karo corn 
syrup (karo) as a sugar source. However, no research has characterized the inflammatory 
response to a glycemic challenge with either karo or stevia. Considering that increases in 
inflammatory markers such as tumor necrosis factor (TNF-α), interleukin-6 (IL-6), and 
interleukin-1β (IL-1β) have been observed postprandially in people with metabolic 
dysfunction [43] and in horses [46], as well as the prevalence of stevioside in the equine 
market, it is of importance to understand its metabolic and inflammatory effects on normal 
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and metabolic syndrome horses. Therefore, the experiment was designed not only to 
measure the effects of the OST using both stevioside and karo on insulin and glucose 
responses but also inflammatory responses in horses with EMS compared with non-EMS 
controls. 
 
2.2. Materials and methods 
2.2.1. Horse selection and EMS determination   
Eight EMS horses and 7 controls were selected from the University of Kentucky, 
Department of Veterinary Science herd. EMS was defined by the criteria established in the 
2010 American College of Veterinary Internal medicine consensus statement [23]. In brief, 
EMS was characterized by ID [12], general or regional adiposity, and a history of or 
predisposition to laminitis. All EMS horses were predisposed to laminitis given their 
increased adiposity and ID status, with 4 of the 8 selected EMS horses having a documented 
history of laminitis. A portable agriculture scale (model 700, Tru Test Inc., Mineral Wells, 
TX) was used to establish body weight, which was used to determine the amounts of stevia 
and karo to administer to each horse for the OST. Body condition score was determined 
and averaged between 3 trained investigators (S. E., M. M., and B. R.) using the 1 to 9 
Henneke scoring system [186] with 1 representing an extremely emaciated animal and 9 
representing an extremely obese animal. The same 3 trained individuals scored and 
averaged neck crests via the 0 to 5 cresty neck score (CNS) system established by Carter 
et al [187] with 0 representing no neck crest and 5 representing a crest so large it 
permanently droops to one side of the neck. Blood collection for serum and plasma samples 
was carried out via jugular venipuncture. To ascertain the presence of ID, the OST was 
performed similar to previously described [13]. Briefly, morning serum samples were 
collected, and oral sugar was administered in the form of 0.15 mL/kg body weight of karo. 
A second serum sample was collected 60 min post karo administration. A fasting insulin 
level of > 20 μIU/mL was considered indicative of hyperinsulinemia, and an increased 
insulin (> 60μU/mL) 60 min post administration of karo was considered diagnostic of ID 
[188]. All OST sampling was performed between 8 AM and 12 AM for all sampling time 
points. Horses were not fasted before sampling. Screening results from the OST along with 
phenotypic data are presented in Tables 2.1 and 2.2. Of the 8 EMS horses, 3 were of mixed 
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breed, 1 was a Thoroughbred cross, 1 horse was a Paint, 1 a Morgan, 1 a Warmblood, and 
1 a Standardbred cross. Of the 7 control horses, 4 were Thoroughbreds, 2 were of mixed 
breed, and 1 was a Quarter Horse. Of the 7 control horses, 2 were of mixed breed, 4 were 
Thoroughbreds, and 1 was a Quarter Horse. 
 
Table 2.1. Characterization of EMS and non-EMS control horses. 
Group 
(Insulin; μIU/mL) 
60 min post oral 
sugar administration BCS CNS Wt (Kg) 
EMS 75 ± 6 6.8 ± 0.3 3.0 ± 1.1 569 ± 88 
Control 31 ± 4 6.4 ± 0.1 1.2 ± 1.0 610 ± 56 
P-value <0.001 0.278 0.009 0.307 
Abbreviations: BCS, body condition score; CNS, cresty neck score; EMS, equine metabolic 
syndrome; Wt, weight. 
Italicized values represent statistical significance in the form of P values. 
 
Table 2.2. Characterization of EMS and non-EMS control horses analysis on ranks. 
Group Baseline Serum (Insulin; μIU/mL) Age 
EMS 44 (95% CI: 26-51) 12 (95% CI: 10-13) 
Control 16 (95% CI: 13-18)  14 (95% CI: 12-15) 
P-value <0.001 0.054 
Abbreviations: EMS, equine metabolic syndrome. 
Italicized values represent statistical significance in the form of P values. 
 
Horses were also screened 1 mo before the start of study via thyrotropin releasing 
hormone (TRH) stimulation and low-dose dexamethasone suppression testing [189, 190] 
to ensure that none were affected by pituitary pars intermedia dysfunction (PPID). TRH 
stimulation testing was carried out as previously described [191, 192] at least 2-wk before 
the first sampling time point, but no further than 2 mo before sampling. In brief, a baseline 
blood sample (0800, EST) was taken via jugular venipuncture into EDTA containing tubes. 
Following this, a 1 mL dose of TRH dissolved to 1 mg/mL in 0.9% saline (Sigma-Aldrich, 
St. Louis, MO) was administered intravenously (IV). Ten min post TRH injection, a second 
blood sample was taken. Tubes were kept on ice for transport to the laboratory and 
immediately centrifuged and plasma isolated within 3 h after collection [193]. Samples 
were stored at -20o C until shipped on dry ice to Cornell University for analysis of ACTH 
concentrations. Low-dose dexamethasone suppression testing was also performed 2 days 
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following TRH stimulation testing and was performed as previously described [194] and 
within the same time frame relative to the start of the study as TRH stimulation testing. In 
brief, a baseline jugular blood sample was taken (3:50 PM–6:00 PM), and an intramuscular 
dexamethasone (Henry Schein, Dublin, OH) bolus (0.04 mg/kg BW) was administered 
with a second blood sample taken 19 h later. A serum separator tube was used to collect 
samples. Tubes were centrifuged, serum was isolated and frozen at -20o C until cortisol 
analysis. Concentrations of ACTH 10 min after TRH injection in excess of 100 pg/mL or 
concentrations of cortisol exceeding 1.0 µg/dL 19 h after dexamethasone injection were 
considered positive for PPID. Any animals meeting these criteria were excluded. 
Analysis of ACTH, cortisol, and insulin were performed by Cornell University’s 
Animal Health Diagnostic Center Endocrinology Laboratory (Ithaca, NY). Serum insulin 
concentrations were measured with a commercially available porcine insulin RIA (EMD 
Millipore Corp, Billerica, MA) validated by Cornell University’s Animal Health 
Diagnostic Center Endocrinology Laboratory for use on equine serum samples. Serial 
dilutions of 3 equine samples with assay buffer were parallel to the standard curve, and 
samples that were spiked with 4 different quantities of porcine insulin (Sigma-Aldrich, St. 
Louis, MO, USA) had observed concentrations that averaged 91% of expected. The 
manufacturer did not report the cross-reactivity of the RIA antibody for equine insulin. 
However, the cross-reactivity for bovine insulin was reported as 90%, and the homology 
between equine and porcine insulins (98%) is greater than the homology between bovine 
and porcine insulins (96%). The sensitivity of the assay, as reported by the manufacturer, 
is 1.61 IU/mL. The mean intra-assay and interassay coefficients of variation were 3.9% 
and 5.3%, respectively. ACTH concentrations were measured via an automated 
chemiluminescent enzyme immunoassay system (Immulite, Erlangen, Germany [195], and 
cortisol concentrations were determined using the Siemens Immulite Cortisol kit (Siemens, 
Erlangen, Germany) [196].   
Glucose analysis was performed by Cornell University’s Animal Health Diagnostic 
Center Clinical Pathology Laboratory (Ithaca, NY) using a hexokinase kinetic method with 
Roche reagents and the Hitachi P Modular from Roche (Roche Diagnostics, Indianapolis, 
IN), with a 2 control intra-assay variation of 0.6% to 0.7% and interassay variation of 
2.04% and 2.28%. 
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2.2.2. Study design 
To determine the effect of stevioside on the equine, 15 mixed breed and mixed sex 
animals (8 EMS and 7 age-matched controls, all non-PPID) were selected. Horse 
demographics are presented in Tables 2.1 and 2.2. Horses were maintained on an all forage 
diet with access to minimal mixed-grass pasture and ad libitum access to mixed-grass hay, 
a trace mineralized salt block, and water. They were housed at the University of Kentucky’s 
Department of Veterinary Science’s facilities. An OST was performed in July of 2015 on 
all horses, as previously described, but with the addition of a third blood sample taken 240 
min after oral administration of either Karo corn syrup or stevioside (stevia). Blood   
samples for metabolic and inflammatory parameters (as described in the following) were 
collected concurrently at the 0, 60, and 240 min time points. Horses were provided either 
0.15 mL/kg of karo or its stevioside equivalent in g stevia. For example, a 500 kg horse 
would be administered 75 mL karo, which contains 25 g sugar. Therefore, a 500 kg horse 
would receive 25 g of stevioside. The study was designed as a crossover with a 1-wk 
washout period; therefore, each horse received both Karo corn syrup and stevioside. Horses 
were randomly assigned to receive either karo or stevioside on week 1 vs week 2. 
2.2.3. Peripheral blood processing for inflammatory cytokine production measured by 
flow cytometry 
Heparinized blood was used to isolate peripheral blood mononuclear cells 
(PBMCs) by Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) gradient 
centrifugation [197].  For in vitro stimulation, 4 x 106 PBMC in 1 mL c-RPMI (RPMI-
1640; Gibco, Grand Island, NY) supplemented with 2.5% fetal equine serum (FES; Sigma-
Aldrich, St. Louis, MO), 100-U/mL penicillin/streptomycin (Sigma), and 55-mM 2- 
mercaptoethanol (Gibco) media was incubated at 37o C, 5% CO2 with Brefeldin A (10 
mg/mL; Sigma) and select wells with the positive control phorbol 12-myristate 13-acetate 
(PMA; 25 ng/mL; Sigma) and ionomycin (1 mM; Sigma) for 4 h. Following this, 
determination of cytokine gene expression was carried out by separating aliquots of the 
cells and placing them into Trizol (Ambion) to isolate RNA (described in the following). 
Remaining cells were assayed by flow cytometry for IFN-γ and TNF-α production by the 
following: cells were fixed in 2% paraformaldehyde (Sigma) and stored overnight at 4o C. 
After overnight storage, IFN-γ and TNF-α intracellular staining were carried out as 
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previously described [198]. After the cells were stained, aliquots of cells were resuspended 
in FACS flow, and flow cytometric acquisition was performed on a FACSCalibur (Becton 
Dickinson, San Jose, CA). Determination of IFN-γ and TNF-α protein production by 
lymphocytes was accomplished with the use of CELL QUEST (Becton Dickinson). 
2.2.4. Inflammatory cytokine gene expression measured by real time-polymerase chain 
reaction (RT-PCR) 
A modified Trizol method was used to extract total RNA. One microgram of RNA 
was reverse transcribed into cDNA as previously described [197].  In brief, 0.5 µg of each 
RNA sample and a reverse transcription master mix (Promega, Madison, WI) were 
incubated for 15 min at 42o C and for 5 min at 95o C. Five microliters of Master Mix 
(SensiMix HI-ROX 2x, Bioline) and 4.5 µL of cDNA were combined with 0.5 µL of the 
primer-probe of interest (TaqMan, Equine-specific, intron-spanning primers and probes; 
Applied Biosystems). Samples were run using Applied Biosystems Real-Time PCR (ABI 
Viia7) against the following genes: Housekeeping gene beta-glucuronidase (β-gus; 
Ec0347-0630_m1), interferon gamma (IFN-γ; Ec03468606_m1), IL-6 (Ec03468678_m1), 
IL-1β (Ec04260298_s1), TNF-α (Ec03467871_m1), and TLR4 (Ec03468994_m1) [199]. 
Samples were processed in duplicate and incubated for 95o C for 10 min. They then 
underwent 10 cycles at 95o C for 15 s and 60o C for 60 s. Relative changes in gene 
expression were determined by the CT method [200] with mean CT for time 0 set as 
the calibrator for all samples. Relative quantity (RQ) was calculated as 2-CT and used to 
express results. 
2.2.5. Data analysis 
Study data were analyzed using a 2-period crossover design with repeated measures 
ANOVA. Analyses were completed using PROC MIXED, SAS 9.4 (SAS Institute Inc, 
Cary, NC, USA). In a typical crossover design, the group is determined by the sequence in 
which the treatment is applied. In this study, both EMS and control horses were in both 
sequences. To accurately test sequence and EMS vs control, a group variable was created. 
There were 4 groups based on period (week = 1 or 2), Stevia vs Karo, and EMS vs control. 
The main effects of sequence (if the horse received karo vs stevia week 1) and EMS vs 
control, as well as, the interaction of sequence x EMS vs control were tested using the error 
term of Horse ID (Group). This model also included the main effects of period, Stevia vs 
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Karo, and time (0, 60, and 240 min). The interactions included Stevia vs Karo x EMS vs 
Control, time x EMS vs Control, time x Stevia vs Karo, and time x Stevia vs Karo x EMS 
vs Control. Horse ID was the subject, and the repeated measure was set as time. Mauchly’s 
Sphericity Test was used to test the form of the common covariance matrix. The sphericity 
assumption was not violated; therefore, compound symmetry covariance structure was 
selected. Pairwise comparisons were made using protected LSD. Only variables that found 
significant in the ANOVA were selected to apply pairwise comparisons. Screening data 
were analyzed with Sigma Plot, version 12 (Systat Software, San Jose, CA) with a 1-way 
ANOVA to compare EMS vs controls. For data not normal per Shapiro-Wilk testing, a 
Kruskal-Wallis 1-way ANOVA on ranks was performed. Differences were considered 
statistically significant when P < 0.05. 
 
2.3. Results 
2.3.1. Metabolic responses 
There was an observed EMS vs Control by time point interaction (P < 0.0001) for 
serum glucose (Figure 2.1) with control horses at time point 60 higher compared with 
control horses at time points 0 and 240. Control horses at time points 0 and 240 were lower 
compared with EMS horses at all 3 time points. Control horses at time point 60 were not 
different from EMS horses at time point 60. There was also a stevia vs karo by time point 
interaction (P = 0.0001) with horses given karo lower at time points 0 and 240 compared 
with time point 60 in horses given karo. Horses given karo were higher at time point 60 
compared with all 3 time points in horses given stevia. Horses given stevia were not 
different regardless of time point. There were also several overall differences observed. 
EMS horses were higher compared with controls (P = 0.0033), horses given karo were 
higher compared with those given Stevia (P = 0.0002), horses were higher at the 60 min 
time point compared with time points 0 and 240 (P = 0.007), and horses were higher in 
serum glucose concentrations during period 2 compared with period 1 (P = 0.0015). 
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Figure 2.1. Serum glucose concentrations in EMS (n=8) and control (n=7) horses given 
Karo corn syrup and stevioside at baseline (0) and after administration (60 and 240 min). 
Differences (P < 0.05) within time point between EMS and non-EMS controls are 
represented by (*). EMS, equine metabolic syndrome. 
 
There was an observed 3-way EMS vs control by stevia vs karo by time point 
interaction (P = 0.0073; Figure 2.2) for serum insulin. At time 0 control, horses given karo 
were lower compared with time point 60 for control horses given karo, EMS horses given 
karo, EMS horses given stevia, and time point 240 for EMS horses given stevia. At time 
point 60, control horses given karo were higher compared with time point 240 for control 
horses given karo, control horses given stevia at all time points, and time points 0 and 240 
for EMS horses given karo. However, they were lower compared with time point 60 for 
EMS horses given karo. At time point 240, control horses given karo were lower compared 
with time point 60 for EMS horses given karo, and time points 60 and 240 for EMS horses 
given stevia. Control horses given stevia at all time points were lower compared with time 
point 60 for EMS horses given karo. At time point 240, control horses given stevia were 
also lower compared with time points 60 and 240 for EMS horses given stevia. EMS horses 
given karo were lower at time point 0 compared with time point 60 for EMS horses given 
karo. At time point 60, EMS horses given karo were higher compared with time point 240 
for EMS horses given and EMS horses given stevia for all 3 time points. No time point 
differences were observed between control or EMS horses given stevia. Overall, horses 
55
60
65
70
75
80
85
90
0 60 240
S
er
u
m
 G
lu
co
se
 (
m
g
/d
L
)
Time Point (min) 
Glucose
EMS Karo
Control
Karo
EMS
Stevia
Control
Stevia
* * 
 21 
given karo had higher serum insulin concentrations compared with those given stevia (P < 
0.0001), and insulin was higher at the 60 min time point compared with time points 0 and 
240 (P < 0.0001). 
 
 
Figure 2.2 Serum insulin concentrations in EMS (n=8) and control (n=7) horses given 
Karo corn syrup and stevioside at baseline (0) and after administration (60 and 240 min). 
Differences (P < 0.05) within time point are represented by (*). EMS, equine metabolic 
syndrome. 
 
2.3.2. Inflammatory cytokine production measured by flow cytometry 
Flow cytometry results are presented in Figure 2.3. PBMCs stained intracellularly 
for IFN-γ had several differences in both the percentage of lymphocytes producing IFN-γ 
(% gated) and the mean fluorescence produced per lymphocyte (MFI). There was an EMS 
vs control by time point interaction (P = 0.0016) for IFN-γ % gated. Regardless of 
administration of karo or stevia, control horses had a higher percent gated at time point 0 
compared with control horses at time points 60 and 240.  Control horses at time point 0 
were also higher than EMS horses at time point 240. However, control horses at time points 
60 and 240 were lower compared with EMS horses at time point 60 for IFN-γ % gated. 
EMS horses at time point 60 were higher compared with EMS horses at time points 0 and 
240. There was also an overall effect of period for IFN-γ % gated with horses higher period 
1 compared with period 2 (P = 0.0346). IFN-γ MFI exhibited interactions between EMS 
vs control by Stevia vs karo (P = 0.0355) and EMS vs control by time point (P = 0.0003). 
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Regardless of administration of karo or stevia, control horses had a higher IFN-γ MFI at 
time point 0 compared with control horses at all other time points as well as compared with 
EMS horses at time points 0 and 240. Control horses at time points 60 and 240, however, 
were lower compared with EMS horses at time point 60. EMS horses were higher at time 
point 60 compared with EMS horses at time points 0 and 240 for IFN-γ MFI. No 
differences were observed between EMS and control horses at time point 240. Overall, 
IFN-γ MFI was lower in control horses given karo vs control horses given stevia.  
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Figure 2.3. Flow cytometry results for PBMCs stained for IFN-γ and TNF-α in EMS (n=8) and control (n=7) horses given Karo corn 
syrup and stevioside at baseline (0) and after administration (60 and 240 min). Differences (P < 0.05) within time point between EMS 
and non-EMS controls are represented by (*). EMS, equine metabolic syndrome; PBMCs, peripheral blood mononuclear cells. 
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Results for TNF-α % gated and MFI were similar to those seen for IFN-γ. There 
was an interaction between EMS vs control and time point (P < 0.0001) for TNF-α % gated. 
Control horses given either karo or stevia were higher at time point 0 compared with control 
horses at time point 60 and EMS horses at time points 0 and 240. Control horses at time 
point 240 were also higher than EMS horses at time point 240. However, EMS horses at 
time point 60 were higher compared with control horses at time point 60 as well as EMS 
horses at time points 0 and 240. TNF-α MFI exhibited an EMS vs control by Stevia vs karo 
interaction (P = 0.0402) with control horses given karo lower compared with controls given 
stevia. In addition, there was an EMS vs control by time point interaction (P = 0.0001) with 
control horses at time points 60 and 240 lower compared with EMS horses at time point 
60 and EMS horses at time point 60 higher compared with EMS horses at time points 0 
and 240. In addition, there was an overall effect of period, with horses higher in TNF-α % 
gated and MFI in period 2 compared with period 1 (P = 0.0496). 
2.3.3. Inflammatory cytokine gene expression measured by RT-PCR 
 PBMC gene expression results expressed as RQs and as measured by RT-PCR are 
presented in Figure 2.4. Gene expression results followed a similar pattern as flow 
cytometry results. There were several interactions for IFN-γ RQ as well; EMS vs control 
by time point (P < 0.0001), and EMS vs control by stevia vs karo (P = 0.0021). Control 
horses at time point 0 had a higher IFN-γ RQ compared with control horses at time point 
60 and EMS horses at time points 0 and 240 regardless of whether horses were given karo 
or stevia. Control horses at time point 240 were higher compared with EMS horses at all 
time points. However, control horses at time point 60 were lower compared with control 
horses at time point 240 and EMS horses at time point 60. EMS horses at time point 60 
were higher for IFN-γ RQ than EMS horses at time points 0 and 240. In addition, there was 
an overall difference of IFN-γ RQ for EMS vs control (P = 0.0028) with EMS horses higher 
compared with controls, and an overall stevia vs karo (P = 0.017) difference with horses 
given stevia higher compared with those given karo. 
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Figure 2.4. RT-PCR PBMC gene expression results in EMS (n=8) and control (n=7) horses given Karo corn syrup and stevioside at 
baseline (0) and after administration (60 and 240 min). Differences (P < 0.05) within time point between EMS and non-EMS controls 
are represented by (*). EMS, equine metabolic syndrome; PBMCs, peripheral blood mononuclear cells; RT-PCR, reverse transcription 
PCR.
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For IL-6 RQ, there was an interaction between EMS vs control by time point (P < 
0.0001). Control horses given either karo or stevia were higher at time point 0 compared 
with control horses at time points 60 and 240 and EMS horses at all time points. Control 
horses at time point 60 were lower compared with control horses at time point 240. Control 
horses at time point 240 were higher compared with EMS horses at time point 0. EMS 
horses at time point 60 were higher compared with EMS horses at time points 0 and 240. 
Overall, horses during period 1 had a higher IL-6 RQ compared with period 2 (P = 0.0117). 
TLR-4 RQ results were similar to those for IL-6 RQ with an interaction between EMS vs 
control by time point (P = 0.0282). Regardless of administration of stevia or karo, control 
horses at time point 240 were lower compared with EMS horse at time point 0. EMS horses 
at time point 0 were higher compared with EMS horses at time point 60. An overall period 
effect was also observed for TLR-4 RQ, with horses higher in period with compared with 
period 1 (P = 0.0277). 
There was an interaction between EMS vs control and time point (P = 0.0231) for 
TNF-α RQ. There were no differences in TNF-α RQ between horses given stevia or those 
given karo. Control horses at time point 0 were higher compared with control horses at 
time point 60 and EMS horses at time points 0 and 240. EMS horses at time point 60 were 
higher compared with EMS horses at time point 240. 
 
2.4. Discussion 
 Horses had expected glycemic and insulinemic responses to karo corn syrup with 
an increase in insulin and glucose at time point 60 and with EMS horses having a greater 
increase in insulin at time point 60 compared with controls. 
Stevia is generally recognized as safe in humans [201] and is thought to decrease 
circulating glucose concentrations by stimulating the pancreatic beta cells to release insulin 
[184]. In this study, an oral bolus of stevioside produced a lower glycemic response when 
compared with karo corn syrup. In horses given stevioside, there was no significant 
increase in serum glucose at time point 60 compared with time points 0 or 240 in contrast 
to the marked rise in serum glucose in horses given karo. Although EMS horses had a 
decrease in serum glucose at time point 60 when given stevia compared with an increase 
when given karo, there was no significant interaction between EMS vs controls and karo 
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vs stevia. In addition, at time point 60, EMS horses given karo had higher serum insulin 
concentrations compared with EMS horses given stevia at any time point. At time point 
60, EMS horses given stevia had similar serum insulin concentrations compared with 
control horses given karo, although control horses given karo were higher compared with 
control horses given stevia. Glucose and insulin responses in horses to stevia at time 60 
indicate that in horses, in particular those with metabolic dysfunction, stevia may provide 
a protective effect on postprandial increases in these metabolic parameters. It is unlikely in 
horses that stevia stimulates insulin release from the pancreas to the extent that it does in 
rats [184], as increases in insulin at  time point 60 in horses given stevia were significantly 
lower than those give karo. It is possible that stevia may induce an increased insulin 
receptor sensitivity in horses with EMS; however, more work needs to be done to discover 
possible explanations for differences in glucose and insulin responses to a glycemic 
challenge with karo or stevia. 
There were observed differences for the flow cytometry analysis of IFN-γ and TNF-
α intracellularly stained PBMCs. Regardless of administration of either karo or stevia, EMS 
horses had an increase in markers of inflammation at time 60, whereas control horses had 
a decrease in these same markers of inflammation. Similar results were observed for PBMC 
gene expression of inflammatory cytokines with EMS and control horses having 
contrasting inflammatory responses to an OST. These data suggest that EMS horses have 
an abnormal proinflammatory response to glycemic challenge when given karo or stevia. 
Data on postprandial inflammation in humans and other species, in particular in those with 
metabolic dysfunction are scarce. Most report an increase in systemic soluble adhesion 
molecules, such as Intercellular Adhesion Molecule-1 (ICAM-1) in response to either a 
high-fat meal or high-fat meal combined with glucose [43, 44]. Soluble adhesion molecules 
are involved in the immune and inflammatory responses [202] and have been linked to 
cardiovascular disease in humans [203, 204]. Some report an increase in adhesion 
molecules or proinflammatory cytokines in both normal and diabetic subjects in response 
to a meal with diabetic subjects having a significantly greater increase compared with 
normal controls [43, 45]. Others did not see this same increase [205], however, this may 
be due to differences in meal type or carbohydrate complexity [206]. 
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In horses, most of the data regarding inflammation and glycemic and insulinemic 
responses have been focused on either basal circulating or tissue inflammatory markers at 
rest. Data have been somewhat conflicting with some groups showing increases in 
inflammatory markers such as TNF-α [28] and serum amyloid A [40] and others showing 
no differences between horses with ID and normal controls [31]. There has also been work 
in the horse focused on oligofructose-induced laminitis models with whole-blood 
inflammatory markers IL-1β, IL-8, and IL-10 increasing 8 h post induction of laminitis 
[51] in 1 study and increases in IL-2, IL-6, IL-8, and IFN-γ noted at the onset of laminitis 
in another study [18]. The available data regarding postprandial inflammation in the horse 
are scarce but have shown postprandial rises in IL-1β in response to feeding a high sugar 
high starch meal [46].  Increases in inflammatory markers following a meal may in part be 
due to oxidative stress or, to increases in bacterial endotoxin concentrations. These 
increases in inflammation appear to mirror the higher insulinemic responses in EMS horses 
and may be a possible mechanism that predisposes these animals to the development of 
laminitis. However, this remains to be further characterized.  
Given these data, stevia appears to be well tolerated in EMS horses, considering 
that stevia did not induce the same metabolic responses as karo corn syrup on challenge. 
Thus, stevia may be a possible candidate as a non-glycemic sugar replacer in horses with 
ID. Further work is needed to explore inflammatory effects of stevia in metabolically 
normal animals and possible metabolically beneficial effects in horses with EMS. Also, 
these data reveal new questions about the response of EMS horses to an oral sugar 
challenge, in particular with regard to postprandial inflammation. 
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CHAPTER 3 COMPARISON OF THE FECAL MICROBIOTA IN HORSES WITH 
EQUINE METABOLIC SYNDROME (EMS) AND METABOLICALLY NORMAL 
CONTROLS FED A SIMILAR ALL FORAGE DIET 
Journal of Equine Veterinary Science, 2016: 44, 9-16 
 
Equine metabolic syndrome (EMS) is an ever-increasing problem in the equine 
industry, especially considering that it is a risk factor for the development of laminitis. 
Equine metabolic syndrome is similar to metabolic syndrome in humans, which has been 
associated with alterations in intestinal microbiota. However, no work to date has been 
published to characterize the fecal microbiota in the EMS horse to determine differences, 
if any, from the metabolically normal animal. Therefore, our objective was to characterize 
the fecal microbiota of horses with EMS compared with non-EMS controls. Ten horses 
were classified as having EMS, and 10 non-EMS controls were selected for this work. 
Equine metabolic syndrome was determined as: insulin resistance, general or regional 
adiposity, and a history of or predisposition to laminitis. Blood collection via jugular 
venipuncture was performed, along with an oral sugar challenge. Concurrent with blood 
collection, phenotypic measurements and fecal grab samples were taken. Fecal samples 
were used to extract DNA for next generation sequence-based analysis of the bacterial 
microbiota. Equine metabolic syndrome horses exhibited a decrease in fecal microbial 
diversity, and there were differences in overall community structure between EMS horses 
and controls. The operational taxonomic unit with the highest linear discriminant analysis 
effect size in association with EMS horses was a member of subdivision 5 of 
Verrucomicrobia incertae sedis (uncertain classification). Interestingly, the control group 
had an overrepresentation of genus Fibrobacter. These data demonstrate that EMS horses 
have differences in their fecal microbiota compared with controls. 
 
3.1. Introduction 
Horse are hindgut fermenters and as such, their gut microbiota is predominantly 
populated by bacteria from the phyla Firmicutes [64, 67]. However, even in healthy horses, 
the gut microbiota is naturally highly diverse and highly variable. It is influenced by factors 
such as diet, age, and individual variation [64-66]. Disease states in particular can have a 
significant impact on the gut bacterial population in the animal. For example, there is 
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evidence that a high-starch diet may increase the abundance of certain taxa from the family 
Veillonellaceae [70]. In addition, horses with chronic laminitis have differences in both 
microbiota abundance and diversity compared with controls [72], and the microbiota has 
significant changes in abundance during the onset of laminitis [73, 74].  
Insulin resistance, general or regional adiposity, and a history of or predisposition 
to laminitis are the three main characteristics associated with equine metabolic syndrome 
(EMS)  [23]. Equine metabolic syndrome is considered to be especially concerning to the 
equine population considering its connection to laminitis, which can result in inability for 
the animal to resume normal work or even euthanasia. Equine metabolic syndrome is 
comparable to metabolic syndrome (MetS) in humans, which is associated with similar 
factors, such as visceral obesity, glucose intolerance, and dyslipidemia [207-209].  
In humans and mice, MetS and obesity have been linked to alterations in the 
intestinal microbiota [77]. It has been shown in high fat–fed mice that bacterial 
lipopolysaccharide (LPS) endotoxemia can induce inflammation and insulin resistance 
[61], both of which are considered to be influential in the pathophysiology of MetS [210]. 
Furthermore, age-related changes in the gut microbiota of mice have resulted in increased 
plasma LPS concentrations and a subsequent increase in markers of inflammation, 
indicating that shifts in the microbiota may play a major role in inducing low-grade 
systemic inflammation [83]. Studies in humans have shown that dietary changes can have 
a positive impact on the gut microbiota by reducing LPS producing bacteria and are 
proposed as a possible therapeutic target for individuals with metabolic dysfunction [84, 
85]. However, no data to date have been presented exploring possible differences in the 
gut microbiota of horses with EMS compared with metabolically normal controls, nor what 
impact these differences may have on the pathophysiology of the syndrome.  
Investigation into the mechanisms and factors contributing to EMS is becoming 
increasingly important considering its negative health consequences in these horses, in 
particular, the increased risk of laminitis. Therefore, the objective of this study was to 
investigate and characterize the fecal microbiota of horses with naturally occurring EMS 
compared with metabolically normal non-EMS controls.  
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3.2. Materials and Methods 
3.2.1. Horse Selection and Sample Collection: 
Twenty horses of mixed gender and breed were selected on the basis of EMS 
criteria as defined in the following section from the University of Kentucky’s Department 
of Veterinary Science herd in the spring of 2014. Of these horses, 10 were classified as 
EMS, and 10 were classified as non-EMS controls. There was no significant difference in 
age between EMS and control horses (P = .903). All horses were housed at the University 
of Kentucky’s Main Chance or Woodford farm facilities, maintained on a similar all forage 
diet of free choice mixed bluegrass, orchard and fescue hay (Table 3.1), and minimal 
pasture of a similar mixed grass type, and had access to water and a mineral block ad 
libitum. Horses were acclimated to their respective pastures for at least 2 months before 
sampling. All materials and methods were approved by the Institutional Care and Usage 
Committee of the University of Kentucky. 
Table 3.1. Nutrient composition of mixed grass hay. 
Component As fed Dry Matter 
% Moisture 7.8  
% Dry Matter 92.2  
% Crude Protein 7.6 8.3 
% Adjusted Crude Protein 7.6 8.3 
% Acid Detergent Fiber 43.0 46.6 
% Neutral Detergent Fiber 63.9 69.3 
% NFC 15.8 17.1 
% TDN 52.0 56.0 
NFL, Mcal/Lb 0.41 0.44 
NEM, Mcal/Lb 0.45 0.48 
NEG, Mcal/Lb 0.21 0.23 
Relative Feed Value  71 
% Calcium 0.39 0.43 
% Phosphorus 0.26 0.28 
% Magnesium 0.13 0.14 
% Potassium 1.65 1.79 
% Sodium 0.0005 0.005 
PPM Iron 427 463 
PPM Zinc 17 18 
PPM Copper 7 7 
PPM Manganese 92 100 
PPM Molybdenum 0.5 0.6 
Horse DE, Mcal/Lb 0.80 0.86 
Nutrient composition of mixed grass hay fed to all horses ad libitum. Analysis provided by 
Dairy One Forage Testing Laboratories (Ithaca, NY). 
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Equine metabolic syndrome was determined by the following criteria from the 2010 
ACVIM consensus statement by Frank et al [23]: insulin dysregulation, general or regional 
adiposity, and a history of or predisposition to laminitis. To ascertain the presence of 
insulin dysregulation, an oral sugar test was performed after overnight fasting as previously 
described [13]. A fasting insulin level of >20 μIU/mL was considered indicative of 
hyperinsulinemia, and an increased insulin (>60 μIU/mL) 60 minutes after administration 
of oral sugar (Karo corn syrup) was defined as insulin resistance [13, 23]. The presence of 
either hyperinsulinemia or insulin resistance was considered positive for insulin 
dysregulation. Obesity and adiposity were determined by body condition score (BCS) and 
cresty neck score (CNS). Body condition score was established using the 1 to 9 Henneke 
scoring system [186], and CNS was determined via the 0-5 system established by Carter et 
al [187]. For both BCS and CNS, three trained investigators scored the animals, and theses 
scores were averaged to determine final BCS and CNS. Individuals scoring were blinded 
to which horses were positive for insulin dysregulation. Equine metabolic syndrome was 
defined as having increased adiposity with a BCS of 6.5 or above or a CNS greater than 
2.5. All EMS horses had a history of or predisposition to laminitis. Insulin, BCS, and CNS 
data are presented in Table 3.2.   
 
Table 3.2. Characterization of phenotypic measures in equine metabolic syndrome (EMS) 
versus non-EMS control horses.  
Group BCS CNS 
Basal Insulin 
(µIU/mL) 
Post oral sugar 
Insulin (µIU/mL) 
EMS 7.13 ± 0.15 3.57 ± 0.27 33.85 ± 2.66 63.26 ± 5.29 
Control 5.85 ± 0.23 1.95 ± 0.18 13.03 ± 1.46 26.11 ± 3.77 
P value <.001 <.001 <.001 <.001 
Average body condition score (BCS) and cresty neck score (CNS), and basal insulin and 
insulin 60 min post oral sugar administration in n = 10 EMS and n = 10 non-EMS control 
horses. Results are represented as the mean plus or minus the standard error of the mean. 
 
All animals were also examined to ensure that none were affected by pituitary pars 
intermedia dysfunction (PPID) by conducting thyrotropin-releasing hormone (TRH) 
stimulation and low-dose dexamethasone suppression testing. Thyrotropin-releasing 
hormone stimulation testing was accomplished similar to previously described [191, 192]. 
In brief, a morning baseline blood sample was taken via jugular venipuncture after which 
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1-mL IV dose of TRH dissolved to 1 mg/mL in 0.9% saline (Sigma-Aldrich, St. Louis, 
MO) was administered. Ten minutes after TRH injection, a second blood sample was 
collected. Blood samples were collected in EDTA-containing tubes, placed on ice, and 
transported to the laboratory for immediate centrifugation for plasma isolation [193]. 
Plasma was stored at -20oC and shipped on dry ice to Cornell University for analysis of 
adrenocorticotropic hormone (ACTH) concentrations. Low-dose dexamethasone 
suppression testing was performed as previously described [194] by taking an afternoon 
(3:50 PM–6:00 PM) baseline jugular blood sample, administering an intramuscular 
dexamethasone bolus (0.04 mg/kg BW), and taking a second blood sample 19 hours later. 
Samples were collected in a gel serum separator tube and serum isolated and frozen at -
20oC until cortisol analysis. Adrenocorticotropic hormone concentrations 10 minutes after 
TRH injection >100 pg/mL or cortisol concentrations in excess of 1.0 μg/dL 19 hours after 
dexamethasone injection were considered indicative of PPID and any positive animals 
excluded. All blood samples were sent to Cornell University’s Animal Health Diagnostic 
Center Endocrinology Laboratory for determination of insulin, ACTH, and cortisol 
concentrations. Insulin was measured using the Millipore Porcine Insulin RIA Kit (EMD 
Millipore Corporation, Darmstadt, Germany), ACTH using an automated 
chemiluminescent enzyme immunoassay system (Immulite, Erlangen, Germany) [195], 
and cortisol using Siemens Immulite Cortisol kit (Siemens, Erlangen, Germany). All blood 
samples and phenotypic measures for all horses were collected within a period of 2 weeks 
in the spring of 2014. 
3.2.2. DNA extraction and 16s rRNA gene PCR  
DNA was extracted from fecal samples using a commercial kit (E.Z.N.A. Stool 
DNA Kit, Omega Bio-tek Inc, Doraville, GA), according to manufacturer’s instructions. 
Quantity and quality of DNA were assessed by spectrophotometry (NanoDrop; Roche, 
Mississauga, Canada), the V4 region of the 16S rRNA gene was amplified [211], and 
amplicons were sequenced by Illumina MiSeq (San Diego, CA). Sequence files are 
available at the University of Guelph Research Data Repository, DOI: 
http://dx.doi.org/10.5887/ UGRDR/10864/XER6B. 
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3.2.3. Data Analysis 
Phenotypic data (insulin, BCS, and so forth) were analyzed by SIGMAPLOT 
version 12.3 (Systat Software Inc). A mixed model one-way analysis of variance was used 
for each quantitative variable and ordinal data analyzed via the Wilcoxon Mann-Whitney 
test. One EMS horse’s CNS was not collected and thus not included in the analysis. Fixed 
effects were set as EMS versus control. Data were normally distributed and of equal 
variance. Data were considered statistically significant when P < .05.   
Microbiota data were analyzed using the open-source platform mothur (v1.35) 
[212]. Initial sequence processing involved aligning paired-end reads, with a series of 
quality control steps to remove sequences that contained any ambiguous base calls, were 
not consistent with the target amplicon size (240 bp), contained holopolymers > 8 bp in 
length, or did not align with the correct 16S rRNA gene region. Chimeras were identified 
using UCHIME [213] and removed. Taxonomy was assigned using the Ribosomal 
Database Project taxonomy database (http://rdp.cme.msu.edu/index.jsp).  
Subsampling was performed to normalize sequence numbers by random selection of 
number of sequences from each sample that corresponded to the sample with the smallest 
number of sequences. Comparison of the relative abundances of taxa between groups was 
done by linear modeling using robust (Huber) estimation to down-weight outliers, with P 
values that were adjusted for false discovery rate using the Benjamini–Hochberg technique. 
Alpha diversity was calculated using Chao1 richness, inverse Simpson’s diversity, and 
Shannon’s evenness tests and compared using Wilcoxon test or Steel–Dwass test. A P 
value of <.05 was considered significant.   
Sequences were binned into phylotypes, and subsampling was performed to 
normalize sequence number for subsequent analyses [214]. Dendrograms for community 
membership (classical Jaccard index, a measure of shared OTUs) and structure (Yue and 
Clayton index of dissimilarity, which considers shared OTUs and their relative 
abundances) were created and compared using unifrac and analysis of similarity 
(ANOSIM). Community membership and structure were also visualized using principal 
coordinate analysis. Linear discriminate analysis effect size (LEfSe) [215] was used to 
identify overrepresented OTUs between horses with metabolic disease and controls. 
Samples were also evaluated using the Dirichlet multinomial mixtures method for 
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probabilistic modeling [216] to determine the number of different metacommunities 
(enterotypes) that they could be assigned to, with the K value that derived the minimum 
Laplace approximation indicating the number of different metacommunities. The observed 
learning technique, random forests [217], was used to determine whether a set of predictive 
features could be used to accurately identify samples from EMS versus control groups. 
Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
States (PICRUSt) [218] was used to predict the relative abundance of predicted Kyoto 
Encyclopedia of Genes and Genomes biochemical pathways and ortholog groups, and 
those were compared between horses with metabolic disease and controls using LEfSe. 
 
3.3. Results 
 At the time of sampling, EMS horses were aged 13 ± 5 years (range 8–20 years), 
and non-EMS controls were aged 13 ± 3 years (range 10–19 years). Equine metabolic 
syndrome horses had greater values for fasting insulin, insulin 60 minutes after oral sugar 
administration, BCS, and CNS compared with controls (Table 3.2).   
From the fecal samples analyzed for fecal microbiota differences, sequence 
processing and filtering yielded a total of 1,446,359 sequences (mean 72,318/sample, 
median 73,371.5, standard deviation 30,815.5, and range 11,491- 137,462). Subsampling 
of 11,491 sequences per sample was performed to normalize data. There were no 
differences in estimated richness (P = 97), observed richness (P = 79), or evenness (P = 
12) between groups; however, diversity was lower in EMS horses (median 6.3 vs. 7.1, P = 
026, Figure 3.1).  
  
 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Intestinal microbiota diversity in equine metabolic syndrome (EMS) versus 
non-EMS control horses. Intestinal microbiota diversity as represented by an inverse 
Simpson’s index in n = 10 EMS and n = 10 non-EMS control horses.   
 
Based on unifrac analysis, there was a significant difference in community structure 
between groups (P = 011, Figure 3.2), with no difference in membership (P = 33, Figure 
3.3). A significant difference in community structure was also identified with ANOSIM (P 
= 012), whereas the difference in membership approached significance (P = 056). 
However, the differences that were present were not to the degree that samples would be 
assigned to two different metacommunities. Similarly, random forest modeling was poorly 
predictive of group membership, with an error rate of 55%. 
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Figure 3.2. Bacterial population structure in equine metabolic syndrome (EMS) versus non-EMS control horses. Representation of 
bacterial population structure as measured by Yue & Clayton similarity coefficient in n = 10 EMS and n = 10 non-EMS control horses.  
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Figure 3.3. Bacterial membership for equine metabolic syndrome (EMS) versus non-EMS 
control horses. Intestinal microbiota membership as measured by a Jaccard index in n = 10 
EMS and n = 10 non-EMS control horses.  
 
 No significant differences in relative abundances of different phyla were identified 
after correction of P values for false discovery rate. Similarly, no significant differences 
remained in lower taxonomic orders after correction of P values. Predominant genera are 
displayed in Figure 3.4. However, 12 OTUs were significantly different based on LEfSe 
(Figure 3.5). No significant differences in predicted functional capacity of the microbiota 
were identified by LEfSe analysis of PICRUSt data.  
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Figure 3.4. Microbiota genera in equine metabolic syndrome (EMS) versus non-EMS 
control horses. Comparison of the most common genera in the fecal microbiota and their 
relative abundance in n = 10 EMS and n = 10 non-EMS control horses.  
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Figure 3.5. Linear discriminate analysis effect size (LEfSe) analysis in EMS versus non-
EMS control horses. Over-represented OTU’s as identified by LEfSe in n = 10 EMS and n 
= 10 non-EMS control horses.  
 
3.4. Discussion 
 As expected, horses with a naturally occurring form of EMS had significantly 
greater measures of insulin resistance and obesity compared to a matched population of 
controls, considering these were the criteria used to establish the presence of EMS versus 
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control. The fecal microbiota of horses with EMS also differed from those of the controls. 
Although differences in individual taxa were limited, there were changes in community 
structure, an overall measure of the components of the microbiota, and their relative 
abundances. There was not a corresponding difference in community membership, 
although some results did approach significance. A difference in community structure but 
not membership implies alterations in relative abundances of a relatively conserved 
microbiota composition, such as might be present when some members are overgrown or 
depleted in the community but are still present. This suggests that EMS does not result in 
significant differences in bacteria colonization in the intestinal tract but can have an impact 
on their relative abundances, resulting in overgrowth or decreased growth of different 
members.  
Despite the differences in community structure, direct comparison of relative 
abundances did not identify specific taxa that were differentially abundant. Yet numerous 
differences were identified by LEfSe. Closer evaluation of these groups raises some new 
questions and hypothesis. The OTU with the highest LDA score in association with EMS 
horses was an incertae sedis (uncertain classification) member of subdivision 5 of 
Verrucomicrobia. Verrucomicrobia is an interesting phylum that is getting increasing 
attention in obesity and metabolic disease. Akkermansia is a genus of mucin-degrading 
bacteria belonging to this phylum that helps maintain the integrity of the mucin layer and 
decrease inflammation [219]. Increases in this genus have been shown to improve glucose 
homeostasis in obese mice [220]. Similarly, normalization of Akkermansia in obese mice 
improved metabolic profiles, potentially through crosstalk between microbiota and host 
[219]. In minipigs with diet-induced obesity, Verrucomicrobia was increased compared 
with lean counterparts [78], and in humans, Akkermansia muciniphila abundance has been 
inversely associated with fasting glucose, waist-to-hip ratio, and subcutaneous adipose 
measures [221]. Verrucomicrobia abundance has been suggested as a microbial biomarker 
for the progression of glucose intolerance based on higher levels in newly diagnosed 
individuals, versus those with normal glucose control or prediabetes [222]. Therefore, it is 
possible that the increase in Verrucomicrobia noted here could be an adapted, protective 
effect of the microbiota in response to MetS- or EMS-associated obesity. 
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Fibrobacter was overrepresented in the control group. This genus of cellulolytic 
bacteria is most commonly identified in ruminants and hindgut fermenters, and it 
presumably plays an important role in digestion in horses. This genus has been identified 
as a component of the core microbiota in horses [223], with numbers increasing as foals 
age [224]. Decreased representation of this genus in horses with EMS that were on the 
same hay-based diet as control horses was interesting. Fibrobacter is a relatively acid-
intolerant genus that has been reported (along with Ruminococcaceae, which were also 
associated with controls) to decrease concurrent with increases in lactic acid bacteria after 
dietary change and intestinal disease [225]. Thus, the association of Lactobacillus with 
EMS horses could be a possible explanation for the underrepresentation of Fibrobacter in 
that group. Although the individual roles of this, and other, members of the microbiota are 
difficult to assess given the relatively limited research, certain groups tend to be recurrently 
associated with “gut health.” Particular attention is now being paid to Ruminococcaceae 
and Lachnospiraceae, members of the Clostridiales order [68, 69]. These butyrate-
producing bacteria are often associated with intestinal health, with decreases associated 
with various disease states. For example, recent studies in horses have identified decreases 
in Clostridiales in horses with colitis [75], and in mares shortly before the onset of colic 
[76]. In the present study, two Ruminococcaceae (Ruminococcus, Saccharofermentans) 
and one Lachnospiraceae were associated with the control group, whereas only one 
(Cellulosilyticum) was associated with EMS horses. These results may provide potential 
links between alterations in gut microbiota, inflammation, and metabolic dysfunction. 
However, further work is warranted to explore these connections and to establish if changes 
in the gut microbiota in EMS horses contribute to inflammation, which in turn leads to 
insulin and glucose dysregulation or if the reverse is more likely.  
A decrease in microbial diversity was also identified in EMS horses. Optimal values 
for diversity are poorly understood. Increasing diversity probably provides some benefits 
because the community may have a broader functional potential and greater ability to 
respond to alterations. However, ultimate diversity (all members of the community are 
different) is not desirable, and some members of the community should be present in higher 
levels because they perform important functions (e.g., cellulolytic bacteria). Lower 
diversity in EMS horses identified here could be of concern as decreased diversity has been 
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reported in association with obesity in humans [79], dogs [80], and in horses in response 
to antimicrobial administration [81] and diet change [69]. 
No differences in predicted functional capacity of the microbiota were identified 
by PICRUSt. This is perhaps not surprising given the relatively limited taxonomic 
differences that were noted (as PICRUSt is a predictive model based on taxa) and the small 
sample size. Further study of microbiota function through larger studies, either through 
inferred function or more specific identification of functional capacity through shotgun 
sequencing approaches is needed.  
 Small sample size is one limitation of this study, and the presence of identifiable 
differences indicates that broader studies should be undertaken. This study (similar to most 
microbiota studies) involved feces, not contents from different intestinal locations. Feces 
have been shown to be a good proxy for colon and to a lesser degree cecum [68], but these 
data may not accurately reflect the composition of more proximal regions. There are also 
potential impacts of various factors such as geography, management, diet, age, and a range 
of other exogenous influences. Although the use of farm-matched controls limits the impact 
of these on the analysis, it must be remembered that these data might only reflect horses 
under similar management.   
 
3.5. Conclusion  
This preliminary study identified differences in the microbiota of horses with EMS 
compared with non-EMS control horses. Although the differences were limited, changes 
that were present could influence health and be associated with some of the clinical 
characteristics of EMS. Understanding the impact of microbiota alterations and factors that 
influence these changes may be important for optimizing management of this common 
syndrome in horses. 
 
 
 
 
 
Copyright © Sarah E. Elzinga 2017  
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CHAPTER 4 PLASMA LIPIDOMIC AND INFLAMMATORY CYTOKINE 
PROFILES OF HORSES F HORSES WITH EQUINE METABOLIC SYNDROME 
Journal of Equine Veterinary Science, 2016: 40, 49-55 
 
Equine metabolic syndrome (EMS) is a growing problem in the equine industry, 
particularly considering it is a risk factor for the development of laminitis. Equine 
metabolic syndrome is similar to metabolic syndrome in humans, which is associated with 
abnormal circulating plasma lipid concentrations. Thus, our objectives were to characterize 
the plasma lipid profiles, or lipidome, of horses with EMS compared to non-EMS controls 
and to further characterize the inflammatory state of these horses. Twenty-three horses of 
mixed breed and sex were selected. Of these, 14 were classified as EMS and 9 as non-EMS 
controls. Equine metabolic syndrome was determined by insulin resistance, general or 
regional adiposity, and a history of or predisposition to laminitis. Fasting serum and plasma 
samples were collected via jugular venipuncture. Serum samples were used to determine 
insulin, leptin, triglyceride, cholesterol, and nonesterified fatty acid concentrations. 
Heparinized plasma samples were used to isolate peripheral blood mononuclear cells for 
inflammatory cytokine determination and ethylenediaminetetraacetic acid plasma to 
analyze lipidomes. Equine metabolic syndrome horses had increased serum leptin and 
triglycerides. Plasma lipidomic analysis indicated that EMS horses had elevated 
triacylglycerides, diacylglycerides, monoacylglycerides, and ceramide compared to control 
horses. They had lower plasma sphingomyelins, suflatide, and choline plasmalogens. 
Peripheral blood mononuclear cell analysis for cytokine protein concentration via flow 
cytometry and gene transcription via real-time polymerase chain reaction showed no 
differences between the two groups; however, high variability may have influenced results. 
These data demonstrate that EMS horses have differences in their plasma lipidome 
compared to controls, similar to what has been observed in humans with metabolic 
syndrome.  
 
4.1. Introduction 
Obesity rates are rising not only in the human population, but in equids as well [2, 
3, 7, 49]. Increased adiposity is one of the defining characteristics of equine metabolic 
syndrome (EMS). Equine metabolic syndrome was classified in 2010 in an ACVIM 
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consensus statement as insulin resistance, general, or regional adiposity and a history of or 
predisposition to laminitis [13, 23]. Equine metabolic syndrome is similar to metabolic 
syndrome (MetS) in humans, which is categorized by three or more of the following: 
visceral obesity, hypertriglyceridemia, glucose intolerance, low high-density lipoprotein 
cholesterol, or hypertension [207, 208]. 
Increased inflammation as well as altered lipid profiles have been associated with 
obesity in humans and mice [139, 226, 227]. Considering that abnormal lipid profiles may 
be a contributing factor to altered cell signaling or increased inflammation [139], as well 
as the influence of certain lipids on insulin resistance [140, 228], it is becoming 
increasingly important to examine possible connections between plasma lipid profiles, or 
lipidomes, and metabolic dysfunction. Lipidomic analysis is a relatively new field, but is 
providing promising new avenues for exploring questions related to metabolic dysfunction 
[108]. 
In humans, over 600 diverse molecular species make up the plasma lipidome [229]. 
It can be categorized into six primary mammalian lipid categories: fatty acyls, prenols, 
sterols, sphingolipids, glycerophospholipids, and glycerolipids. Changes in lipidome 
composition may affect human health [229, 230]. Differences in plasma lipidomes have 
been observed in humans and mice that experience obesity or hypertension. For example, 
changes in ether lipid or plasmalogen concentrations have been shown to be associated 
with atherogenic status and hypertension [231-233]. In particular, decreases in plasma ether 
phosphatidylethanolamines and phosphatidylcholines are indicative of hypertension in 
middle aged men [230] and patients with coronary artery disease with significant stenosis 
had a decrease in serum choline plasmalogens compared to patients without significant 
stenosis [232]. Additionally, differences in lipid composition between individuals who 
exercise regularly and those who consume a high fat diet have been demonstrated [125]. 
Research is also indicating a role of the immune response in lipid metabolism. The 
immune system has been shown to have the ability to recognize lipids as antigens [127]. 
One notable instance of this is the stimulation of T lymphocytes by CD1 antigen-presenting 
cells. CD1 cells recognize both foreign and self-lipids, such as phosphoglycerolipids and 
glycosphingolipids as stimulatory antigens [127-129]. Likewise, elevated levels of certain 
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lipids have been shown to impact cell signaling, including activation of NF-κB and 
programmed cell death [234-236]. 
Work in humans and mice has allowed for analysis of the lipidome in obese, 
hypertensive, or normal individuals, as well as those with metabolic dysfunction [112, 
115]. However, no published work has been done to classify the lipidome of horses with 
EMS. Existing data in the horse have allowed for characterization of EMS and explored 
connections to laminitis, but have yielded conflicting results, particularly in regards to 
inflammation [31]. Some studies have shown differences in inflammatory cytokines such 
as gene expression of interleukin 1β (IL-1β) and IL-6 in equine nuchal adipose tissue in 
EMS horses versus controls [41], and an increase in circulating plasma and serum 
concentrations of tumor necrosis factor alpha (TNF-α) in horses with EMS [28] as well as 
in ponies with a history of pasture associated laminitis [237]. However, others have shown 
a trend for circulating plasma TNF-α concentrations to be lower in obese horses compared 
to controls as well as a decrease in gene expression of IL-1β and IL-6 in the peripheral 
blood mononuclear cells (PBMCs) of obese horses [31]. Conflicting results may in part 
stem from the fact that many studies were carried out on ponies or on horses with an 
induced form of hyperinsulinemia [28, 237]. Not only that, but it is unclear if many were 
tested for confounding factors, such as pituitary pars intermedia dysfunction (PPID), which 
can influence insulin/glucose dynamics. 
Considering the negative effects of obesity and insulin dysregulation, in particular 
the increased risk of laminitis in horses, it is important to examine contributing mechanisms 
to the disorder. Thus, the objective of this study was to investigate and characterize the 
plasma lipidome as well as the inflammatory status of horses with naturally occurring EMS 
compared to non-EMS controls. 
 
4.2. Materials and Methods 
4.2.1 Horse Selection and Sample Collection 
Twenty-three horses of mixed sex and breed were selected from the University of 
Kentucky’s Department of Veterinary Science herd. Of these horses, n = 14 were classified 
as EMS (mean 13 ± 4 years) and n = 9 were non- EMS controls (mean 13 ± 3 years). There 
was no significant difference in age between EMS and control horses. Of the horses 
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classified as EMS, three were Standardbred or Standardbred crosses, three of mixed breed, 
and three were paints. In addition, one EMS horse was a Morgan, one a draft, one a 
warmblood cross, one a Walking horse, and one a Thoroughbred. Of the control horses, 
two were Quarter horses, three were Thoroughbreds, and four were of mixed breed. Ten of 
the 14 EMS horses were mares and four geldings. Seven of the controls were mares, and 
the remaining two were geldings. All horses were housed at the University of Kentucky’s 
Main Chance or Woodford farm facilities, maintained on a similar all forage diet of free 
choice mixed grass hay and minimal pasture, and had access to water and a mineral block 
ad libitum. Horses were acclimated to their respective pastures for at least 2 months before 
sampling. All materials and methods were approved by the Institutional Care and Usage 
Committee of the University of Kentucky.   
Equine metabolic syndrome was determined by the following criteria from the 2010 
ACVIM consensus statement, insulin dysregulation, general or regional adiposity, and a 
history of or predisposition to laminitis. To ascertain the presence of insulin dysregulation, 
an oral sugar test was performed following overnight fasting. In brief, fasting serum sample 
collection was followed by PO administration of 0.15 mL/kg of Light Corn syrup (Karo; 
ACH Food Companies, Cordova, TN) and a second serum sample collected 1 hour later 
[13, 23]. All blood collection was carried out via jugular venipuncture. After 
centrifugation, aliquots of serum samples were kept at -20oC until analysis. A fasting 
insulin level of >20 µIU/mL was considered indicative of hyperinsulinemia, and an 
increased insulin (>60µU/mL) 60 minutes post administration of oral sugar was defined as 
insulin resistance [13, 23]. The presence of either hyperinsulinemia or insulin resistance 
was considered positive for insulin dysregulation. Obesity and adiposity were determined 
by body condition score (BCS) and cresty neck score (CNS). Body condition score was 
established and averaged between three trained investigators using the 1 to 9 Henneke 
scoring system [186] with a 1 representing an extremely emaciated animal and a 9 
representing an extremely obese animal. Investigators were blinded to which horses were 
positive for insulin dysregulation. The same trained individual’s scores were averaged for 
CNS via the 0 to 5 system established by Carter et al [187], with a 0 representing no neck 
crest and a 5 representing a crest so large it permanently droops to one side of the neck. 
Equine metabolic syndrome was defined as having increased adiposity with a BCS of 6.5 
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or above or a CNS greater than 2.5. Equine metabolic syndrome horses also had a known 
history of or predisposition to laminitis. Body condition score and CNS scores, as well as 
insulin values from the oral sugar challenge are presented in Table 4.1. 
 
Table 4.1. BCS, CNS, basal insulin, and insulin post glycemic challenge in horses with 
EMS and controls. 
Phenotypic measure Control EMS P value 
BCS 5.9 + 0.3 6.9 + 0.2 .025 
CNS 2.0 + 0.3 3.2 + 0.3 .015 
Basal Insulin (uIU/mL) 13.9 + 2.5 35.5 + 1.9 <.001 
Post Sugar Insulin (uIU/mL) 24.3 + 6.1 72.2 + 4.6 <.001 
Abbreviation: EMS, equine metabolic syndrome. 
Data are presented as least square means, mean + standard error of the mean. n=9 controls 
and n=14 EMS.  BCS (body condition score) and CNS (cresty neck score) are presented as 
an average condition score between 3 trained individuals. 
 
All animals were also examined to ensure that none were effected by PPID by 
conducting thyrotropin-releasing hormone (TRH) stimulation and low-dose 
dexamethasone suppression testing. TRH stimulation testing was accomplished similar to 
previously described [191, 192] by taking an aseptic baseline blood sample, administering 
a 1 mg IV dose of TRH dissolved to 1 mg/mL in 0.9% saline (Sigma-Aldrich, St. Louis, 
MO) and taking a second sample 10 minutes following TRH injection. Samples were 
collected in ethylenediaminetetraacetic acid tubes, stored immediately on ice for transport, 
and centrifugation [193]. Plasma aliquots were removed and then stored at _20o C until 
shipped on dry ice to Cornell University Animal Health Diagnostic Center’s Endocrinology 
Laboratory. Low-dose dexamethasone suppression testing was performed similar to 
previously described [194] by taking an afternoon (15:50–18:00 hours) baseline sample, 
administering 0.04 mg/kg BW dexamethasone bolus IM and taking a second sample 19 
hours later. Samples were collected in a gel serum separator tube and frozen at_2o C until 
cortisol analysis. ACTH concentrations 10 minutes post-TRH injection >100 pg/mL and 
cortisol concentrations in excess of 1.0 µg/dL 19 hours following dexamethasone injection 
were considered indicative of PPID and any positive animals excluded. Samples were sent 
to Cornell University’s endocrinology laboratory for determination of insulin, ACTH, and 
cortisol concentrations. Insulin was measured using the Millipore porcine insulin RIA kit 
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(EMD Millipore Corporation, Darmstadt, Germany), ACTH using an automated 
chemiluminescent enzyme immunoassay system (Immulite, Diagnostic Products 
Corporation, Los Angeles, CA) [195], and cortisol using Siemens Immulite Cortisol kit 
(Siemens, Washington, D.C.). All samples and phenotypic measures were collected within 
a period of 2 weeks in the spring of 2014. 
4.2.2. Lipid and plasma lipidome analysis 
Determination of fasting serum triglyceride, leptin, cholesterol, and nonesterified 
fatty acid (NEFA) concentrations were accomplished by Cornell University’s 
endocrinology laboratory. Leptin analysis was carried out using the Millipore Multispecies 
Leptin RIA (EMD Millipore Corporation) and triglycerides, cholesterol, and NEFA 
determined using colorimetric assays with a Roche ModP chemical analyzer (Roche 
Diagnostics, Indianapolis, IN). Plasma samples were sent to Dr. Paul Wood at Lincoln 
Memorial University’s metabolomics laboratory for lipidomics analysis by direct infusion 
electrospray ionization with high resolution (140,000; 0.3–3 ppm mass error) mass 
spectrometry of a large array of targeted lipid metabolites, followed by tandem mass 
spectrometry for further validation [238]. 
4.2.3. Inflammatory Cytokine analysis by Flow Cytometry 
Heparinized blood was used to isolate PBMCs by Ficoll–Paque PlusTM 
(Amersham Biosciences, Piscataway, NJ) gradient centrifugation [197].  For in vitro 
stimulation, 107 PBMC in 1 mL c-RPMI (RPMI-1640; Gibco, Grand Island, NY), with 
2.5% fetal equine serum (Sigma–Aldrich), 100 U/ml penicillin/streptomycin (Sigma), and 
55 mM 2- mercaptoethanol (Gibco) media was incubated at 37oC, 5% CO2 with Brefeldin 
A (10 mg/mL; Sigma) and select wells with the positive control C-RPMI media with 
phorbol 12- myristate 13-acetate (PMA; 25 ng/mL; Sigma) and ionomycin (1 mM; Sigma) 
for 4 hours. Following this, determination of cytokine gene expression was carried out by 
separating aliquots of the cells and placing them in Trizol (Ambion, Austin, TX) to isolate 
RNA (see below). Remaining cells were isolated for flow cytometry assay for interferon 
gamma (IFN-γ) and TNF-α production. Cells were fixed in 2% paraformaldehyde (Sigma) 
and stored overnight at 4oC. After overnight storage, IFN-γ and TNF-α intracellular 
staining was carried out as previously described [198, 239]. After the cells were stained, 
aliquots of cells were resuspended in fluorescence-activated cell sorting flow and flow 
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cytometric acquisition was performed on a FACSCALIBUR (Becton Dickinson, San Jose, 
CA). Determination of the percent of IFN-γ and TNF-α lymphocytes was accomplished 
with the use of CELL QUEST (Becton Dickinson).  
4.2.4. Inflammatory Cytokine analysis by Real Time-PCR 
A modified Trizol method was used to extract total RNA. RNA purity was assessed 
with a NanoDrop Spectrophotometer using 260/280 and 260/230 ratios of ~2.0 and 
between 2.0 and 2.2, respectively. One microgram of RNA was reverse transcribed into 
cDNA, as previously described [198].  In brief, 0.5 µg of each RNA sample and a reverse 
transcription master mix (Promega, Madison, WI) was incubated for 15 minutes at 42oC 
and for 5 minutes at 95oC. Reactions included 4.5 µl cDNA and 5 µl of SensiMix (Bio-
Line, Taunton, MA). Equine-specific, inventoried intron-spanning primers and probes 
(Life Technologies, Carlsbad, CA) were used with Applied Biosystems (Foster City, CA) 
real-time polymerase chain reaction (RT-PCR) (ABI 7900HT) against the following genes: 
housekeeping gene beta-glucuronidase [198, 239] and the following genes: IFN-γ (catalog 
number 4331182), IL-6 (catalog number 4351372), IL-10 (catalogue number 4331182), 
TNF-α (catalog number 4331182), and transferrin (catalog number 4351372). Samples 
were processed in duplicate and incubated for 95oC for 10 minutes. They then underwent 
10 cycles at 95oC for 15seconds and 60oC for 60 seconds. Relative changes in gene 
expression were determined by the CT method  [200], with mean CT of nonpositive 
controls set as the calibrator for all samples. Relative quantity, or RQ, was calculated as 2-
CT and used to express results. 
4.2.5. Data Analysis 
Data were analyzed by SIGMAPLOT version 12.3 (Systat Software Inc., San Jose, 
CA). A mixed model two-way ANOVA was used for each quantitative variable (insulin, 
triglyceride concentrations, and so forth). Fixed effects were set as EMS versus control and 
age. Data that were not normally distributed as determined by a Shapiro–Wilk test were 
log-transformed and resulted in normality. Data were considered statistically significant 
when P < .05. Any outliers identified by a modified Thompson tau technique was removed 
before statistical analysis.  
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4.3. Results 
4.3.1. Lipid and lipidomics analysis 
Triglyceride and leptin concentrations were significantly higher in EMS horses 
compared to controls (Table 4.2). Although there were differences between the two groups 
in triglycerides, only two of the horses (both EMS) fell outside the 0.16 to 0.87 mmol/L 
normal reference range. Cholesterol and NEFA concentrations did not differ between the 
two groups (Table 4.2).  
 
Table 4.2. Serum triglycerides, leptin, cholesterol, and NEFA in horses with EMS and 
controls. 
Biomarker Control EMS P value 
Triglycerides (mmol/L) 0.32 + 0.06 0.62 + 0.04 .002 
Leptin (ng/mL) 3.4 + 1.1 7.5 + 0.8 .012 
Cholesterol (mg/dL) 91.5 + 3.8 91.6 + 2.9 .975 
NEFA (mEq/L) 0.15 + 0.02 0.15 + 0.01 .891 
Abbreviation: EMS, equine metabolic syndrome; NEFA, nonesterified fatty acid. 
Data are presented as least square means, mean + standard error of the mean, n=9 controls 
and n=14 EMS.   
 
Lipidomics analysis revealed that EMS horses had significantly increased plasma 
triacylglycerides, diacylglycerides, monoacylglycerides, and ceramide compared to 
controls. They also had significantly lower plasma sphingomyelins, suflatide, and choline 
ether lipids/plasmalogens (Figure 4.1 and Figure 4.2). No differences were seen between 
the two groups for ethanolamine plasmalogens (data not shown).  
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Figure 4.1. Plasma triacylglyceride (TAG), diacylglyceride (DAG), and monoacylglyceride (MAG) levels. Values are presented as the 
lipid ratio to an internal standard  SEM * indicates significant (p<0.05) differences between EMS and controls. EMS, equine metabolic 
syndrome; SEM, standard error of the mean. 
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Figure 4.2. Plasma sphingomyelin (SM), sulfatide, ceramide, and choline plasmalogen (PlsCh) levels. Values are presented as the lipid 
ratio to an internal standard  SEM * indicates significant (p<0.05) differences between EMS and controls. EMS, equine metabolic 
syndrome; SEM, standard error of the mean.
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4.3.2. Inflammatory Cytokine analysis 
No differences were observed for any of the PBMC values, either for intracellular 
protein production analyzed via flow cytometry or for gene expression analyzed via 
RTPCR (Table 4.3). However, high variability and low power may have influenced results. 
In addition, there was an observed trend for IL-6 and TNF-α RQs, with the EMS horses 
lower compared to controls. 
 
Table 4.3. Flow cytometry and RT-PCR data in horses with EMS and controls. 
Inflammatory marker EMS Control P value 
IFN % gated 8.7 + 2.3 12.8 + 1.8 .208 
IFN geo mean 23.2 + 4.0 24.0 + 5.3 .911 
TNF % gated 20.7 + 4.2 20.9 + 4.9 .978 
TNF geo mean 19.1 + 2.2 17.3 + 3.0 .657 
IFN RQ a 2.8 + 0.1 3.1 + 0.2 .251 
IL10 RQ 10.7 + 4.1 16.2 + 5.2 .441 
IL6 RQ 7.0 + 0.9 9.8 + 1.1 .076 
TNF RQ 19.1 + 3.8 31.0 + 5.1 .098 
Transferrin RQ 2.2 + 0.8 4.6 + 1.0 .101 
Abbreviations: EMS, equine metabolic syndrome; IFN, interferon; IL, interleukin; RT-
PCR, real-time polymerase chain reaction; RQ, relative quantity; TNF, tumor necrosis 
factor. 
Data are presented as least square means, mean + standard error of the mean, n=9 controls 
and n=14 EMS.  
a Indicates log transformed data.  
 
4.4. Discussion 
This study used a group of horses with a naturally occurring form of 
hyperinsulinemia. As expected and similar to humans with MetS, EMS horses had an 
increase in serum triglycerides and leptin, as well as differences in lipid profiles compared 
to controls. These differences, in the plasma lipidome in particular, may have implications 
on cell signaling, membrane fluidity, and inflammation.  
Cell signaling, including activation of inflammatory pathways in multiple cell types (such 
as macrophages, adipocytes, and hepatocytes), and gene expression of proteins involved in 
metabolism and inflammation (such as SOCS-3 and MCP-1) have been shown in humans 
and mice to be influenced by many different factors, including changes in circulating lipids 
[112-114]. Increases in these lipids appear to affect not only inflammation, but insulin 
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resistance as well [114, 228, 240]. In addition to influencing inflammation and insulin 
signaling, bioactive lipids such as ceramide and other sphingolipids can act as intracellular 
messengers and chemoattractants [118, 119], which may contribute to or exacerbate 
alterations in insulin dysregulation or inflammation. Further evidence of the role of the 
lipidome in metabolic dysfunction is demonstrated considering that nutritional 
modification can cause changes in the plasma lipidome, which can result in a decrease in 
markers of inflammation and increase in insulin sensitivity [121, 122]. 
Research has also compared circulating plasma lipidomes with tissue lipid profiles, 
finding that serum lipids correlate best with those lipids in the liver [208]. This same study 
also observed an increase in ceramide in subcutaneous adipose tissue of humans with fatty 
liver disease as well as in skeletal muscle of obese insulin insensitive individuals. Indeed, 
changes in ceramide concentrations in particular seem to play a major role in cell signaling 
and metabolism [113, 115, 116]. Therefore, increased levels of triacylglycerides, 
diacylglycerides, monoacylglycerides, and ceramide in EMS horses point to possible 
alterations in normal cell signaling and contribute to a viscous cycle of insulin resistance 
and lipid dysregulation in these animals. However, further research is warranted to 
understand the relationship between the lipidome and cell signaling in the horse.  
Lipids play a vital role in almost all cell types’ membrane health and function [109], 
particularly sphingomyelin and plasmalogens. Cell membrane health and function has 
direct implications on cell signaling, including influencing voltage-gated ion channels 
[110, 111]. Equine metabolic syndrome horses had decreased levels of these critical 
membrane lipids, which may point to changes in membrane fluidity and possibly impact 
membrane permeability [109-111]. However, results from this work are limited to 
circulating plasma, and more work is needed to understand the potential sources and 
influences of and on these lipids. 
Not only do lipids impact cell signaling and cellular membrane health and function, 
there is considerable data linking lipids to immune function in humans and mice. For 
example, both foreign lipids such as KOD2-lipid A from Escherichia coli [126], and self-
lipids such as gangliosides and glycosphingolipids [127-129] can be recognized as 
antigens. Not only that, but lipids can act a chemoattractants for lymphocytes [118] 
 56 
Although there were differences in plasma lipidomes between EMS and control 
horses, there were no significant differences in markers of inflammation measured in 
PBMCs. However, high levels of variability, in particular with regard to flow cytometry 
data, may have masked differences. It is possible that a larger sample size is required to 
detect these differences. It is also important to note that these results are based on PBMCs 
stimulated with the mitogen PMA, and a different mitogen may yield different results. 
Regardless, EMS animals had numerically lower values for all RT-PCR results and a trend 
for lower IL-6 and TNF-α RQs which could point to changes in cell-mediated immunity. 
These trends may suggest that EMS horses have reduced systemic inflammation compared 
to controls. However, obese humans and mice have been shown to have decreased cell-
mediated immunity compared to lean individuals [134-137], and some studies in obese 
insulin resistant horses have shown increases in inflammatory cytokines compared to 
controls [28, 41]. Considering this, as well as the fact that inflammatory data are from 
stimulated PBMC cultures which are typically more representative of cellular versus 
systemic responses, it is more likely that the trend for reduction in IL-6 and TNF-α RQs is 
due to reduced cell-mediated immunity as opposed to a reduction in systemic 
inflammation. 
It is important to note that work in categorizing the inflammatory state of the obese 
insulin resistant horse has been mixed. Some report an increase in gene expression of IL-
1β and IL-6 in equine nuchal adipose tissue in EMS horses versus controls [41] and others 
an increase in circulating plasma or serum concentrations of TNF-α in hoses with EMS 
[28] as well as in ponies with a history of pasture-associated laminitis [237]. Correlations 
in the horse have likewise been made between insulin sensitivity, obesity, and 
inflammatory cytokines where insulin sensitivity decreases with increasing obesity [8]. 
Also associated with increasing obesity and decreased insulin sensitivity has been elevated 
gene expression of TNF-α, IL- 1, and TNF-p, but no change in or decreasing IL-6 [8, 28]. 
However, these changes in inflammation, such as increasing TNF-α and decreasing IL-6, 
were in some instances age dependent [8]. Changes in inflammation have been more 
frequently observed in adipose tissue compared to circulation and often are only observed 
at the gene expression level [8, 39, 41]. Equine metabolic syndrome horses have also been 
observed to have an increase in macrophage and lymphocyte infiltration in adipocytes, as 
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well as increased adipocyte diameter [28]. In whole blood when increases in inflammation 
were observed in response to endotoxin administration, EMS and control horses both had 
an equivalent increase in gene expression of certain cytokines, however, the elevated 
expression of some, namely IL-6, IL-8, IL-10, and TNF-α persisted for a longer period of 
time in the EMS horses compared to controls [30]. 
Still, more research is needed in this area to determine true differences in 
inflammation in horses with naturally occurring EMS. Future work is also warranted to 
examine different cell types and tissues to further determine the presence inflammation as 
well as the presence of and effect from changes in lipid profiles. In particular, serological 
markers of inflammation should be examined to detect possible levels of low-grade 
systemic inflammation, similar to what is observed in humans with MetS.  
 
4.5. Conclusion 
These data indicate that horses with EMS have abnormal lipidomes compared to 
non-EMS control horses. This may have implications on cell membrane fluidity and cell 
signaling. Data support the idea that horses with metabolic dysfunction and obesity have 
altered lipidomes, similar to humans with MetS. These results allow for a more targeted 
exploration of mechanisms behind EMS, including changes in lipidomes as contributing 
factors to the disorder. 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Sarah E. Elzinga 2017
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CHAPTER 5 DO HORSES WITH EQUINE METABOLIC SYNDROME (EMS) 
HAVE REDUCED IMMUNE RESPONSES TO VACCINATION? 
 
Obesity is an increasing problem in the equine population with recent reports 
indicating that the percentage of overweight horses may range anywhere from 20.6-51%. 
Obesity in horses has been connected to more serious health concerns such as equine 
metabolic syndrome (EMS). The potentially devastating condition laminitis, insulin 
dysregulation (ID), and obesity are the three main characteristics of EMS, making this 
syndrome a serious problem in the equine industry. Ongoing and past research has been 
focused on better characterizing and understanding mechanisms responsible for EMS. 
However, little research has been conducted to determine the effects of EMS on routine 
healthcare of these horses, in particular how they respond to vaccination. It has been shown 
that obese humans and mice have decreased immune responses to vaccination. EMS may 
have similar effects on vaccine responses in horses. If this is the case, these animals may 
be more susceptible to disease, acting as unknown disease reservoirs. Therefore, we 
investigated the effects of EMS on immune responses to routine influenza vaccination.  
Twenty-five adult horses of mixed-sex and mixed-breed (8-21 years old) horses; 13 EMS 
and 12 non-EMS were selected. Within each group, 4 horses served as non-vaccinate saline 
controls and the remaining horses were vaccinated with a commercially available equine 
influenza vaccine. Vaccination (influenza or saline) was administered on weeks 0 and 3, 
and peripheral blood samples taken on week 0 prior to vaccination and on weeks 1, 2, 3, 4, 
and 5 post vaccination. Blood samples were used to measure hemagglutination inhibition 
(HI) titers and equine influenza specific IgGa, IgGb, and IgGT levels. Blood samples were 
also used to isolate peripheral blood mononuclear cells (PBMCs) for analysis of cell 
mediated immune (CMI) responses via real-time polymerase chain reaction (RT-PCR). All 
horses receiving influenza vaccination responded with significant increases (P < 0.05) in 
HI titers, and IgGa and IgGb EIV specific antibodies following vaccination compared to 
saline controls. EMS did not significantly affect (P > 0.05) humoral immune responses as 
measured by HI titers or IgG antibody isotypes to influenza vaccination. There was an 
effect of metabolic status on CMI responses, with influenza vaccinated EMS horses having 
lower gene expression of IFN-γ (P = 0.02) and IL-2 (P = 0.01) compared to vaccinated 
non-EMS control horses. Given these results, it appears that while metabolic status does 
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not influence humoral responses to an inactivated influenza vaccine in horses, horses with 
EMS appear to have a reduced CMI response to vaccination compared to metabolically 
normal, non-EMS control horses. 
 
5.1. Introduction 
An obesity epidemic is emerging in the horse population, with reports of 45% of 
319 randomly selected horses classified as “fat” or “very fat” [7]. Still others have reported 
that of 300 horses, 54% were overweight or obese [3, 49]. Of these overweight or obese 
horses, 18% were hyperinsulinemic compared to only 1.4% of lean horses. While there is 
information regarding the number of horses affected by obesity, the prevalence of 
metabolic dysfunction in the horse is unknown. Both obesity and metabolic dysfunction 
are considered risk factors for the development of laminitis in the horse [14, 15]. All three 
of which (obesity, metabolic dysfunction, and laminitis) are components of equine 
metabolic syndrome (EMS). 
EMS is closely related to MetS (metabolic syndrome) in humans. Associated 
characteristics of MetS include: adipose tissue dysfunction, insulin resistance, 
inflammation, and hypertension [207, 208]. Equine metabolic syndrome was defined in a 
2010 ACVIM consensus statement [23]. The statement ascribes three major characteristics 
to horses with EMS; general or regional (fatty deposits around the neck, tail head, behind 
the shoulder, or in the mammary gland region) adiposity, an abnormal glycemic or 
insulinemic response upon challenge, and a history of or predisposition to laminitis. 
Hypertriglyceridemia, dyslipidemia, hyperleptinemia, arterial hypertension, abnormal 
reproductive cycling in mares, and an increase in systemic makers of inflammation 
associated with obesity are also considered possible hallmarks of EMS [23]. 
Considering correlations between obesity, insulin resistance, systemic 
inflammation, and the immune response [31, 130, 131], it begs the question; is there an 
effect of obesity and metabolic dysfunction on the immune response to vaccination in 
horses? Work in naïve mice has indicated that obesity significantly reduces antibody 
responses and antibody neutralizing capability to influenza vaccination [134]. In response 
to a hepatitis B vaccine, diet-induced obese mice exhibited an increased proliferation of T 
and B cells, increased levels of IFN-γ and TNF-α, but decreased levels of hepatitis specific 
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antibody and hepatitis specific T cell activation [135]. Type 1 diabetes in adult humans has 
also been associated with a risk for non-responsiveness to vaccination [136], and obesity 
is considered a risk factor for low levels of circulating antibody >3ys post hepatitis 
vaccination [137]. A human influenza vaccination study [138] positively correlated body 
mass index with higher initial IgG antibody responses, however 12 months following 
vaccination a greater body mass index was correlated with a greater decline in influenza 
antibody titers. In vivo, investigators also found that obese individuals had lower 
expression of functional proteins and decreased activation of their CD8+ T-cells. 
Additionally, both adult and elderly obese individuals had impaired B cell function in 
response to influenza vaccination [241] and obese adult human PBMCs upon viral 
challenge with influenza, had a lower production of IFN-γ  by their γδ T cells compared to 
lean controls [242]. In spite the evidence in humans and mice linking increased adiposity 
to an impaired immune response to vaccination, there has been no work to date regarding 
response to vaccination in the EMS horse. 
Therefore, this study was designed to compare humoral and cell-mediated immune 
(CMI) responses to influenza vaccination of EMS and non-EMS horses, with the 
hypothesis that EMS horses would have a decreased immune response to vaccination 
compared to metabolically normal controls. 
 
5.2. Materials and Methods 
Horses of mixed-breed and mixed-sex (ranging in age from 8-21 years old) were 
utilized from the University of Kentucky’s existing Department of Veterinary Science 
Main Chance herd. Criteria to determine EMS was as previously described; insulin 
resistance, regional or general adiposity, and a predisposition to or history of laminitis [13, 
23]. Two weeks prior to the start of the study, EMS and non-EMS horses were screened 
for insulin resistance, existing HI influenza antibody titers, and to insure that they did not 
have Pituitary Pars Intermedia Dysfunction (PPID). PPID determination was established 
using both dexamethasone suppression and Thyroid Releasing Hormone (TRH) testing as 
previously described [191-194]. This was deemed especially important by investigators, as 
horses with PPID may have similar metabolic dysfunction as those with EMS [11]. Horses 
 61 
were housed in a dry lot with ad libitum access to water, trace mineralized salt blocks, and 
a mixed-grass hay.  
5.2.1. Phenotype determination 
A portable agriculture scale (model 700, Tru Test Inc., Mineral Wells, TX) was 
used to determine body weight. General adiposity was measured by body condition scoring 
(BCS). BCS was established by three trained investigators using the 1Henneke scoring 
system [186]. The same trained individuals also performed cresty neck scoring (CNS) on 
horses with the 0-5 scale system established by Carter et al. [187] to measure regional 
adiposity. To ascertain the presence of insulin resistance, an oral sugar test was performed; 
following overnight fasting and 0800-1100 EST serum sample collection, 0.15 ml/kg of 
Karo Light Corn syrup was administered orally, and a second serum sample collected 60 
min later [13, 23]. Serum samples were kept at -20º C until sent on dry ice to Cornell 
University’s endocrinology lab for insulin determination. A fasting insulin level of >20 
μIU/mL was considered indicative of hyperinsulinemia, and an increased insulin 
(>60μU/mL) 60 minutes post administration of oral sugar classified as insulin resistance 
[13, 23]. Horses were pre-screened and tested via HI as described below to establish IgG 
antibody levels specific to influenza. All animal methods were approved by the University 
of Kentucky’s IACUC (institutional animal care and use committee). 
5.2.2. Vaccination and Sample Collection 
Thirteen EMS and 12 non-EMS horses were used in this study. Within each 
category (EMS vs non-EMS controls) horses were blocked by pre-existing antibody titers 
(HI titers) and systematically allocated to one of the following treatment groups: 1) 
vaccinate (Fluvac InnovatorTM, Zoetis, vaccine containing KY/97) (n=8 non-EMS control 
horses or n=9 EMS horses) or 2) saline controls (n=8, 4 horses within each metabolic 
group). There was no significant difference in median age between vaccine group vs saline 
(P = 0.55, vaccine group median age 11 years; IQR 9.5 – 16 years, and saline median 13 
years; IQR 11.3 – 16.3 years), Nor was there a significant difference in median age between 
EMS group vs non-EMS control horses (P = 0.4, EMS group median age 13 years; IQR 10 
– 18 years vs non-EMS control group median 12.5 years; IQR 9.3 – 14.8 years).  
 Blood collection was carried out via jugular venipuncture for all time points. For 
baseline and phenotypic determination, serum and plasma sample collection was 
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performed following fasting on day -14. As some horses had an unknown vaccine history 
as well as to determine if a second vaccination would result in additional effect on immune 
responses measured, horses received an inactivated influenza vaccination or saline at both 
weeks 0 and 3. Peripheral serum and heparinized blood samples were taken on week 0 prior 
to vaccination and on weeks 1, 2, 3, 4, and 5 post vaccination. Throughout the study horses 
were monitored for vaccine site reactions.  
5.2.3. Equine Influenza Virus (EIV)-Specific Antibody Assays  
5.2.3.1. HI assay 
Humoral immune total IgG responses were determined using serum samples from 
all sampling time points by HI (hemagglutination inhibition) assay with ether treated 
KY/97 equine influenza virus, as previously described [243]. 
5.2.3.2. ELISA assay   
Serum samples were also used as previously described [197] in a modified ELISA 
procedure to determine influenza specific antibody isotype responses to vaccination. The 
assay was carried out as follows: purified influenza virus (Eq/KY/97; 10 HA units per well) 
was used to coat a 96-well polystyrene plate (IMMULON®, Dynatech Laboratories Inc., 
Chantilly, VA) and incubated at 4°C overnight. The next morning, plates were washed 
(PBS/0.05% TWEEN®-20 (PBS-T; Sigma, St. Louis, MO)) and blocked (2% non-fat dried 
milk powder in PBS-T (Sigma)) at 37°C for 1 hr. Serum samples from an influenza virus 
hyperimmune horse were serial diluted and used to create a standard curve. Experimental 
serum samples were diluted in a volume of PBS-T to ensure that OD values were within 
the standard curve and plates were incubated at 37°C for 90 min. Plated were washed and 
incubated at 37°C for 1 hr with IgGa (CVS 40), IgGb (CVS 39), and IgG(T) (CVS 48) 
specific monoclonal antibodies. After being washed again, an incubation at 37°C for 1 hr 
took place with horseradish peroxidase-conjugated goat-anti-mouse IgG antibody (Jackson 
Laboratories Inc., West Grove, PA). Following the incubation, plates were washed and a 
substrate (KPL, Gaithersburg, MD) used for development. Development was stopped by 
the addition of a stop solution (KPL). A 450 nm optical density was determined with the 
use of an ELISA reader (BioRAD, Hercules, CA). Serum antibody concentrations relative 
to the standard curve were calculated and are represented as ELISA units.  
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5.2.4. EIV-specific CMI Assays 
5.2.4.1. Peripheral blood processing 
Heparinized blood was used to isolate peripheral mononuclear cells (PBMCs) by 
Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) gradient centrifugation 
[197].  For EIV in vitro stimulation, aliquots of 107 PBMC were plated in 1 ml c-RPMI 
[RPMI-1640 (Gibco, Grand Island, NY); supplemented with 2.5% fetal equine serum 
(FES; Sigma–Aldrich, St. Louis, MO), 100 U/ml penicillin/streptomycin (Sigma), and 55 
mM 2-mercaptoethanol (Gibco) media. Select aliquots were incubated at 37 °C, 5% CO2 
for 45 min with influenza virus homologous strain used in the vaccine (KY/Eq/97).  After 
incubation all flu simulated cells were pelleted by centrifugation at 500 × g for 5 min to 
remove the virus inoculum. All virus-stimulated and unstimulated PBMC were 
resuspended with c-RPMI.  Brefeldin A (10 mg/ml; Sigma) was added to all wells. For all 
time points and horses an addition well was (non-flu stimulated) was stimulated with 
phorbol 12-myristate 13-acetate (PMA; 25 ng/ml; Sigma) and ionomycin (1 mM; Sigma) 
to serve as a positive control. Cells were incubated for an additional 4 hrs. Following this, 
determination of cytokine gene expression was carried out by separating an aliquot of the 
cells and placing them into Trizol (Ambion) to isolate RNA (see below).  
5.2.4.2. Real Time-PCR  
A modified Trizol method was used to extract total RNA.  One µg of RNA was 
reverse transcribed into cDNA, as previously described [197].  In brief; 1 µg of each RNA 
sample and a reverse transcription master mix (Promega, Madison, WI) was incubated for 
15 min at 42oC and for 5 min at 95oC. Reactions included 5µl cDNA and 20µl of master 
mix. Master mix included; 6.25µl nuclease-free water (Qiagen), 1.25µl primer/probe 20X 
assay mix (Applied Biosystems, Foster City, CA), and 12.5µl TaqManTM (Applied 
Biosystems). Equine-specific, intron-spanning primers and probes were used with Applied 
Biosystems Real-Time PCR (ABI 7900HT) against the following genes: Housekeeping 
gene beta-glucuronidase (β-gus) and CMI induced cytokine genes; interferon gamma (IFN-
γ), GrzB, and Perforin [244]. Samples were processed in duplicate and incubated for 95oC 
for 10 min. They then underwent 10 cycles of 95oC for 15s and 60oC for 60s. Relative 
changes in gene expression were determined by the CT method [200], with mean CT 
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for week 0 from all horses set as the calibrator for all samples. Relative quantity, or RQ, 
was calculated as 2-CT and was used to express results. 
5.2.5. Statistical analysis   
Data were analyzed utilizing SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA). 
Data were analyzed with proc mixed with the repeated measure set at time and subject as 
horse ID. Horse ID, metabolic status, vaccination vs saline, and time point (week) were set 
as fixed effects and all possible interactions analyzed. A first-order autoregressive 
variance/covariance structure was used the statistical model.  Results are expressed as least 
square means ± standard error of the mean (SEM). Normality was assessed using 
studentized residuals with a visual analysis as well as skew (>2) and kurtosis (>7). Non-
normal data were natural log transformed and resulted in normality.   
 
5.3. Results 
Phenotypic data, including OST results used for EMS determination are presented 
in Table 5.1. As expected, EMS horses had a greater CNS (P = 0.002), and insulin (both 
pre (P = 0.003) and post (P < 0.001) oral sugar administration) compared to non-EMS 
control horses. However, EMS and non-EMS control horses did not different in BCS (P = 
0.227) or weight (P = 0.514). 
 
Table 5.1. Phenotypic and endocrine data for EMS and non-EMS horses. 
Phenotypic measure EMS horses Non-EMS horses 
Basal Insulin (µIU/ml) 37.4 ± 4.7 b 13.3 ± 5.4 a 
Insulin 60 min post oral sugar 
administration (µIU/ml) 
81.6 ± 5.8 b 23.8 ± 6.5 a 
BCS 6.9 ± 0.3 6.6 ± 0.2 
CNS 3.0 ± 0.3 b 1.6 ± 0.2 a 
Weight (kg) 588.1 ± 22.1 604.4 ± 18.6 
Phenotypic measures and endocrine data in EMS (n=13) versus non-EMS (n=12) horses. 
Results are presented as least square means (± SEM). Within a row, differences (P < 0.05) 
are represented by differing superscripts. 
 
5.3.1. Antibody responses 
 All horses that received influenza vaccination had a significant antibody response 
to vaccination as compared to those given saline (P < 0.05) measured by HI titers against 
KY/97 (Figure 5.1). Horses given saline had lower HI titers compared to vaccinated horses 
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for all weeks post vaccination. Vaccinated horses at week 0 had lower HI titers compare to 
vaccinated horses at all other time points, whereas saline horses did not differ over time. 
Vaccinated horses at week 4 had higher HI titers compared weeks 2, 3, and 5. There was 
not effect of metabolic status on HI titers in response to vaccination.   
 
 
Figure 5.1. HI titers over time in vaccinated EMS horses (n = 9), vaccinated control horses 
(n = 8), EMS horses given saline (n = 4), and control horses given saline (n = 4). Results 
are presented as least square means (± SEM). Differences (P < 0.05) within time point 
between all vaccinated horses and all given saline are represented by *. Within all 
vaccinated horses differences between time points are represented by differing alphabetic 
superscripts. There were no significant differences over time point within all horses given 
saline. Arrows represent time points of vaccination or saline administration. 
 
 IgGa isotype flu specific antibody responses are represented in Figure 5.2. All 
vaccinated horses responded to vaccination, with higher levels of IgGa compared to horses 
given saline at all weeks post vaccination (Figure 5.2). Vaccinated horses were lower at 
week 0 compared to all other weeks. In addition, vaccinated horses were lower at week 3 
compared to weeks 1, 2, 4, and 5. Again, there was no effect of metabolic status on flu 
specific IgGa isotype antibody responses.  
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Figure 5.2. IgGa isotype flu specific antibody responses over time in vaccinated EMS 
horses (n = 9), vaccinated control horses (n = 8), EMS horses given saline (n = 4), and 
control horses given saline (n = 4). Results are presented as least square means (± SEM). 
Differences (P < 0.05) within time point between all vaccinated horses and all given saline 
are represented by *. Within all vaccinated horses differences between time points are 
represented by differing alphabetic superscripts. There were no significant differences over 
time point within all horses given saline. Arrows represent time points of vaccination or 
saline administration. 
 
Similar to HI and IgGa antibody results and regardless of metabolic status, all 
vaccinated horses responded to vaccination in respect to their flu specific IgGb isotype 
antibody responses as compared to horses given saline (Figure 5.3). Horses given saline 
were lower in IgGb antibody compared to vaccinated horses for all weeks following 
vaccination, with the exception of week 1. Vaccinated horses were lower at week 0 
compared to all other weeks. 
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Figure 5.3. IgGb isotype flu specific antibody responses over time in vaccinated EMS 
horses (n = 9), vaccinated control horses (n = 8), EMS horses given saline (n = 4), and 
control horses given saline (n = 4). Results are presented as least square means (± SEM). 
Differences (P < 0.05) between all vaccinated horses and all given saline are represented 
by *. Within all vaccinated horses differences between time points are represented by 
differing alphabetic superscripts. There were no significant differences over time point 
within all horses given saline. Arrows represent time points of vaccination or saline 
administration. 
 
There were no significant differences for time point, vaccine versus saline, or 
metabolic status, nor were there any significant interactions for IgGT isotype flu specific 
antibodies (data not shown). For all measures of humoral responses to vaccination, with 
the exception of IgGT isotype responses, vaccinated horses responded to vaccination 
compared to saline controls. There was, however, no effect of metabolic status on antibody 
responses to vaccination.  
5.3.2. Flu specific cell mediated (CMI) responses 
For granzyme B flu stimulated gene expression (Figure 5.4), there was a significant 
overall effect of vaccination (P = 0.023), with horses given saline lower in granzyme B 
compared to vaccinated horses. There was also an overall effect of time (P = 0.018); with 
horses having higher gene expression at weeks 2 and 3 compared to week 0. In addition, 
horses were higher at weeks 2, 3, and 5 compared to week 4. There were no differences or 
interactions for any variable for PMA stimulated granzyme B gene expression, data not 
shown. 
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Figure 5.4. Relative quantity (RQ) of granzyme b gene expression for flu stimulated 
PBMCs (A) in vaccinated horses (n=17) and in horses given saline (n=8) and (B) over time 
for all horses (n = 25). Results are presented as least square means (± SEM). Differences 
(P < 0.05) between vaccinated horses and those given saline are represented by * and 
differences between time points are represented by differing alphabetic superscripts. 
Arrows represent time points of vaccination or saline administration. 
 
Flu stimulated IFN-γ gene expression (Figure 5.5) was different between 
vaccinated horses and horses given saline, with horses given saline having lower 
expression compared to vaccinated horses (P = 0.032). In addition, there was an overall 
time point difference (P = 0.002). Horses were higher in flu stimulated IFN-γ gene 
expression at weeks 1, 2, and 3 compared to weeks 0 and 4. For PMA stimulated IFN-γ 
gene expression there were observed interactions (Figure 5.6). There was a metabolic status 
by vaccine vs saline (P = 0.019) interaction. Non-EMS control horses administered saline 
were lower in IFN-γ gene expression compared to non-EMS control horses administered 
vaccine. Non-EMS control vaccinated horses were higher compared to EMS horses 
regardless of vaccination status. In addition, there was a significant metabolic status by 
time point (P = 0.015) interaction, with non-EMS control horses lower in gene expression 
at weeks 0, 1, 2, and 3 compared to weeks 4 and 5. Non-EMS control horses at weeks 1 
and 3 were higher compared EMS horses at those time points in IFN-γ gene expression. 
EMS horses were higher in gene expression at week 0 compared to weeks 1, 3, 4, and 5, 
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and higher at week 2 compared to weeks 1 and 5. Additionally, EMS horses at week 4 were 
higher compared to week 5.   
 
 
Figure 5.5. Relative quantity (RQ) of IFN-γ gene expression for flu stimulated PBMCs 
(A) in vaccinated horses (n = 17) and in horses given saline (n = 8) and (B) over time for 
all horses (n = 25). Results are presented as least square means (± SEM). Differences (P < 
0.05) between vaccinated horses and those given saline are represented by * and 
differences between time points are represented by differing alphabetic superscripts. 
Arrows represent time points of vaccination or saline administration. 
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Figure 5.6. Relative quantity (RQ) of IFN-γ gene expression for PMA stimulated PBMCs (A) in vaccinated horses (EMS n = 9; non-
EMS control n = 8) and in horses given saline (EMS n = 4; non-EMS control n = 4) and (B) over time in EMS (n = 13) vs non-EMS 
control horses (n = 12). Results are presented as least square means (± SEM). Differences (P < 0.05) between EMS vs non-EMS control 
horses within time point are represented by * and differences between time points within non-EMS control horses and for (A) are 
represented by differing alphabetic superscripts. Differences between time points within EMS horses are represented by differing 
numeric superscripts. Arrows represent time points of vaccination or saline administration. 
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Vaccinated horses were not significantly different from horses given saline for flu 
stimulated IL-2 gene expression (P = 0.461; data not shown). However, there was an 
overall effect of metabolic status, with non-EMS control horses higher compared to EMS 
horses (non-EMS control horses ln RQ = 1.28 ± 0.13, EMS horses ln RQ = 0.83 ± 0.11; P 
= 0.016). There was also an effect of time, with horses at week 0 lower in IL-2 gene 
expression compared to horses at week 3. Horses at week 1 were also lower compared to 
weeks 2 and 3, and horses at week 3 were higher compared to weeks 4 and 5. Similar to 
PMA stimulated IFN-γ gene expression, there were significant interactions for PMA 
stimulated IL-2 gene expression (Figure 5.7). There were significant interactions for 
metabolic status by vaccine vs saline (P = 0.013) and metabolic status by time point (P = 
0.029). The only significant pairwise comparison for the metabolic status by vaccination 
status interaction involved vaccinated horses, where non-EMS controls were higher in 
PMA stimulated IL-2 gene expression than EMS horses. Metabolic status by time point 
differences showed non-EMS control horses to be higher at week 0 compared weeks 1, 4, 
and 5. Non-EMS control horses at week 1 were also higher compared to weeks 4 and 5. 
Additionally, at week 1 non-EMS control horses were higher in IL-2 gene expression 
compared to EMS horses. EMS horses were lower in gene expression at week 0 compared 
to all other time points, and EMS horses at week 5 were lower than week 2.
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Figure 5.7. Relative quantity (RQ) of IL-2 gene expression for PMA stimulated PBMCs (A) in vaccinated horses (EMS n = 9; non-
EMS control n = 8) and in horses given saline (EMS n = 4; non-EMS control n = 4) and (B) over time in EMS (n = 13) vs non-EMS 
control horses (n = 12). Results are presented as least square means (± SEM). Differences (P < 0.05) between EMS vs non-EMS control 
horses within time point are represented by * and differences between time points within non-EMS control horses and for (A) are 
represented by differing alphabetic superscripts. Differences between time points within EMS horses are represented by differing 
numeric superscripts. Arrows represent time points of vaccination or saline administration. 
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Perforin gene expression (data not shown) for flu stimulated lymphocytes had a 
significant vaccine vs saline by time point interaction (P = 0.026). Horses given saline had 
a lower gene expression at week 5 compared to all other weeks. Vaccinated horses were 
highest in perforin gene expression at weeks 1 and 4 compared to week 2. For gene 
expression of perforin in PMA stimulated lymphocytes, there was a significant metabolic 
status by time point interaction (P = 0.007; data not shown). Non-EMS control horses at 
weeks 0, 1, and 3 were higher compared to week 2, and higher at week 3 compared to week 
5. EMS horses at weeks 0, 1, and 4 were higher in perforin gene expression compared to 
week 5. Within time point there were no differences between EMS and non-EMS control 
horses. 
There was an observed metabolic status by time point interaction for flu stimulated 
lymphocyte TNF-α gene expression (P = 0.009; data not shown). Non-EMS control horses 
were lower at week 0 compared to weeks 1, 3, 4, and 5. Non-EMS control horses at weeks 
1 and 3 were higher compared to week 2. Similar to perforin gene expression, within time 
point there were no differences between EMS and non-EMS control horses. There was 
likewise a metabolic status by time point interaction for PMA stimulated lymphocyte TNF-
α gene expression (P = 0.032; Figure 5.8). Non-EMS control horses were highest at week 
0 compared to weeks 2, 4, and 5, and at week 1 were higher compared to weeks 2 and 5. 
Non-EMS control horses were higher at week 3 compared to weeks 2, 4, and 5. Non-EMS 
control horses at week 4 were also higher compared week 5. At week 3, non-EMS control 
horses were higher compared to EMS horses at that same time point. EMS horses were 
highest in TNF-α gene expression at week 0 compared to weeks 2 and 5.  EMS horses were 
also higher weeks 1 and 4 compared to week 5.  
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Figure 5.8. Relative quantity (RQ) of TNF-α gene expression for PMA stimulated PBMCs 
over time in EMS (n = 13) vs non-EMS control horses (n = 12). Results are presented as 
least square means (± SEM). Differences (P < 0.05) between EMS vs non-EMS control 
horses within time point are represented by * and differences between time points within 
non-EMS control horses are represented by differing alphabetic superscripts whereas 
differences between time points within EMS horses are represented by differing numeric 
superscripts. Arrows represent time points of vaccination or saline administration. 
 
Overall and time point dependent effects of vaccination were seen for lymphocyte 
gene expression of flu stimulated granzyme B, flu and PMA stimulated IFN-γ, PMA 
stimulated IL-2, and flu stimulated perforin with vaccinated horses higher than controls. 
There were also both overall and time point dependent effects of metabolic status for 
lymphocyte gene expression of PMA stimulated IFN-γ, flu and PMA stimulated IL-2, 
PMA stimulated perforin, and flu and PMA stimulated TNF-α with EMS horses lower 
compared to non-EMS control horses.  
 
5.4. Discussion 
All horses responded to vaccination regardless of metabolic status as determined 
by influenza specific antibody responses. Vaccinated horses had an increase in HI titers, 
and IgGa and IgGb antibody isotypes following both the initial (week 0) and the second 
administration (week 3) of Fluvac InnovatorTM, whereas horses given saline did not change 
over time. There was, however, no effect of metabolic status on humoral immune measures. 
It is possible that obesity plays a larger role in the immune process as compared to 
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metabolic status. EMS horses all met the three criteria necessary for classification as EMS. 
However, some had increased regional but little to moderate general obesity. Indeed, 
although EMS horses had a significantly higher CNS (a measure of regional adiposity) 
compared to non-EMS control horses, they did not differ in BCS (a measure of general 
adiposity). In naïve, diet induced obese mice, differences in primary humoral immune 
responses to influenza vaccination [134, 135] have been observed. This has similarly been 
observed in humans where type 1 diabetes was associated with a risk for non-
responsiveness to influenza vaccination [136], however investigators found no differences 
in humoral immune responses due to metabolic status. Obesity in humans was a risk factor 
>3ys post hepatitis vaccination for lower circulating levels of antibody [137] and body 
mass index, but not diabetes status, was positively correlated with a greater decline in 
influenza antibody titers 12 months following influenza vaccination [138]. A greater body 
mass index in a group of non-diabetic women given a HIV vaccine was associated with 
decreased HIV specific IgG titers and obese women had a greater likelihood to be non-
responders [245]. Further, independent from age and in response to influenza vaccination 
obese humans had lower HI titers, decreased percentage of memory B cells, increased B 
cell production of the pro-inflammatory IL-6, and decreased B cell production of the anti-
inflammatory IL-10 [241]. Also, the number of human γδ T cells is negatively correlated 
with obesity and obese individuals γδ T cells produce less IFN-γ upon in vitro influenza 
challenge compared to lean controls [242]. It is important to note that for human studies 
with influenza vaccine, similar to this work, participants presumably have been previously 
exposed to influenza and responses to vaccination are primarily recall responses.  
Inactivated or killed vaccines, similar to the inactivated vaccine used in this study, 
tend to produce a robust humoral immune response, but a weaker CMI response [246]. 
This may have contributed to the results seen here considering that differences between 
EMS and non-EMS controls were observed not for humoral but for CMI responses. For 
this study, results for CMI responses when comparing vaccinated horses to those given 
saline were few. An overall effect of vaccination was seen for flu stimulated PBMC 
granzyme B and IFN-γ gene expression, and a vaccine vs saline by time point interaction 
for perforin. Vaccinated horses were higher overall for granzyme B and IFN-γ compared 
to horses given saline. Within time point, there were no differences between vaccinated 
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horses and those given saline for flu stimulated perforin gene expression, however 
vaccinated horses did have increases in gene expression at weeks 1 and 4 (the weeks 
following vaccine administration). 
There was an overall effect of metabolic status for flu stimulated PBMC IL-2 gene 
expression with EMS horses lower compared to non-EMS controls. There was also an 
interaction between metabolic status and time point for flu stimulated PBMC TNF-α gene 
expression. Although within time point there were no differences due to metabolic status, 
the non-EMS control horses had significant changes over time in TNF-α whereas the EMS 
horses did not. There were several interactions between metabolic status and vaccination 
status and/or time point for PMA stimulated PBMC gene expression of IFN-γ, IL-2, 
perforin, and TNF-α. EMS horses were lower in gene expression of IFN-γ at weeks 1 and 
3 compared to non-EMS controls. Also, EMS horses were lower in IL-2 gene expression 
at week 1 compared to non-EMS controls. Vaccinated EMS horses were overall lower in 
IFN-γ and IL-2 compared to vaccinated non-EMS control horses.  
Lower gene expression of IL-2 in flu and PMA stimulated PBMCs indicate that 
EMS horses may have a decrease in lymphocyte proliferation [247] compared to 
metabolically normal controls. Pro-inflammatory cytokines TNF-α and IFN-γ play an 
important role in antigen-specific CMI responses [248, 249]. A lack of change in TNF-α 
gene expression in flu stimulated PBMCs and over time in EMS horses and lower gene 
expression of IFN-γ in PMA stimulated PBMCs at weeks 1 and 3 compared to non-EMS 
control horses, further points to a reduced CMI response to vaccination in these animals. 
Further supporting a reduced CMI in EMS horses were the differences in PMA stimulated 
PMBCs between vaccinated EMS and vaccinated non-EMS control horses for IFN-γ and 
IL-2, with vaccinated non-EMS controls significantly higher compared to vaccinated EMS 
horses.  
These data indicate that the EMS horse is able to produce a robust humoral immune 
response to vaccination. However, their ability to mount a CMI response may be reduced 
in comparison to horses without metabolic dysfunction, and requires further study. In 
particular, the impact of obesity as opposed to metabolic status, as well as a better 
characterization of CMI responses to vaccination in horses with metabolic dysfunction 
utilizing an attenuated live or other vaccine able to induce stronger CMI responses should 
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be investigated. Furthermore, given data in other species and indications here of potential 
differences in CMI responses, vaccine efficacy and duration of immunity in the obese or 
EMS horse should be evaluated to further understand the effects of theses parameters on 
immune responses. 
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CHAPTER 6 EFFECTS OF SUPPLEMENTATION WITH YEAST CELL WALL ON 
METABOLIC AND INFLAMMATORY MEASURES IN INSULIN 
DYSREGULATED HORSES  
 
Insulin dysregulation (ID) is a common problem associated with serious health 
concerns in the equine, however its pathogenesis and underlying mechanisms are not well 
understood. There has been increasing attention on the role of the gut in metabolic 
dysfunction, including the influence of an oral glycemic or meal challenge on both 
metabolic and inflammatory processes. Therefore, the objective of this study was to 
determine the effects of supplementation with a mannan-rich fraction of the yeast cell wall 
(ActigenTM) on metabolic and inflammatory measures in ID horses compared to non-ID 
controls. To accomplish this, we supplemented 24 ID and non-ID control horses (13 ID 
and 11 non-ID, 4 non-supplemented horses within each metabolic group) with 
supplemented horses receiving 6 g/horse/day of ActigenTM for 45 days, with blood samples 
collected via jugular venipuncture both pre and post oral glycemic challenge (time point) 
as well as pre and post the 45-day supplementation period (period). Samples were analyzed 
for serum glucose and insulin concentrations, circulating and peripheral blood 
mononuclear cells (PBMCs) inflammatory markers at both the protein and gene expression 
levels, and circulating plasma endotoxin concentrations were established. Metabolic results 
indicated that serum glucose and insulin increased following the supplementation period 
and in response to oral glycemic challenge, with the ID horses having a greater increase 
compared to non-ID controls (P < 0.04). There was no effect of treatment on either serum 
glucose or insulin concentrations. Few effects of metabolic status or treatment on 
inflammatory markers were observed, however non-supplemented horses or non-ID 
controls often had a decrease in markers of inflammation at both the protein and gene 
expression levels in response to the oral sugar challenge, as opposed to ID horses. There 
were, however, multiple inflammatory parameters affected by period, including LPS 
stimulated lymphocyte or whole blood gene expression and lymphocyte inflammatory 
protein as well as circulating LPS plasma concentrations. Overall these results indicate that 
supplementation had minimal effects on metabolic and inflammatory responses, however 
these variables were affected by both oral sugar challenge and period. In addition, it appears 
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that metabolic and inflammatory responses of horses with ID may be especially sensitive 
to changes in either metabolic stimuli or season, however further investigation regarding 
the influence of these factors is needed. 
 
6.1. Introduction 
Insulin dysregulation (ID) is a major problem in the equine industry, particularly as 
it predisposes the horse to the development of laminitis, which can be a career or even life 
ending condition [12, 14, 15]. However, underlying mechanisms of ID remain unclear. 
Some have proposed a role of inflammation in ID, but results concerning this have been 
mixed with reports of both increases in circulating or tissue markers of inflammation [28, 
40, 41] as well as no differences or a trend for lower circulating markers of inflammation 
[31, 42]. This may in part be explained as in some cases ponies were utilized instead of 
horses, or ID was induced rather that naturally occurring. In addition, many studies were 
carried out in a fasted state. Establishing fed versus fasted state becomes important 
considering the role of the gut in metabolic regulation and hormonal control [250, 251]. 
Further, it has been demonstrated in humans and mice that inflammatory markers increase 
postprandially following a meal high in fat or high in both fat and sugar/starch [43-45]. 
This has similarly been observed in the horse in response sugar/starch given either as a 
meal or orally administered  [46, 47].  
Yeast cell wall supplementation has been shown to reduce inflammation in dairy 
cows [95], poultry [96], humans [97-99], and horses [100, 101]. Supplementation with 
yeast cell wall has also influenced metabolic parameters in cattle [102], and reduced 
circulating triglyceride and cholesterol levels in poultry [103, 104]. The mannan 
oligosaccharides (MOS) found in the yeast cell wall modulate the immune response by 
binding to mannose-specific lectin on gram negative bacteria, thus preventing it from 
binding to intestinal epithelial cells [252, 253]. Concentrations of lipopolysaccharide 
(LPS), a component of the outer membranes of gram negative bacteria, have been shown 
to be reduced following MOS supplementation in pigs [105], and modulated the 
inflammatory response to LPS challenge in chickens [254]. Given the fact that there have 
been multiple studies showing probable links between inflammation and metabolic 
dysfunction [127, 139, 140], there is ample evidence to further investigate not only these 
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relationships in the horse with ID, but also possible ways to improve these parameters. 
Therefore, the aim of this study was to further establish the role of inflammation in the ID 
horse in response to an oral sugar challenge as well as the ability of the gut modulating 
product ActigenTM to modify circulating LPS concentrations, and improve metabolic and 
inflammatory parameters in these animals. 
 
6.2. Materials and methods 
6.2.1. Horse selection and study design  
Twenty-four horses of mixed-breed and mixed-sex, both ID (n=13) and non-ID 
controls (n=11) [12], were selected from the University’s Department of Veterinary 
Science Woodford County herd for use in this study. ID was established three months prior 
to the start of the study with an oral sugar test (OST) as previously reported [13, 47], with 
hyperinsulinemia diagnosed as a fasting insulin level of > 20 μIU/mL and a concentration 
of insulin > 60μU/mL 60 minutes post OST considered further indicative of ID. General 
and regional adiposity were assessed for all horses by body condition scoring (BCS; based 
on the 1-9 Henneke scoring system [186]) and cresty neck scoring (CNS; based on the 0-5 
Carter et. al. scoring system [187], respectively. Screening results presented in Table 6.1. 
Of the 13 ID horses (7 geldings and 6 mares), 4 were of mixed breed, 2 were Warmbloods, 
2 were Standardbred or Standardbred cross, 2 were walking horses, 1 was a Thoroughbred 
cross, 1 a Morgan, and 1 a Quarter Horse. Of the 11 non-ID control horses (6 geldings and 
5 mares), 5 were of mixed breed, 4 were Thoroughbreds or Thoroughbred cross, 1 was a 
Quarter Horse, and 1 a walking horse cross. 
 
Table 6.1. Endocrine and measures of adiposity in ID and control horses.  
 
Baseline 
Insulin 
Insulin 60 min 
post oral sugar 
administration BCS CNS 
ID 36.8 ± 6.3 76.5 ± 12.1 7.0 ± 0.2 2.7 ± 0.3 
Non-ID control 12.9 ± 0.9 24.2 ± 3.7 6.1 ± 0.1 1.4 ± 0.2 
p value 0.0026 0.00095 0.0019 0.00131 
Data are presented as least square means ± standard error of the mean for n = 13 ID and n 
= 11 controls. Body condition score (BCS) and cresty neck score (CNS) are presented as 
an average score between 3 trained individuals. 
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To ensure that none of the horses were affected with PPID (Pituitary Pars 
Intermedia Dysfunction), all horses were screened at least 3 mo prior to the start of the 
study via thyrotropin releasing hormone (TRH) stimulation testing as previously described 
[47, 191, 192]. Briefly, a.m. (between 0800 and 1000, EST) blood samples from jugular 
venipuncture were collected and a subsequent 1 mg/mL of TRH (Sigma-Aldrich, St. Louis, 
MO) given intravenously (IV). Ten min following TRH administration, a second blood 
sample was collected. All samples were collected in ethylenediaminetetraacetic acid 
(EDTA) containing tubes which were kept on ice for transport to the lab and immediate 
centrifugation and isolation of plasma [193]. ETDA plasma was stored -20 º C until sent 
on dry ice for ACTH analysis by Cornell University’s Animal Health Diagnostic Center 
Endocrinology Laboratory (Ithaca, NY) by chemiluminescence (Immulite, Erlangen, 
Germany) as previously described [195]. A 10 min post TRH administration ACTH 
concentration of > 110 pg/mL was considered positive for PPID and any horse exceeding 
this concentration excluded.  
To determine the response of metabolic and inflammatory parameters following 
supplementation with a mannan-rich fraction of the yeast cell wall (YCW) (ActigenTM; 
Alltech Inc., Nicholasville, KY) in the equine, 24 non-PPID mixed-breed and mixed-sex 
animals (13 ID and 11 non-ID controls; 4 non-supplemented horses in each metabolic 
group) were selected as described above. Horses were blocked by insulin responses to the 
OST as well as age and randomly assigned to either the YCW supplemented or non-
supplemented groups. All horses were acclimated to their respective paddocks at the 
University of Kentucky’s Department of Veterinary Science Woodford County facility for 
> 9 months with ad libitum access to mixed-grass hay, a trace mineralized salt block, and 
water. None of the horses received any form of concentrate prior to the study. Two weeks 
prior to the start of supplementation, all horses were acclimated to study feeding protocols, 
with a 0800-0900 EST individual pen feeding with 0.45 kg balancer pellet (M30; Mc 
Cauley Bros Inc., Versailles, KY) which was used for the duration of the study. The OST 
was performed as described above prior to supplementation (July of 2016) as well as 
following 45 days of supplementation (September of 2016) with 6 g/horse/day of 
ActigenTM top-dressed on balancer pellet or balancer pellet only for the non-supplemented 
horses. For both the OST 0 and 60 min time points, blood samples were collected for 
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determination of metabolic (serum glucose and insulin), inflammatory (cytokine or TLR 
protein and gene expression in lymphocytes as well as circulating), and plasma LPS 
concentrations.  
6.2.2. Metabolic parameters 
All serum samples for insulin determination from the OST were sent to Cornell 
University’s Animal Health Diagnostic Centers Endocrinology Laboratory using a 
commercially available radioimmunoassay for human insulin (RIA) (EMD Millipore Corp, 
Billerica, MA). This RIA assay was validated for use on equine serum samples as follows; 
serial dilutions of 4 equine samples with assay buffer were parallel to the standard curve, 
and samples that were spiked with four different quantities of porcine insulin (Sigma-
Aldrich, St. Louis, MO) had observed concentrations that averaged 96% of expected. The 
manufacturer did not report the cross-reactivity of the RIA antibody for equine insulin. 
However, the cross-reactivity for porcine insulin was reported as 100%, and the homology 
between equine and porcine insulin is 98%. The sensitivity of the assay, as reported by the 
manufacturer, is 2.72 IU/mL. The mean intra- and inter-assay coefficients of variation 
were 7.4 and 6.3%, respectively. In addition to serum insulin analysis, serum was analyzed 
for glucose concentrations. Glucose analysis was performed by Cornell University’s 
Animal Health Diagnostic Center Clinical Pathology Laboratory (Ithaca, NY) with a 
hexokinase kinetic method as previously described [47].  
6.2.3. Inflammatory parameters 
6.2.3.1. Lymphocyte inflammatory cytokine production as measured by flow 
cytometry  
Heparinized blood samples were taken both pre and post OST as well as pre and 
post supplementation. Peripheral blood mononuclear cells (PBMCs) were isolated from 
heparinized blood by Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) 
gradient centrifugation [197].  PBMCs at a concentration of 2 X 108 were frozen suspended 
in media (10% dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO), 40% fetal 
bovine serum (FBS; Sigma), and 50% RPMI-1640 (Gibco, Grand Island, NY)) in liquid 
nitrogen until the end of the study, at which point they were thawed by horse for stimulation 
and analysis. For in vitro stimulation, cells were thawed in c-RPMI media [RPMI-1640 
supplemented with 2.5% fetal equine serum (FES; Sigma–Aldrich, St. Louis, MO), 100 
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U/mL penicillin/streptomycin (Sigma), and were plated and incubated for 4H at 37 ° C, 
5% CO2. Select wells were incubated with 10 mg/mL Brefeldin A (Sigma) and select wells 
additionally incubated with 25 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma) and 
ionomycin (1 mM; Sigma) as a positive control. Separate select wells were also incubated 
with 10 ng LPS (catalogue #L5293; Sigma) for 2 H. Following incubation, aliquots of the 
cells were isolated for determination of gene expression by a Trizol (Ambion) method to 
isolate RNA (see below). Remaining cells incubated with BFA alone, or the combination 
of BFA and PMA, were used to determine IFN-γ and TNF-α protein production by flow 
cytometry. In brief, using 2% paraformaldehyde (Sigma), cells were fixed and allowed to 
incubate at 4º C overnight. Following this, intracellular staining was performed as 
previously described [198]. Stained cells were re-suspended in FACS flow (Becton 
Dickinson (BD), San Jose, CA) and a BD AccuriTM (BD) used for flow cytometric 
acquisition and determination of IFN-γ and TNF-α protein production.  
6.2.3.2. Lymphocyte gene expression measured by real-time polymerase chain 
reaction (RT-PCR) 
RNA was extracted using a modified Trizol method. cDNA was generated by 
reverse transcription using 1 µg of RNA as previously described [197]. Briefly, RNA 
sample and a master mix (Promega, Madison, WI) were combined and incubated at 42º C 
for 15 min and at 95º C for 5 min. cDNA (4.5 µL) was then combined with a Master Mix 
(5 µL; SensiMix, HI-ROX 2x, Bioline) and the equine-specific, intron-spanning, primer-
probe of interest (0.5 µL; TaqManTM, Applied Biosystems). An Applied Biosystems RT-
PCR ABI 7900HT was used to run samples for the following genes of interest: beta-
glucuronidase (house-keeping gene; β-gus; Ec03470630_m1), interferon gamma (IFN-γ; 
Ec03468606_m1), IL-6 (Ec03468678_m1), IL-1β (Ec04260298_s1), TNF-α 
(Ec03467871_m1), and TLR4 (Ec03468994_m1) [199]. All samples were run in duplicate. 
Following a 10 min incubation at 95o C, they underwent 40 cycles of 15 sec at 95o C and 
60 sec at 60o C. The CT method [200] was used to determine relative changes in gene 
expression, with the average pre supplementation time 0 samples mean CT for all horses 
set at the calibrator for all samples. Results are expressed as relative quantities (RQ), 
calculated as 2-CT. 
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6.2.3.3. Whole blood gene expression measured by real-time polymerase chain 
reaction (RT-PCR) 
Samples (3 ml whole blood) were collected pre and 60 minutes post oral sugar test 
as well as pre and post supplementation into Tempus™ Blood RNA Tubes (Life 
Technologies, Grand Island, NY). Tubes were shaken vigorously following blood 
collection and incubated at room temperature for 24 hrs. Following incubation, they were 
stored at -20 ºC for later analysis.  Prior to analysis, tubes were thawed and total RNA 
extracted using iPrep RNA isolation kit (Thermo Fisher Scientific, Waltham, MA) 
following the manufacturer's instructions. Following this, reverse transcription reactions 
and RT-PCR took place as described above. 
6.2.3.4. Serum inflammatory parameters as measured by enzyme-linked 
immunosorbent assay (ELISA) and Luminex bead-based multiplex assay 
The commercially available equine TNF-α ELISA (R&D Systems, Inc., 
Minneapolis, MN) was used for determination of serum concentrations of TNF-alpha 
protein both pre and post OST as well as pre and post supplementation. Assay was carried 
out per the manufacturer’s instructions, with the exception the following: dilutions were 
performed with buffer (2.5 mmol NaH2PO4, 7.5 mmol Na2HPO4, 145 mmol NaCl, 0.1% 
(v/v) Tween 20, pH 7.2) and samples plated in duplicate in a 96-well plate. The sensitivity 
of the ELISA was 15.6 pg/ml with a mean intra- and inter-assay coefficients of variation 
of 2.0% and 5.4%, respectively. 
Serum C-reactive Protein (CRP) concentrations were also measured pre and post 
OST as well as pre and post supplementation. CRP concentrations were determined by the 
equine specific commercially available kit (Kamiya Biomedical Company, Tukwila, WA) 
and was used according to the manufacturer’s instructions. 
Pre and post OST as well as pre and post supplementation, a multiplex assay using 
a Luminex x200 (Luminex Corporation, Austin, TX) was used to further measure serum 
markers of inflammation. The equine specific assay (EMD Millipore Corporation Billerica, 
MA; EQCYTMAG-93K) contained antibodies against IL-6, IFN-γ, and MCP-1 (Monocyte 
chemotactic protein-1). The protocol was performed per manufacturer’s instructions. 
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6.2.4. LPS as measured by LAL chromogenic endotoxin assay 
Heparinized plasma collected from all time points and immediately isolated using 
sterile techniques following collection upon arrival to the lab. Plasma was transferred to 
LPS free glass 15 ml tubes and frozen at -20 º C until further analysis. Samples were 
analyzed using a Pierce™ LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher 
Scientific, Waltham, MA) per the manufactures’ instructions, with the following 
exceptions; plasma samples were diluted 1:3 in endotoxin free water and reactions were 
mixed by gently swirling plates. 
6.2.5. Data analysis 
Prior to analysis, data points within variables determined to be outliers were 
removed from the analysis. Outliers were established as being 1.5 times the interquartile 
range below or above the 1st or 3rd quartiles, respectively. Analysis of data were completed 
with a repeated measures ANOVA using PROC MIXED, SAS 9.4 (SAS Institute Inc., 
Cary, NC, USA). Horse ID, metabolic group (ID vs non-ID controls), period (pre vs post 
supplementation), time (0 vs 60 min OST time points), and treatment (supplemented vs 
non-supplemented horses) were set at fixed effects and all potential interactions between 
these effects analyzed. Horse ID was set as a random effect and time and period with the 
subject horse set as the repeated measures. Pairwise comparisons were made using 
protected LSD.  Significance was set at P < 0.05 and trends considered at P < 0.10. Pairwise 
comparisons were examined for both trends and significant differences as determined by 
ANOVA. Normality was determined by analysis of residuals. Data with residuals not 
visually normal or with a skew of < 2 and/or kurtosis of < 7 were natural log transformed 
and resulted in normality.  
 
6.3. Results 
6.3.1. Metabolic parameters 
Metabolic results are presented in Figures 6.1 and 6.2. There was no effect of 
treatment on serum insulin concentrations (Figure 6.1). All horses responded to OST (P = 
0.0005) with an increase in insulin concentrations from time point 0 to time point 60. 
Overall (P = 0.0003), ID horses had higher insulin responses compared to non-ID controls 
and there was a significant metabolic group (ID vs non-ID controls) by period (pre vs post 
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supplementation) interaction (P = 0.0067). Prior to supplementation, non-ID control horses 
were lower compared to ID horses (P = 0.0111) in serum insulin. This did not change 
following supplementation, with non-ID control horses still lower in serum insulin 
compared to ID horses (P < 0.0001) however, ID horses had a significant increase in insulin 
following the supplementation period (P = 0.0023) whereas non-ID control horses did not 
(P = 0.4116).  
  
8
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Figure 6.1. Mean (± SEM) natural log of serum insulin concentrations (µIU/mL) in supplemented non-ID control horses (n = 7), non-
supplemented non-ID control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two different 
time points (baseline prior to oral sugar administration (time point 0; represented in black) and 60 min following (time point 60; 
represented in gray) as well as at the pre (represented by solid bars) and post (represented by corregated bars) supplementation periods. 
Significant (P < 0.05) group by period interaction with non-ID control horses having lower insulin than ID horses regardless of period, 
and ID horses higher at the post supplementation period compared to pre. Significant overall effect of time with time point 0 lower 
compared to time point 60. Significant overall effect of group with ID horses higher compared to non-ID controls horses. 
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Serum glucose concentrations (Figure 6.2) were likewise not affected by YCW 
supplementation. However, there was a trend for a metabolic group by treatment by period 
interaction (P = 0.0737) where YCW supplemented ID horses increased in serum glucose 
from pre to post supplementation (P = 0.0084) and were higher post supplementation 
compared to supplemented non-ID control horses (P = 0.0295). There was an effect of OST 
on serum glucose, with a significant time (time point 0 vs time point 60) by period (pre vs 
post supplementation) interaction (P = 0.0137) where time point 0 was consistently lower 
compared to time point 60, regardless of period (P < 0.0001), and glucose concentrations 
increased pre vs post supplementation within time point 0 (P = 0.002). Further, there was 
also a significant metabolic group by time interaction (P < 0.0001) for serum glucose, with 
ID and non-ID control horses both having a significant increase in glucose in response to 
the OST (P < 0.0001). ID horses had no differences in glucose compared to non-ID controls 
at time point 0 (P = 0.4415), but were higher at time point 60 (P = 0.0233). In addition, 
there was an overall effect of period (P = 0.0401), with horses higher in serum glucose 
following the supplementation period.  
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Figure 6.2. Mean (± SEM) serum glucose concentrations (mg/dL) in supplemented non-ID control horses (n = 7), non-supplemented 
non-ID control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two different time points 
(baseline prior to oral sugar administration (time point 0; represented in black) and 60 min following (time point 60; represented in gray) 
as well as at the pre (represented by solid bars) and post (represented by corregated bars) supplementation periods. Significant (P < 0.05) 
time by period interaction with horses lower in glucose at time point 0 compared to time point 60 regardless of period, and horses within 
time point 0 at the pre supplementation period lower compared to post. Significant group by time interaction with both groups increasing 
in glucose from time point 0 to time point 60 and ID horses higher compared to non-ID control horses at time point 60. Significant 
overall effects of time and period with horses higher at time point 60 compared to time point 0 and higher at the post supplementation 
period compared to pre, respectively. 
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While there was no effect of treatment, horses responded as expected to the OST 
for both serum insulin and glucose, and had an increase in both of these metabolic 
parameters from the pre to post supplementation period.  
6.3.2. Inflammatory parameters 
6.3.2.1. Lymphocyte inflammatory cytokine production  
Lymphocytes stimulated with PMA and intracellularly stained with TNF-α for flow 
cytometric cytokine protein analysis (Figure 6.3) were not significantly affected by YCW 
supplementation. However, there was a trend for a four-way metabolic group by treatment 
by time by period interaction (P = 0.0828). When examining pairwise comparisons, for 
most horses there was a decline in TNF-α % gated (percentage of the lymphocyte 
population stained positive for TNF-α %) in response to OST and from pre to post 
supplementation. Prior to supplementation, non-supplemented non-ID control horses at 
time point 0 had the highest TNF-α % gated, and were higher compared to all other periods 
and time points (P < 0.0233). They were also higher compared to supplemented non-ID 
control horses for all time points and periods (P < 0.0247), with the exception time point 
60 prior to supplementation. Supplemented non-ID control horses did not change in TNF-
α % gated in response to OST ether pre (P = 0.247) or post supplementation (P = 0.383). 
Prior to supplementation, supplemented non-ID control horses at time point 0 were lower 
compared to supplemented ID horses (P = 0.0355). This was similarly true for the post 
supplementation period (P = 0.0434). Supplemented non-ID control horses decreased 
significantly from pre supplementation at time point 60 compared to that same time point 
post supplementation (P = 0.0024). They were also lower compared to ID horses, 
regardless of treatment, for all periods and time points (P < 0.0302), with the exception of 
non-supplemented ID horses post supplementation at time point 60 (P = 0.9203). Finally, 
supplemented ID horses at time point 0 decreased from pre to post supplementation in 
TNF-α % gated (P = 0.022). There was an overall trend (P = 0.0773) for an effect of time, 
with horses decreasing in TNF-α in response to OST. There was a significant overall effect 
of period (P < 0.0001) for TNF-α % gated where, regardless of metabolic status or 
supplementation, horses were overall lower following the supplementation period.  
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Figure 6.3. Mean (± SEM) percentage of PMA stimulated lymphocytes intracellularly stained positive for TNF-α in supplemented non-
ID control horses (n = 7), non-supplemented non-ID control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID 
horses (n = 4) at two different time points (baseline prior to oral sugar administration (time point 0; represented in black) and 60 min 
following (time point 60; represented in gray) as well as at the pre (represented by solid bars) and post (represented by corregated bars) 
supplementation periods. Significant (P < 0.05) overall effect of period, with horses higher pre vs post supplementation.  
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There was no effect of treatment on PMA stimulated lymphocytes intracellularly 
stained with IFN-γ (data not shown). While there was a trend for a metabolic group by 
treatment interaction (P = 0.0544), there were no significant pairwise comparisons. There 
was also a treatment by period interaction (P = 0.0628) with non-supplemented horses 
lower in IFN-γ post supplementation compared to pre (P = 0.0029). There was no effect of 
OST on IFN-γ in PMA stimulated lymphocytes. However, there was a significant overall 
effect of period (P = 0.0021) with horses lower post supplementation compared to pre 
supplementation, and a metabolic group by period interaction (P = 0.0822) with non-ID 
control horses lower post supplementation compared to pre supplementation (P = 0.0015).  
6.3.2.2. Lymphocyte gene expression 
For lymphocytes stimulated with PMA (data not shown) cytokine and TLR gene 
expression did not differ significantly for any of the variables measured, with the exception 
of IFN-γ. There was a significant effect of time (P = 0.0319) on IFN-γ PMA stimulated 
gene expression with all horses decreasing in response to OST. There were a number of 
trends observed. There was a trend (P = 0.0883) for a metabolic group by time by period 
interaction for TNF-α gene expression where post supplementation, non-ID control horses 
were lower compared to ID horses at time point 60 (P = 0.012). TLR-4 gene expression 
had trends for overall difference of time (P = 0.0554; horses increasing in response to OST) 
and period (P = 0.066; horses increasing from pre to post supplementation). There was also 
a trend for metabolic group by time interaction (P = 0.0886) for IL-6 gene expression, 
however none of the pairwise comparisons were significant. 
There were differences or trends for cytokine and TLR gene expression of 
lymphocytes stimulated with LPS (Figures 6.4 - 6.7). There was no effect of treatment on 
LPS stimulated TNF-α gene expression, however there was a trend for a metabolic group 
by treatment by period interaction (P = 0.0676). Non-supplemented ID horses prior to 
supplementation were higher compared to supplemented ID horses both pre (P = 0.0411). 
There was also a trend for an overall effect of treatment (P = 0.0966), with non-
supplemented horses having a trend to be higher compared to supplemented horses. The 
only significant effect on LPS stimulated TNF-α gene expression (P = 0.0379) was an 
effect of time, with all horses increasing in response to the OST (Figure 6.4).  
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Figure 6.4. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC TNF-α gene 
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID 
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n 
= 4) at two different time points (baseline prior to oral sugar administration (time point 0; 
represented in black) and 60 min following (time point 60; represented in gray)) as well as 
at the pre (represented by solid bars) and post (represented by corregated bars) 
supplementation periods. Significant (P < 0.05) overall effect of time point with horses 
lower at time point 0 compared to time point 60. 
 
There was no significant effect of treatment on TLR-4 LPS stimulated gene 
expression (Figure 6.5), however there was a trend for a metabolic group by treatment by 
period interaction (P = 0.0934), with non-supplemented ID horses post supplementation 
lower in TLR-4 gene expression compared to pre supplementation (P = 0.0395). There 
were significant effects of OST on TLR-4, with an overall increase in response to OST for 
all horses (P = 0.007). Further, there was a significant metabolic group by time by period 
interaction (P = 0.0334) where ID horses had a decrease in TLR-4 gene expression from 
the pre to post supplementation periods within time point 60 (P = 0.0042). Prior to 
supplementation, ID horses also had a significant increase in gene expression in response 
to OST (P = 0.0005). In addition, there was a significant metabolic group by period 
interaction (P = 0.039) for TLR-4 LPS stimulated gene expression, but no pairwise 
comparisons were significant.  
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Figure 6.5. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC TLR-4 gene 
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID 
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n 
= 4) at two different time points (baseline prior to oral sugar administration (time point 0; 
represented in black) and 60 min following (time point 60; represented in gray) as well as 
at the pre (represented by solid bars) and post (represented by corregated bars) 
supplementation periods. Significant (P < 0.05) group by time by period interaction with 
ID horses increasing in TLR-4 between time points where they were higher at time point 
60 compared to non-ID controls at the pre supplementation period. Significant group by 
period interaction with no significant pairwise comparisons and an overall significant effect 
of time point with horses lower at time point 0 compared to time point 60. 
 
LPS stimulated IL-6 lymphocyte gene expression (data not shown) had no 
significant differences for any of the variables measured. There was however a trend for a 
metabolic group by treatment by time interaction (P = 0.0585), with non-supplemented 
non-ID control horses increasing in IL-6 gene expression in response to OST (P = 0.0479). 
Non-supplemented non-ID control horses at time point 60 were also higher compared to 
supplemented non-ID control horses at that same time point (P = 0.0275).  
There was an overall effect of treatment (P = 0.0041) for IL-10 (Figure 6.6), with 
treated horses lower compared to non-supplemented horses. There were no effects or trends 
of metabolic status, time, or period on IL-10 LPS stimulated gene expression. For IFN-γ 
(Figure 6.7), there was a significant metabolic group by treatment by time by period 
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interaction (P = 0.036). Post supplementation, non-supplemented horses had a significant 
increase in IFN-γ in response to OST (P = 0.042). Time points 0 and 60 pre 
supplementation were lower compared to time point 0 post supplementation for non-
supplemented horses (P < 0.0265). Supplemented horses at the post supplementation 
period had a significant increase in IFN-γ LPS stimulated gene expression (P = 0.0183). 
Supplemented horses post supplementation at time point 60 were also higher than 
compared to pre supplementation at that same time point (P = 0.0182). Further, there was 
a treatment by time interaction (P = 0.0259), with supplemented horses increasing in IFN-
γ in response to OST (P = 0.0328). Similarly, there was a significant metabolic group by 
time interaction (P = 0.0239) for IFN-γ LPS stimulated gene expression, with a trend for 
ID horses to have an increase in gene expression in response to OST (P = 0.0631). Finally, 
there was a significant effect of period (P = 0.0107) with horses increasing from the pre to 
the post supplementation period.  
 
 
Figure 6.6. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC IL-10 gene 
expression in supplemented non-ID control horses (n = 7), non-supplemented non-ID 
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n 
= 4) at two different time points (baseline prior to oral sugar administration (time point 0; 
represented in black) and 60 min following (time point 60; represented in gray) as well as 
at the pre (represented by solid bars) and post (represented by corregated bars) 
supplementation periods. Significant (P < 0.05) overall effect of treatment with non-
supplemented horses lower compared to supplemented horses. 
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Figure 6.7. Mean (± SEM) relative quantity (RQ) of LPS stimulated PBMC IFN-γ gene 
expression in supplemented  non-ID control horses (n = 7), non-supplemented non-ID 
control horses (n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n 
= 4) at two different time points (baseline prior to oral sugar administration (time point 0; 
represented in black) and 60 min following (time point 60; represented in gray) as well as 
at the pre (represented by solid bars) and post (represented by corregated bars) 
supplementation periods. Significant (P < 0.05) treatment by time by period interaction 
with non-supplemented horses higher in IFN-γ at the post supplementation period for time 
point 0 compared to time point 60 as well as pre supplementation for time point 0, and 
supplemented horses were higher in IFN-γ at the post supplementation period for time point 
60 compared to time point 0 as well as pre supplementation for time point 60. Significant 
treatment by time interaction with supplemented horses lower in IFN-γ at time point 0 
compared to time point 60. Significant group by time interaction, no significant pairwise 
comparisons. Significant overall effect of period with horses higher at the post 
supplementation period compared to pre. 
 
6.3.2.3. Whole blood inflammatory gene expression  
There were no differences in whole blood gene expression of TLR-4 (data not 
shown), regardless of time point, metabolic group, period, or treatment. There was an effect 
of period on IL-6 (P = 0.0009) and IL-10 (P = 0.0009) gene expression (data not shown). 
Horses had higher IL-6 but lower IL-10 at the pre supplementation period compared to 
post. There were no other effects on IL-6 or IL-10 whole blood gene expression. There 
were no significant effects for any variable measured on TNF-α, but there was a trend for 
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an effect of period (P = 0.0539) (Figure 6.8), where horses increased in TNF-α from the 
pre supplementation to post supplementation period. Additionally, there was a trend for a 
metabolic group by period interaction (P = 0.0766), however while results reflected an 
increase in gene expression of TNF-α in non-ID control horses from the pre to post 
supplementation period, pairwise comparisons were only trending. 
 
 
Figure 6.8. Mean (± SEM) relative quantity (RQ) of whole blood IFN-γ gene expression 
in supplemented non-ID control horses (n = 7), non-supplemented non-ID control horses 
(n = 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two 
different time points (baseline prior to oral sugar administration (time point 0; represented 
in black) and 60 min following (time point 60; represented in gray) as well as at the pre 
(represented by solid bars) and post (represented by corregated bars) supplementation 
periods.  
 
6.3.3. Serum inflammatory protein markers 
There were no differences or trends for serum inflammatory markers as measured 
by CPR ELISA, or Luminex multiplex assay for IL-6, MCP-1, or IFN-γ concentrations for 
any variable measured (data not shown). There was an effect of time on TNF-α serum 
protein concentrations (P = 0.0302) (Figure 6.9) as measured by ELISA, with horses 
decreasing in TNF-α in response to OST.  
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Figure 6.9. Mean (± SEM) natural log of serum TNF-α concentrations (ELISA) in 
supplemented non-ID control horses (n = 7), non-supplemented non-ID control horses (n 
= 4), supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two 
different time points (baseline prior to oral sugar administration (time point 0; represented 
in black) and 60 min following (time point 60; represented in gray) as well as at the pre 
(represented by solid bars) and post (represented by corregated bars) supplementation 
periods. Significant (P < 0.05) overall effect of time point with horses higher at time point 
0 compared to time point 60. 
 
6.3.4. Plasma LPS concentrations 
LAL assay was able to detect differences in LPS plasma concentrations (Figure 
6.10). There was a metabolic group by treatment by period interaction (P = 0.0261). Non-
supplemented non-ID control horses at prior to supplementation were higher compared to 
post (P = 0.009), as well as compared to supplemented ID horses post supplementation (P 
= 0.042). They also had trends to be higher compared to non-supplemented ID horses at 
either periods (P = 0.0761 pre, P = 0.0562 post). Additionally, there was a treatment by 
period interaction (P = 0.0338) with non-supplemented horses decreasing in LPS 
concentrations from the pre to post supplementation period (P = 0.0159), and an overall 
effect of period (P = 0.0338) with horses having lower LPS concentrations following the 
supplementation period.  
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Figure 6.10. Mean (± SEM) natural log of plasma LPS concentrations in supplemented 
non-ID control horses (n = 7), non-supplemented non-ID control horses (n = 4), 
supplemented ID horses (n = 9) and non-supplemented ID horses (n = 4) at two different 
time points (baseline prior to oral sugar administration (time point 0; represented in black) 
and 60 min following (time point 60; represented in gray) as well as at the pre (represented 
by solid bars) and post (represented by corregated bars) supplementation periods. 
Significant group by treatment by date interaction, with non-supplemented non-ID controls 
higher in LPS pre supplementation period compared to post. Significant (P < 0.05) 
treatment by period interaction, with non-supplemented horses higher pre supplementation 
period in LPS compared to post, and an overall effect of date with horses higher pre 
compared to post supplementation period. 
 
6.4. Discussion 
There was no effect of supplementation with a manna-rich fraction of the YCW on 
either serum insulin or glucose concentrations in either ID or non-ID control horses. 
However, there was a trend for a metabolic group by treatment by period interaction for 
serum glucose. This trend indicated that supplemented ID horses increased in serum 
glucose from pre to post supplementation, and at the post supplementation period were 
higher compared to supplemented non-ID controls. In a bovine study, the opposite effect 
was seen in metabolically normal heifers supplemented for 52 days with Saccharomyces 
cerevisiae yeast cell wall [102], where heifers had a decrease in serum glucose and an 
increase in insulin. However, while the increase in insulin was seen following 
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supplementation, the decrease in glucose was observed following supplementation but only 
in response to an endotoxin challenge in supplemented heifers. In addition, pigs fed a high 
chromium yeast supplement had an increased glucose tolerance and clearance following 
23-30 days of supplementation [255]. The differences in these results may indicate that 
yeast cell wall supplementation contributes to an increase in serum glucose concentrations 
in horses with ID. Conversely, this increase in glucose may be due to an increased 
susceptibility to dietary changes in ID horses, be it caloric or other nutrient intake, or 
treatment period or dosing may have been inadequate to positively impact the metabolic 
parameters measured. Metabolically, horses responded as expected to glycemic challenge 
in the form of an OST, increasing in glucose and insulin concentrations between the 0 and 
60 time points, with ID horse having greater serum concentrations compared to non-ID 
control horses. There was an effect of period on concentrations of both glucose and insulin, 
with horses increasing from the pre supplementation (July) to post supplementation 
(September) period. This may indicate an effect of season on metabolic parameters, which 
have been proposed to be higher in the fall months in horses with PPID [256] and higher 
in February compared to August and November and June compared to November in 
healthy horses [257]. However, others have not observed the same in a group of healthy or 
ID horses [258]. Regardless, these data support an effect of season on serum concentrations 
of both glucose and insulin, in particular in horses with ID.  
Effects of YCW supplementation on inflammatory markers were minimal. Non-
supplemented horses had a decrease in LPS concentrations following the 45 day 
supplementation period whereas supplemented horses did not. Further, when examining 
pairwise comparisons for the metabolic group by treatment by period interaction, it was 
the non-ID control horses who were non-supplemented that had this decrease in LPS 
concentrations between periods. For LPS stimulated lymphocyte IFN-γ gene expression, 
there was a significant treatment by time by period interaction, indicating that both 
supplemented and non-supplemented horses had an increase following the 45 day 
supplementation period (within time point 60 for supplemented horses and within time 
point 0 for non-supplemented horses). Interesting, post supplementation, supplemented and 
non-supplemented horses had opposing responses to the OST with supplemented horses 
increasing from time point 0 to time point 60 in LPS stimulated lymphocyte IFN-γ gene 
 101 
expression whereas non-supplemented horses decreased. There was also a significant 
overall effect of treatment on LPS stimulated lymphocyte IL-10 gene expression, with non-
supplemented horses having higher gene expression compared to those who received 
YWC. There were no other significant effects of treatment, although several trends were 
observed. Of interest was the trend for the 4 way interaction between metabolic group, 
treatment, time, and period for the percentage of lymphocytes stained positive for TNF-α. 
Within time point 0, ID supplemented horses had a decrease in TNF-α following 
supplementation. Non-ID control horses, regardless of supplementation status, had a 
similar decrease between periods. However, non-supplemented ID horses had no 
difference in their percentage of lymphocytes stained positive for TNF-α between the pre 
and post supplementation period. These data suggest that supplementation with yeast cell 
wall in horses may have some impact on lymphocyte mediated inflammation. 
Differences due to metabolic status, in particular in response to the OST, in respect 
to inflammatory parameters were varied. We and others have previously shown that in 
response to a meal or an oral sugar challenge, ID and non-ID control horses have an 
inflammatory response [46, 47], and that this response can differ between the two 
metabolic groups [47]. There was a significant metabolic group by time by period 
interaction for LPS stimulated lymphocyte TLR-4 gene expression. ID horses had a large 
increase in TLR-4 gene expression in response to oral sugar prior to supplementation that 
was not seen post supplementation or in the non-ID control horses. There was also a 
significant metabolic group by time interaction for LPS stimulated lymphocyte IFN-γ gene 
expression with ID horses having a trend to increase in IFN –γ in response oral sugar 
administration whereas non-ID horses had a (non-significant) decrease. For TNF-α gene 
expression in PMA stimulated lymphocytes, post supplementation ID horses were higher 
in TNF-α gene expression compared to non-ID control horses at time point 60. In addition, 
there was a trend for a metabolic group by treatment by time interaction for LPS stimulated 
lymphocyte IL-6 gene expression. This trend was due to the higher IL-6 gene expression 
in non-supplemented non-ID control horses at time point 60. There were also trends for an 
effect of metabolic group on the percentage of lymphocytes stained positive for both TNF-
α and IFN-γ. ID and non-ID control horses supplemented with yeast cell wall decreased in 
TNF-α following supplementation, as discussed above, whereas non-supplemented ID 
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horses did not. For IFN-γ, non-ID control horses decreased in IFN-γ between the two 
periods, whereas the ID horses did not change. Finally there was a trend for a metabolic 
group by period interaction for whole blood IFN-γ gene expression, and while pairwise 
comparisons were only trends, they indicated that post supplementation non-ID controls 
had a tendency to be lower compared to ID horses regardless of period. These data may 
further point to an increased sensitivity to changes in season in horses with ID. 
In respect to overall differences between the 0 and 60 time points, PMA stimulated 
lymphocyte IFN –γ gene expression and TNF-α serum protein concentrations (ELISA) in 
horses were overall higher at time point 0 vs time point 60. However, for LPS stimulated 
lymphocyte TNF-α and TLR-4 horses were higher at time point 60 compared to time point 
0. Further indications of an effect of time were observed in significant interactions for LPS 
stimulated lymphocyte TLR-4 gene expression (discussed above) and LPS stimulated 
lymphocyte IFN –γ gene expression. Interactions involving time point seen with IFN –γ 
show that following the supplementation period, supplemented horses had an increase in 
gene expression in response to the OST whereas non-supplemented horses had a decrease. 
Further, regardless of period and treatment, this pattern was observed in respect to 
metabolic status (discussed above). Trends were observed for an overall effect of time as 
well. They indicated that gene expression of TLR-4 in PMA stimulated lymphocytes was 
increased in response to OST, likely due to a large increase prior to supplementation in the 
ID horses. Gene expression of IL-6 in PMA and LPS stimulated lymphocytes was also 
increased in response to OST, but this increase was seen in non-ID controls or non-
supplemented non-ID controls, not in ID horses or horses receiving YCW supplementation. 
Additionally, the percentage of lymphocytes producing TNF-α (% gated) had a trend to 
decrease from the 0 to 60 time points and a trend for a 4 way interaction indicating that 
non-supplemented non-ID control horses pre supplementation were primarily responsible 
for this decrease in TNF-α % gated in response to the OST.  
Similar to metabolic parameters, there was an apparent effect of period on 
inflammatory markers. There was an overall increase following the 45 day 
supplementation period in IFN-γ gene expression of LPS simulated lymphocytes, and 
horses had trends to be higher in TLR-4 gene expression of PMA simulated lymphocytes 
and TNF-α gene expression in whole blood. On the other hand, they had a decrease 
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following the supplementation period in plasma LPS concentrations, the percentage of 
lymphocytes stained positive for both TNF-α and IFN-γ, whole blood gene expression of 
IL-10, and whole blood gene expression of IL-6. There have been indications in other 
species, such as baboons, fish, and rodents that season is able to impact the immune 
response [259-261]. Specifically, serum concentrations of CRP were greater in June 
compared to December, and a seasonal influence was also seen for serum IL-6 levels in 
baboons [259]. In fact, a decrease in IL-6 and IL-1β in Siberian hamsters in response to 
LPS and shorter day lengths indicate a that the immune response may be reduced in the 
winter months [260]. There has been some work related to the immune response and season 
in the horse [262-264]. Seasonal allergy responses in PBMCs in particular have been 
utilized [265, 266] and show increased PBMC production of IFN-γ and a decreased 
production of IL-4 in the winter compared to summer months [265]. However, another 
study in horses with summer pasture-associated obstructive pulmonary disease (SPAOPD) 
as well as controls, showed increases in PBMC IFN-γ gene expression in the summer as 
compared to the winter [266]. For this study horses had an increase from July to September 
in pro-inflammatory cytokine or TLR gene expression of IFN-γ, TNF-α, and TLR-4. 
However, horses had a decrease in gene expression of the anti-inflammatory IL-10 as well 
as IL-6, lymphocyte protein concentrations of IFN-γ and TNF-α, and plasma LPS 
concentrations. This may point to seasonal variations in post transcriptional factors, but 
more research is needed to better understand possible seasonal influences on inflammatory 
responses in both the ID and metabolically normal horse.  
Metabolic parameters were increased from pre to post supplementation and in 
response to oral sugar administration, in particular in ID horses. However there was not a 
significant effect of YCW supplementation on either basal or OST responses of serum 
insulin or glucose. There were limited effects of treatment and metabolic status on 
inflammatory markers, however non-supplemented horses or non-ID controls frequently 
had a decrease in pro-inflammatory markers of inflammation at both the protein and gene 
expression levels in response to OST whereas ID horses increased. Overall, these data show 
a strong effect of period and OST on the variables measured and suggest that ID horses 
may be particularly sensitive to changes in metabolic stimuli or season.  
Copyright © Sarah E. Elzinga 2017  
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CHAPTER 7 EQUINE WHOLE BLOOD INFLAMMATORY GENE EXPRESSION 
IN INSULIN DYSREGULATED (ID) AND CONTROL HORSES IN RESPONSE TO 
A TLR-4 AGONIST, LPS  
 
Insulin dysregulation (ID) in the horse is considered to be an increasing problem, 
due in large part to its association with the often career or life ending condition, laminitis. 
However, underlying mechanisms of ID and the development of laminitis, in particular as 
they relate to inflammation, remain unclear. There have been reports that horses with ID 
have increased levels of inflammatory cytokines, especially in response to oral glycemic 
challenge. It has also been shown that both levels of inflammation as well as bacterial 
endotoxin, or lipopolysaccharide (LPS), are increased in humans in response to a meal. 
The primary pattern recognition LPS receptor in humans and horses is a member of the toll 
like receptor family, TLR-4 (toll like receptor 4). It can function in response to LPS through 
the MyD88 (Myeloid differentiation primary response gene 88) dependent or independent 
pathways. However, it remains to be seen if differences in postprandial inflammatory 
responses in ID horses are driven in part by differential regulation of LPS TLR-4 
inflammatory signaling. We therefore hypothesized that horses with ID would have 
differences in their TLR4 mediated inflammatory response to an oral glycemic challenge 
in response to LPS stimulation. To accomplish this, a total of 14 adult, non-PPID, mixed-
breed and mixed-sex horses (7 ID and 7 non-ID controls, not different in age) were used in 
this study. Horses were administered an oral sugar test (OST), and blood collected via 
jugular venipuncture prior to (time point 0) and 60 min post oral sugar administration (time 
point 60). Blood was analyzed at both time points for serum insulin concentrations as well 
as whole blood inflammatory markers in both LPS stimulated and unstimulated samples. 
As expected, ID horses had significantly greater serum insulin at time point 60 in 
comparison to controls (P < 0.0001). LPS was able to induce gene expression in relation 
to unstimulated samples in all horses for all inflammatory markers, with the exception of 
the chemokine CCL2 (chemokine (C-C motif) ligand 2; P < 0.005). Inflammatory markers 
associated with the MyD88 independent pathway were however only minimally increased 
or did not change in response to LPS stimulation. There was an effect of oral sugar 
administration, with decreases in CCL2 and TLR-4 in LPS stimulated samples. Further, 
whole blood gene expression of the chemokines IL-8 (interleukin 8) and CCL2 were lower 
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in ID compared to control horses. This indicates that in whole blood, LPS stimulates 
inflammatory responses primarily of MyD88 dependent associated genes, regardless of 
metabolic status, and that horses with ID may have an impaired innate immune response. 
However, more work is needed to understand possible differences in immune responses of 
ID compared to metabolically normal horses. 
 
7.1. Introduction 
Metabolic dysfunction, in particular insulin dysregulation, is considered to be of 
concern in the equine due to its association with numerous health concerns including the 
potentially fatal condition, laminitis [12, 15]. In humans, low grade systemic inflammation 
is often observed in individuals with metabolic dysfunction [267], but although this is 
suggested to be the case in the horse as well [127, 139, 140], the link between inflammation 
and ID, as well as underlying mechanisms of ID and relationship to laminitis in the horse 
remains unclear. Environmental factors, in particular over-nutrition and a lack of exercise 
leading to an increased fat mass are thought to be influential in the development of 
metabolic dysfunction in the horse [142]. Adipose tissue is itself categorized as an 
endocrine organ, and as such is capable of producing inflammatory cytokines [268]. There 
has been evidence in obese or insulin resistant humans and mice however, that adipose 
tissue macrophages, not adipose tissue, have a greater role in the production of 
inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) [145, 146]. Adipose 
tissue dysfunction is often a prominent aspect of obesity and ID. This dysfunction involves 
macrophage accumulation, wherein these cells accumulate in greater numbers and size in 
the tissue, and favor M1 (largely proinflammatory) over M2 (largely anti-inflammatory) 
macrophages [131, 147].  
Recognition of pathogens by macrophages principally occurs via pattern 
recognition receptors (PRR). In particular, the PRR toll-like receptor 4 (TLR4), is primarily 
responsible for recognition of bacterial lipopolysaccharide (LPS) [148]. Once triggered by 
LPS, TLR4 (along with its co-receptors cluster of differentiation 14 (CD14) and 
lymphocyte antigen 96 (MD-2)) activate a signaling cascade which ultimately allows the 
release of NF- κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and its 
translocation into the cell’s nucleus for induction of proinflammatory gene expression 
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[149]. TLR-4 predominantly functions in response to LPS through one of two pathways; 
MyD88 (Myeloid differentiation primary response gene 88) dependent TIRAP (TIR 
Domain Containing Adaptor Protein) pathway, resulting in proinflammatory cytokine 
production (such as TNF-α and IL-6 (interleukin 6)), or the MyD88 independent TRIF 
(TIR-domain-containing adapter-inducing interferon-β) pathway, resulting in the 
production of type I interferons (such as interferon beta, or IFN-β), and chemokines such 
as CCL5 (Chemokine (C-C motif) ligand 5, or RANTES) and CCL2 (Chemokine (C-C 
motif) ligand 2, or MCP-1) [269, 270]. Not only is this receptor complex able to recognize 
LPS, but it is also able to recognize free fatty acids (FFA), resulting in a similar activation 
of NF- κB and subsequent production of proinflammatory cytokines, including TNF-α 
[148, 150, 270].  
There have been reports that TLR4 concentrations and gene expression are elevated 
in both animals and humans with metabolic dysfunction [271, 272]. Indeed, high fat fed 
mice have been used to show that endotoxemia can induce both inflammation and insulin 
resistance [61]. Further, increases in inflammatory markers and endotoxin concentrations 
[43, 46, 47, 59, 60, 273] have been observed in multiple species, including the horse, 
following a meal. Considering the proposed involvement of the gut both in metabolism and 
the inflammatory process, these postprandial increases in concentrations of bacterial 
endotoxin are not surprising [62, 63]. Therefore, the goal of this work was to examine 
mechanisms relating to differences in inflammatory responses in ID horses, possibly due 
to alterations in TLR-4 inflammatory signaling in response to glycemic challenge as well 
as endotoxin stimulation.   
 
7.2. Materials and methods 
7.2.1. Horse selection and study design  
A total of 14 mixed-breed and mixed-sex horses were selected from the 
University’s Department of Veterinary Science Woodford County herd; 7 ID and 7 non-
ID controls. ID was established using an oral sugar test (OST) [13, 47], with 
hyperinsulinemia diagnosed as a fasting serum insulin level of > 20 μIU/mL and a 
concentration of insulin > 60μU/mL 60 minutes post OST was considered further 
indicative of ID. Horses were also scored for body condition (BCS) based on the 1-9 
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Henneke scoring system [186] and cresty neck score (CNS) based on the 0-5 Carter et. al. 
scoring system [187] to determine overall and regional adiposity, respectively. Phenotypic 
data is presented in Table 7.1. Breed distribution of the ID horses (3 geldings and 4 mares; 
average age 13.6 yrs) was as follows; 1 was of mixed breed, 2 were Warmbloods, 2 were 
Standardbred or Standardbred cross, 1 a Morgan, and 1 a Quarter Horse. Breed distribution 
of the 7 non-ID controls horses (3 geldings and 4 mares; average age 13.1 yrs) was as 
follows; 3 were of mixed breed, 3 were Thoroughbreds, and 1 was a Quarter Horse. Horses 
were housed at the University of Kentucky’s Department of Veterinary Sciences Woodford 
County facility and allowed to acclimate for > 9 mo to their respective pastures prior to the 
start of the study. They were provided ad libitum access water and a trace mineralized salt 
block. While none of the horses were fed any form of concentrate and pasture was minimal 
and composed of mixed-grass, they were given unrestricted access to a mixed-grass hay. 
 
Table 7.1. Phenotypic measures of ID and control horses. 
Group 
Baseline 
Insulin 
Insulin 60 min 
post oral sugar 
administration BCS CNS 
Control 13.9 ± 11.4 21.8 ± 11.4 6 ± 0.3 1.8 ± 0.3 
ID 40.7 ± 11.4 113.8 ± 11.4 7 ± 0.4 2.8 ± 0.4 
p value 0.1108 < 0.0001 0.1061 0.0798 
Data are presented as least square means ± standard error of the mean for insulin, body 
condition score (BCS), and cresty neck score (CNS). n = 7 ID and n = 7 controls. BCS and 
CNS are presented as an average score between 4 trained individuals. 
 
This was an observational study with all horses sampled during the winter season 
of 2017. Fourteen non-PPID (see below) mixed-breed and mixed-sex animals (7 ID and 7 
non-ID controls) were selected. An OST (described above) was administered, and blood 
samples from time points 0 and 60 were collected for determination of serum insulin 
levels as well as whole blood gene expression of markers of inflammation. 
Thyrotropin resealing hormone (TRH) stimulation was used to rule out any horses 
affected by Pituitary Pars Intermedia Dysfunction (PPID). TRH stimulation testing was 
performed as previously described [47, 191, 192], with a blood sample collected via jugular 
venipuncture in the a.m. (between 0800 and 1000, EST). Following this, TRH (1 mg/mL; 
Sigma-Aldrich, St. Louis, MO) was administered intravenously and 10 min later a second 
 108 
blood sample collected. Blood tubes (containing ethylenediaminetetraacetic acid, or 
EDTA) were placed on ice, transported to the lab, and upon arrival were centrifuged to 
isolate  plasma [193] which was stored at -20 º C. Samples were sent on dry ice to Cornell 
University’s Animal Health Diagnostic Center Endocrinology Laboratory (Ithaca, NY) for 
ACTH analysis. Analysis of ACTH was accomplished with a chemiluminescent assay 
(Immulite, Elangen, Germany) as previously described [195]. ACTH concentrations 
exceeding either > 35 pg/mL for the baseline sample or > 180 pg/mL for the 10 min sample 
were considered positive for PPID and were the basis for exclusion from the study.  
7.2.2. Insulin determination 
Serum insulin concentrations were analyzed by Cornell University’s Animal Health 
Diagnostic Center Endocrinology Laboratory using a commercially available human 
insulin radioimmunoassay (RIA; EMD Millipore Corp, Billerica, MA). This assay was 
validated for use in equine serum as follows; 4 equine samples were serial dilutions with 
assay buffer parallel to the standard curve. Four different quantities of porcine insulin 
(Sigma-Aldrich, St. Louis, MO) were used to spike samples and concentrations averaged 
96% of expected. Cross-reactivity of the RIA antibody with equine insulin was not reported 
by the manufacturer however, cross-reactivity was reported as 100% with porcine insulin. 
Homology between equine and porcine insulin is 98%. Assay sensitivity is reported as 2.72 
IU/mL by the manufacturer. Mean intra-assay coefficient of variation was 7.4 and inter-
assay coefficient of variation was 6.3%.  
7.2.3. Whole blood gene expression 
Blood was collected via jugular venipuncture into 2 (15 mL) glass heparinized 
vacutainer tubes at each time point (0 and 60) and kept warm and consistently inverted to 
prevent separation until arrival at the lab. Following arrival, one tube per horse per time 
point was stimulated with 1 µg LPS (catalogue #L5293; Sigma). This dose was based on 
an earlier study in equine monocytes [274] and modified based on data from a pilot study 
that determined responses to LPS in equine whole blood (data not shown). The second tube 
served as an unstimulated control. All tubes were incubated at 37º Celsius on an automated 
shaker (Max Q4450, Thermo Fisher Scientific, Waltham, MA) for 2 hours. Following this 
2 H incubation, 3 mL of blood was transferred into Tempus™ Blood RNA Tubes (Life 
Technologies, Grand Island, NY). Tubes were vigorously shaken following addition of 
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blood and incubated at room temperature for 24 hrs. Tubes were then stored at -20 ºC for 
later analysis. Tubes were thawed prior to analysis and Tempus Spin RNA isolation kit 
(Thermo Fisher Scientific, Waltham, MA) was used following the manufacturer’s 
instructions to isolate total RNA. Once isolated, cDNA was generated by transcription of 
1 µg of RNA as previously described [197]. Briefly, RNA was combined with a master 
mix (Promega, Madison, WI) and incubated at 42o C for 15 min and at 95o C for 5 min. The 
resulting cDNA (4.5 µL) was combined with 5 µL of Master Mix (SensiMix HI-ROX 2x, 
Bioline) and the primer-probe of interest (0.5 µL; TaqMan™). Primer-probes were equine-
specific (Applied Biosystems, Foster City, CA). An Applied Biosystems Real-Time PCR 
system (ABI Viia7) was used to run samples against: Housekeeping gene beta-
glucuronidase (β-gus; Ec03470630_m1), IL-6 (Ec03468678_m1), IL-1β 
(Ec04260298_s1), TNF-α (Ec03467871_m1), TLR4 (Ec03468994_m1), IFN-γ 
(Ec03468606_m1), IL-8 (Ec0346880_m1), IL-10 (Ec03468647_m1), CCL5 
(Ec03468106_m1), and CCL2 (Ec03468496_m1) [199]. All samples analyzed in duplicate 
and after an initial 10 min incubation at 95o C underwent 10 cycles of 15s at 95o C followed 
by 60s at 60o C. Changes in gene expression, relative to both β-gus and mean CT for non-
ID horses’ time 0 media samples set as a calibrator, were calculated using the CT method 
[200]. Results are expressed as relative quantity (RQ), calculated as 2-CT. 
7.2.6. Statistical analysis 
Prior to analysis, data points determined to be outliers as established as being 1.5 
times the interquartile range below or above the 1st or 3rd quartiles, respectively were 
removed from the data set. Analysis of data were completed with repeated measures 
ANOVA using PROC MIXED, SAS 9.4 (SAS Institute Inc., Cary, NC). Horse ID, group 
(ID vs non-ID controls), time (0 vs 60 min OST time points), and treatment (non-stimulated 
tubes vs those stimulated with LPS) were set at fixed effects and all possible interactions 
were considered. The repeated measure was set as time, with the subject of horse ID. 
Pairwise comparisons were made using protected LSD. All data were normally distributed 
as determined by analysis of residuals. Residuals were visually normally distributed and 
had a skew of < 2 and kurtosis of < 7. Differences were considered statistically significant 
when P < 0.05 and trends were considered at P < 0.10. 
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7.3. Results 
While ID horses met the criteria for hyperinsulinemia, having resting insulin 
concentrations > 20 µIU/mL, they were not significantly in higher serum insulin 
concentrations (Table 7.1) compared to controls at time point 0 prior to oral sugar 
administration (P = 0.1108). However, they significantly increased from time point 0 to 
time point 60 (P = 0.0002) and were higher at that time point compared to controls (P < 
0.0001). 
Results for gene expression of inflammatory markers in LPS treated and 
unstimulated whole blood samples from ID and control horses both prior to (time point 0) 
and 60 min following oral sugar administration (time point 60) are presented in Figures 7.1 
and 7.2. Regardless of metabolic status or time point, LPS stimulation was able to 
significantly increase whole blood gene expression for all variables measured (P < 0.005), 
with the exception of CCL2 (P = 0.3013, Figure 7.2). It especially effected interleukin gene 
expression, inducing the highest expression in IL-1β and IL-6 (Figure 7.1).  
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Figure 7.1. Mean (± SEM) mRNA gene expression represented as relative quantities (RQ) 
of (A) TNF-α, (B) IL-8, (C) IL-1β, (D) IL-6, (E) IL-10, and (F) IFN-γ in equine whole 
blood both incubated for 2 hrs with 1 µg LPS (LPS stimulated; left panel of the graphs) 
and incubated without LPS (Unstimulated; right panel of the graphs) at two different time 
points (baseline prior to oral sugar administration (time point 0) and 60 min following (time 
point 60)). Differences between ID and controls (P < 0.05) are represented by *. 
  
 112 
There were some overall effects of time on gene expression. For TLR-4 (Figure 
7.2), time point 0 was lower compared to time point 60 (P = 0.0126). However, time point 
0 was higher compared to time point 60 for CCL2 (MCP-1) gene expression (P = 0.018). 
Additionally, there was a trend for an effect of time (P = 0.0972) for IFN-γ (Figure 7.1), 
with horses at time point 0 lower compared to time point 60. 
 
 
Figure 7.2. Mean (± SEM) mRNA gene expression represented as relative quantities (RQ) 
of (A) CCL5 (RANTES), (B) CCL2 (MCP-1), and (C) TLR-4 in equine whole blood both 
incubated for 2 hrs with 1 µg LPS (LPS stimulated; left panel of the graphs) and incubated 
without LPS (Unstimulated; right panel of the graphs) at two different time points (baseline 
prior to oral sugar administration (time point 0) and 60 min following (time point 60)). 
Differences between ID and controls within time point (P < 0.05) are represented by *. 
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IL-8 gene expression had a significant overall effect of group (P = 0.0189; Figure 
7.1), with control horses higher compared to ID horses. There was also a significant group 
by treatment interaction (P = 0.0329). All groups and treatments were significantly 
different from each other for IL-8 gene expression (P < 0.0018), with the exception of 
unstimulated samples where control and ID horses were not different (P = 0.726). There 
was also a significant group by time point interaction (P = 0.0125) for CCL2 gene 
expression, with control horses higher compared to ID horses within time point 0 (P = 
0.0217) and control horses having a significant decrease in gene expression between time 
points 0 and 60 (P = 0.0009).  
While there were no significant three-way group by time by treatment interactions, 
there were some significant pairwise comparisons. For TLR-4 gene expression (Figure 
7.2), ID horses had an increase from time point 0 to time point 60 in their LPS stimulated 
samples (P = 0.0098). ID horses were lower compared to controls for gene expression of 
IL-8 in LPS stimulated samples at time point 60 (P = 0.0021) and there was a trend for a 
difference for ID to be lower compared to control horses for LPS stimulated samples at 
time point 0 (0.0976), as well as a trend for an increase in control horses’ LPS simulated 
samples between time point 0 and 60 (P = 0.0722). ID horses had a trend for an increase 
in IL-10 (Figure 7.2) from time point 0 to time point 60 in LPS stimulated samples (P = 
0.0663). IFN-γ gene expression in ID horses increased from time point 0 to time point 60 
in LPS stimulated samples (P = 0.055). Finally, for CCL2 gene expression, control horses 
LPS treated samples decreased in CCL2 gene expression between time points 0 and 60 (P 
= 0.0017). Control horses had a higher gene expression in LPS treated samples at time 
point 0 compared to ID horses (P = 0.0248). There was also a trend for control horses 
unstimulated samples to be higher at time point 0 compared to 60 (P = 0.0938), and for 
time point 0 unstimulated samples the control horses had a trend to be higher compared to 
the ID horses (P = 0.0805). 
 
7.4. Discussion 
While gene expression was increased in response to incubation with LPS for all 
markers of inflammation (with the exception of CCL2), expression was increased 
minimally for most. It was particularly low for CCL5 (RANTES) and CCL2 (MCP-1), 
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genes associated with the MyD88-independent TRIF pathway. Similar results have 
previously been seen by others in monocytes of metabolically normal horses stimulated 
with 100 pg/mL LPS [274]. Surprisingly, TLR-4 gene expression was also low. This may 
be due to potential crosstalk between TLR-4 and TLR-2 [275]. Interestingly, the cytokine 
and chemokine with significant differences between ID and controls, IL-8 and CCL2, have 
been shown to be released in human keratinocytes in response to a TLR2/TLR1 
heterodimer specific mitogen [276]. In other species, MyD88 dependent TLR-4 signaling 
has been demonstrated to be activated prior to MyD88 independent signaling, and TLR-4 
internalized within 60-120 min following LPS binding [277, 278]. Therefore, lower gene 
expression of TLR-4 and other proinflammatory cytokines typically associated with 
MyD88 dependent signaling (such as TNF-α) is likely due to LPS incubation length. After 
2 h, MyD88 dependent signaling has presumably passed its peak activity, TLR-4 
internalized and in the process of being degraded, and later stage activation of MyD88 
independent signaling in process. However, more work would be needed to see if this is 
the case in the horse. In particular, further investigations of these pathways in adipose tissue 
macrophages would be of interest. 
Small sample size and subsequent lack of power likely contributed to the lack of 
differences between ID and control horses. Interestingly, though not statically significant, 
horses with ID often had an opposing inflammatory responses to oral sugar administration 
in stimulated samples compared to controls. This is similar to previous, where we 
demonstrated that in response to the OST, PMA (phorbol myristate acetate) stimulated 
lymphocytes of horses with ID had either an increase or no change in markers of 
inflammation as opposed to metabolically normal controls, who had a decrease in these 
same markers of inflammation [47]. For this work, CCL2, CCL5, IL-1β, and IL-6 gene 
expression in ID horses LPS stimulated samples numerically increased in response to oral 
sugar whereas control horses decreased. In addition, while the three-way group by time by 
treatment interaction was not significant for any variable measured, some pairwise 
comparisons were significant. These differences showed that ID horses LPS stimulated 
samples had an increased TLR-4 and IFN-γ gene expression in response to oral sugar for 
with ID horses higher at time point 60 compared to controls. Additionally, control horses 
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LPS treated samples decreased in CCL2 gene expression between time points 0 and 60, 
whereas ID horses did not. 
There were significant effects of metabolic status on IL-8 and CCL2 gene 
expression. Obese humans or those with metabolic dysfunction have been shown to have 
increased circulating or levels of TNF-α, IL-6, CCL2, and IL-8 [279-282]. Healthy elderly 
humans have been shown to have an increased whole blood inflammatory cytokine protein 
production (IL-1, IL-6, and IL-8) in response to LPS stimulation compared with young 
controls [283]. This has similarly been observed in elderly horses and those with PPID, 
with reported increases in IL-8 LPS stimulated gene expression in equine leukocytes [284]. 
Further, McFarlane and colleagues described increased chemotactic ability in elderly 
horses and those with PPID [285]. However, IL-8 lymphocyte gene expression was not 
different between obese hyperinsulinemic and non-obese normoinsulinemic controls in 
another study [31], although investigators did see an increase in neutrophil oxidative 
activity in the obese hyperinsulinemic group. For the horses in this work, all were classified 
as adults with no difference in age between the control and ID groups. Therefore, lower 
IL-8 LPS stimulated whole blood gene expression in ID horses, in particular in response to 
oral sugar administration, indicates a reduced chemotactic and therefore reduced neutrophil 
function in metabolically dysfunctional animals. Interestingly, the other inflammatory 
marker with significant differences related to group was the chemokine CCL2, or MCP-1. 
At time point 0 control horses were higher compared to ID horses for this chemokine, 
further supporting the hypothesis that horses with metabolic dysfunction may have a 
decreased innate immune response.  
 
7.5. Conclusions 
These data suggest that equine whole blood gene expression of inflammatory 
markers, particularly interferons, are induced by LPS. Increases in gene expression in 
response to LPS appear to occur primarily in MyD88 dependent associated genes, with 
little or no increase in gene expression MyD88 independent TRIF associated genes, as 
evidenced by weak induction of TRIF associated inflammatory markers, CCL5 (RANTES) 
and CCL2 (MCP-1). Oral sugar administration appears to affect LPS induced gene 
expression of inflammatory markers, with a significant effect on CCL2 (MCP-1) and TLR-
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4, and a trend for changes in IFN-γ and IL-10 gene expression. Further, reduced whole 
blood gene expression of chemokines IL-8 and CCL2 in ID compared to control horses 
indicate that horses with metabolic dysfunction may have an impaired innate immune 
response, however more work is need to further understand possible differences and their 
implications in the horse. 
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CHAPTER 8 THE EFFECT OF ALGAL DOCOSAHEXAENOIC ACID (DHA) 
CONTAINING SUPPLEMENTATION ON METABOLIC AND INFLAMMATORY 
PARAMETERS OF HORSES WITH EQUINE METABOLIC SYNDROME (EMS) 
 
There is a high incidence of obesity in the equine population, with some reporting 
up to 51% of the population classified as overweight or obese. Obesity in horses is 
associated with more serious health concerns such as insulin dysregulation (ID) and equine 
metabolic syndrome (EMS). Accepted treatments for EMS are limited and not always 
effective. Omega-3 fatty acid supplementation has been suggested as a therapeutic for 
humans with metabolic dysfunction, as it has been purported to improve insulin sensitivity 
and reduce inflammation in these individuals. However, no work has been conducted to 
investigate the effects of the omega-3 fatty acid docosahexaenoic acid (DHA) provided 
from an algal source on metabolic or inflammatory parameters in the metabolic syndrome 
horse. To investigate its possible effects on insulin and glucose dynamics as well as 
inflammation in horses with EMS, 10 mixed-sex and mixed-breed adult (8-21 years old) 
EMS horses were selected. Horses were supplemented with a DHA-rich microalgae 
containing 16 g DHA/horse/day top dressed on a vehicle or vehicle only for 46 days. Pre 
and post supplementation blood samples were collected via jugular venipuncture. Blood 
samples were used to isolate serum and plasma. Further, plasma was utilized for isolation 
of peripheral blood mononuclear cells (PBMCs). Classification of the animals’ 
inflammatory state was carried out by serologic enzyme-linked immunosorbent assay 
(ELISA), and analysis of PBMCs via flow cytometry and reverse transcription polymerase 
chain reaction (RT-PCR). Circulating fatty acids and triglyceride, leptin, and adiponectin 
concentrations were also determined. Insulin and glucose dynamics were assessed pre and 
post supplementation with an oral sugar test (OST) and a frequently sampled intravenous 
glucose tolerance test (FSIGTT). Post supplementation, horses receiving DHA rich 
microalgae had a significant increase in many circulating fatty acids, in particular an 
increase in DHA (P < 0.001), compared to controls. Treated horses also had lower serum 
triglycerides post supplementation (P = 0.023) and there was a trend (P = 0.066) for a 
reduction in the amount of TNF-α produced per lymphocyte post supplementation in the 
treated horses. Interestingly, post supplementation horses given DHA rich microalgae did 
not have the same rise in insulin concentrations 60 minutes post oral sugar administration 
 118 
(P = 0.689) as seen in controls (P = 0.012). These results indicate that DHA rich microalgae 
supplementation is able to affect circulating fatty acids, reduce inflammation, and modulate 
metabolic parameters in EMS horses. Considering the negative impact of obesity on the 
health of the horse, continued research on the underlying mechanisms and treatment of 
associated diseases is imperative. 
 
8.1. Introduction 
More than 30% of the human population is considered to be obese [2]. Obesity is 
an increasing problem not only in humans, but in the horse population as well. Similar to 
statistics in people, reports indicate that the percentage of overweight or obese horses may 
range anywhere from 20.6-51% [3-6]. Obesity in horses, as in humans, has been connected 
to more serious health concerns such as insulin dysregulation (ID) [12] and equine 
metabolic syndrome (EMS).  EMS was defined in a 2010 ACVIM consensus statement as 
the following: regional (neck crest, rump, etc.) or general adiposity, hyperinsulinemia or 
abnormal glycemic or insulinemic response to challenge, and a history of or predisposition 
towards laminitis [23]. Traditionally EMS is treated with dietary restriction and exercise. 
While this treatment is effective in most instances by increasing insulin sensitivity and 
decreasing inflammation [29], it is a process that can take months. In addition, due to 
complications from underlying or other conditions (such as laminitis), an increased 
exercise regimen is not always possible. There are two pharmaceutical options available at 
this time. They act to decrease hepatic glucose production (Metformin) and increase 
metabolism via synthetic thyroid hormone (levothyroxine sodium). However, metformin 
and levothyroxine sodium are used off label in the EMS animal and the mechanism of 
action of either is not well known. In addition, published findings have yielded conflicting 
results as to the long term safety and efficacy of these drugs in the horse [9, 154-156]. 
Therefore investigation into alternative methods of treatment for inflammation and insulin 
resistance associated with EMS is warranted.  
One method that has proven effective in humans with Metabolic Syndrome (MetS) 
[24], diabetes, obesity, or those with metabolic dysfunction [157] is supplementation with 
omega-3 fatty acids. Supplementation with the long chain omega-3 fatty acids 
docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA), is shown to improve insulin 
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sensitivity [162, 163], promote oxidation of body fat, decrease lipogenesis, and reduce 
inflammation [167, 168, 286]. Omega-3 fatty acid supplementation in horses has been 
shown to positively influence glucose clearance [171] and reduce inflammatory mediators 
[174-176]. It has also been shown in horses to change circulating fatty acid concentrations, 
including DHA, triglycerides, and phospholipids [159, 177, 178]. In addition, increases in 
DHA concentrations following supplementation have been noted not only in circulation, 
but are incorporated into skeletal muscle [160]. Therefore, the objective of this study was 
to determine the effects of omega-3 fatty acid supplementation in the form of a DHA-rich 
microalgae on metabolic and inflammatory responses in horses with EMS. 
 
8.2. Materials and Methods 
Ten EMS horses of mixed-sex and mixed-breed who were residing on the 
University of Kentucky’s Maine Chance Farm were selected for this study. All horses were 
acclimated at least 2 months prior to the start of study to dry lot paddocks, with 2 horses 
housed per paddock, and to feed and feeding protocols. Horses were provided a low fat 
diet of mixed grass hay fed at 2% body wt (BW)/day split between a morning (0800-1000, 
EST) and afternoon (1500-1600, EST) feeding. Nutrient analysis of the hay is presented in 
Table 8.1. Horses were also provided with the morning feeding; 1 lb/day balancer pellet 
(Essential K®, Tribute Equine Nutrition, OH) and 1 lb/day alfalfa pellet (Hallway feeds, 
Farmers Feed Mill, KY), and had access to water and a mineral block ad libitum. EMS 
horses were randomly assigned to one of two groups, treatment group (n=6; mean age 13.2 
± 4.4 years) or control (n=4; mean age 11.5 ± 2.6 years). Horses in were not different in 
age between treated groups (P = 0.48). At the start of the 46 day supplementation period 
the treatment group received a DHA-rich microalgae supplement (FORPLUS™, Alltech, Inc, 
Nicholasville KY) containing 16 g DHA mixed with 25 ml water, 15 ml molasses (Double 
S Liquid Feed Services, Inc., Danville, IL), and 4 ml anise extract (A1 Spice World, Glen 
Head, NY) top dressed onto their balancer and alfalfa pellets to make the supplement 
palatable and to ensure horses received their entire daily portion of supplement. Control 
horses received the vehicle of 25 ml water, 15 ml molasses, and 4 ml anise extract without 
the algal supplement top dressed onto their balancer and alfalfa pellets only. Analysis of 
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algal supplements nutritional and fatty acid content was performed by Eurofins Analytical 
Laboratories (New Orleans, LA, USA) and is presented in Table 8.2.  
 
Table 8.1. Mixed grass hay dietary analysis. 
Component DM 
DE (Mcal/kg) 1X 2.68 
ME (Mcal/kg) 1X 2.26 
% Moisture (as fed) 8.5 
% Dry Matter (as fed) 91.5 
% Crude Protein 16.3 
% Adjusted Crude Protein 16.3 
% Acid Detergent Fiber 41.0 
% Neutral Detergent Fiber 55.3 
% NFC 22.5 
% Starch 1.6 
% WSC (water soluble carbohydrates) 6.0 
% NSC 7.6 
% ESC (simple sugars) 4.5 
% Crude Fat 2.8 
% TDN 59 
NEL, Mcal/Lb 0.56 
NEM, Mcal/Lb 0.54 
NEG, Mcal/Lb 0.29 
% Calcium 1.01 
% Phosphorus 0.27 
% Magnesium 0.18 
% Potassium 2.18 
% Sodium 0.043 
PPM Iron 137 
PPM Zinc 23 
PPM Copper 9 
PPM Manganese 26 
PPM Molybdenum 3.5 
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Table 8.2. Algal supplement dietary analysis and fatty acid content. 
Component As fed basis 
% Moisture 2.4 
% Acid Hydrolysis Fat 58 
% Crude Fiber 0.9 
Calculated % Carbohydrate 17.3 
Combustion % Protein  13.5 
% Total Ash 3.1 
% Calcium 0.34 
% Phosphorus 0.47 
% Sulfur 0.74 
% Potassium 0.55 
% Sodium 0.10 
PPM Iron 13 
PPM Zinc 36 
PPM Copper 2 
PPM Selenium 0.13 
Fatty Acid % of fat content 
C6:0 Caproic acid < 0.10% 
C7:0 Heptanoic acid < 0.10% 
C8:0 Caprylic acid < 0.10% 
C9:0 Nonanoic acid < 0.10% 
C10:0 Capric acid < 0.10% 
C11:0 Undecaniod acid < 0.10% 
C12:0 Lauric acid 0.13 % 
C13:0 Tridecanoic acid < 0.10% 
C14:0 Myristic acid 4.16% 
C14:1 Myristoleic acid < 0.10% 
C15:0 Pentadecanoic acid 1.98% 
C15:1 Pentadecenoic acid < 0.10% 
C16:0 Palmitic acid 52.55% 
C16:1 Palmitoleic acid 0.11% 
C17:0 Margaric acid 0.82% 
C17:1 Margaroleic acid < 0.10% 
C18:0 Stearic acid 1.65% 
C18:1n7c Vaccenic acid < 0.10% 
C18:1n9c Oleic acid < 0.10% 
C18:1n9t Elaidic acid < 0.10% 
C18:2n6c Linoleic acid < 0.10% 
C18:2n6t Linolelaidic acid < 0.10% 
C18:3n3c alpha-linolenic acid < 0.10% 
C18:3n6c gamma-linolenic acid < 0.10% 
C19:0 Nonadecanoic acid < 0.10% 
C20:0 Aracidic acid 0.21% 
C20:1 Eicosenoic acid < 0.10% 
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Table 8.2 Algal supplement dietary analysis and fatty acid content. (continued) 
Fatty Acid % of fat content 
C20:2n6c Eicosadienoic acid < 0.10% 
C20:3n3c Eicosatrienoic acid 0.74% 
C20:3n6c homo-gamma-Linolenic acid 0.13% 
C20:4n6c Arachidonic acid 0.14% 
C20:5n3c Eicosapentaenoic acid 0.56% 
C21:0 Heneicosanoic acid < 0.10% 
C22:0 Behenic acid 0.11% 
C22:1 Erucic acid < 0.10% 
C22:2n6c Docosadienoic acid 0.41% 
C22:5n3c Docosahexaenoic acid 0.17% 
C22:6n3c Docosahexaenoic acid 27.74% 
C23:0 Tricosanoic acid < 0.10% 
C24:0 Lingoceric acid 0.11% 
C24:1 Nervonic acid 0.32% 
Analysis of algal supplement fatty acid content by high-
performance liquid chromatography (HPLC) 
 
Originally, the study was intended to be carried out with 12 horses and as a 
crossover-design, with a 60 day washout period. However, 2 horses were dropped from the 
study for health reasons. In addition, the second half of the crossover was not completed 
due to significantly elevated concentrations of circulating DHA in treated horses compared 
to controls as far as 263 days (P = 0.01, DHA-rich microalgae treated horses median 0.30; 
IQR 0.24 – 0.40 versus control horses median 0.06; IQR 0.06 – 0.172) following cessation 
of supplementation. All experimental procedures were approved by the University of 
Kentucky’s IACUC (institutional animal care and use committee).  
8.2.1. EMS determination  
EMS was determined by the criteria established in a 2010 ACVIM consensus 
statement [23]. In brief, hyperinsulinemia, general or regional obesity, and a history of or 
predisposition to laminitis. A portable agriculture scale (model 700, Tru Test Inc., Mineral 
Wells, TX) was used to establish body weight, which was monitored weekly. Body 
condition score (BCS) was determined and averaged between three trained investigators 
using the 1-9 Henneke scoring system [186], with a 1 representing an extremely emaciated 
animal and a 9 representing an extremely obese animal. The same trained individuals 
scored and regional adiposity via the 0-5 cresty neck score (CNS) system established by 
Carter et al. [187], with a 0 representing no neck crest and a 5 representing a crest so large 
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it permanently droops to one side of the neck. Blood collection for serum and plasma 
samples was carried out via jugular venipuncture. To ascertain the presence of insulin 
dysregulation, an oral sugar test (OST) was performed; following overnight fasting serum 
samples were collected and 0.15 ml/kg of Karo Light Corn syrup (ACH food companies, 
Cordova, TN) orally administered and a second serum sample collected 60 minutes later 
[13, 23]. Serum samples were kept at -20º C until analysis. A fasting insulin level of >20 
μIU/mL was considered indicative of hyperinsulinemia, and an increased insulin 
(>60μU/mL) 60 minutes post administration of oral sugar was classified as insulin 
dysregulation [13, 23]. These cut-off values were also utilized as they are recommended 
by the Tufts University Equine Endocrinology Group (EEG).  
Horses were screened using the TRH (thyrotropin releasing hormone) stimulation 
test and low-dose dexamethasone suppression testing to ensure that none were affected by 
pituitary pars intermedia dysfunction (PPID). TRH stimulation testing was carried out as 
previously described [191, 192]. Briefly; an A.M. (between 0800 and 1200, EST) baseline 
blood sample was taken via jugular venipuncture. Following this, a 1ml dose of TRH 
dissolved to 1 mg/ml in 0.9% saline (Sigma-Aldrich, St. Louis, MO) was administered 
intravenously (IV) and 10 minutes post TRH injection a second blood sample was taken. 
Ethylenediaminetetraacetic acid (EDTA) containing tubes were used to collect blood 
samples. Tubes were placed on ice and transported to the lab for immediate centrifugation 
and plasma isolation [193]. Plasma was stored at -20 º C until shipped on dry ice to Cornell 
University for determination of ACTH concentrations. Low-dose dexamethasone 
suppression testing was performed as previously described [194]. In brief, an afternoon 
(1550-1800 hours) baseline jugular blood sample was taken. Following this, an 
intramuscular (IM) dexamethasone bolus (0.04 mg/kg BW) was administered and a second 
blood sample taken 19 hours later. A gel serum separator tube was used to collect samples. 
Tubes were centrifuged, and serum isolated and frozen at -20 º C until cortisol analysis. As 
recommended by the EEG, concentrations of ACTH 10 minutes post TRH injection in 
excess of 100 pg/mL or concentrations of cortisol exceeding 1.0 µg/dL 19 hours following 
dexamethasone injection were considered positive for PPID. Any animals meeting these 
criteria were excluded.  
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Analysis of ACTH, cortisol, and insulin were performed by Cornell University’s 
Animal Health Diagnostic Center Endocrinology Laboratory. The Millipore porcine 
insulin RIA kit (EMD Millipore Corporation, Darmstadt, Germany) was used to measure 
insulin concentrations [47], ACTH was measured via an automated chemiluminescent 
enzyme immunoassay system (Immulite, Erlangen, Germany) [195], and cortisol 
concentrations were determined using the Siemens Immulite Cortisol kit (Siemens, 
Erlangen, Germany).  
8.2.2. Sample collection and timeline 
Serum and EDTA plasma samples were taken after an overnight fast at baseline 
and following the OST both prior to (day 0; time point 1) and following supplementation 
(day 46; time point 2). Horses were administered a frequently sampled intravenous glucose 
tolerance test (FSIGTT; see below) one day following blood collection and OST. Serum 
samples were utilized for determination of insulin, leptin, and triglyceride analysis. EDTA 
plasma samples were used to determine fatty acid concentrations.  
8.2.3 Frequently sampled intravenous glucose tolerance test (FSIGTT)-Optimized  
At time points 1 and 2 a FSIGTT was performed as previously described [287]. In 
brief; an indwelling, long-term intravenous catheter was placed to administer treatments 
and collect blood samples. Following baseline blood sample collection, a 50% glucose (100 
mg/kg, IV) was administered, followed 20 minutes later by administration of insulin (20 
mU/kg, IV). Blood samples were obtained at -10, -5, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 
19, 22, 23, 24, 25, 27, 30, 35, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 minutes after 
glucose administration. Blood samples from the FSIGTT were analyzed for glucose 
concentrations on an YSI analyzer (YSI Incorporated, Xylem Inc., Yellow Springs, OH). 
8.2.4 Endocrine and lipid measures 
Serum samples from the OST for time points 1 and 2, as well as EDTA plasma 
from the FSIGTT were sent to Cornell University’s endocrinology lab for determination of 
insulin using RIA (see above). In addition, fasting serum samples were sent to Cornell 
University’s Clinical Pathology lab for leptin and triglyceride analysis via colometric assay 
using a Roche ModP analyzer (Roche Diagnostics, Indianapolis, IN) [49]. Fasting EDTA 
plasma samples from time points 1 and 2 were sent to Michigan State University’s 
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Diagnostic Center for Population and Animal Health for plasma fatty acid analysis using 
high-performance liquid chromatography (HPLC) [288].  
8.2.4. Peripheral blood mononuclear cell (PBMC) inflammatory cytokine production  
Heparinized blood was used to isolate peripheral mononuclear cells (PBMCs) by 
Ficoll-Paque PlusTM (Amersham Biosciences, Piscataway, NJ) gradient centrifugation 
[197].  Cells were frozen in 10% fetal bovine serum (FBS; Sigma–Aldrich, St. Louis, MO), 
40% dimethyl sulfoxide (DMSO), and 50% Roswell Park Memorial Institute medium 
(RPMI-1640, Gibco, Grand Island, NY) until thawed for in vitro stimulation. For 
stimulation, 107 PBMC were incubated in 1 ml c-RPMI (RPMI-1640 with 2.5% fetal 
equine serum (FES; Sigma–Aldrich, St. Louis, MO), 100 U/ml penicillin/streptomycin 
(Sigma), and 55 mM 2-mercaptoethanol (Gibco) media. Cells were incubated at 37 °C, 5% 
CO2 with Brefeldin A (10 mg/ml; Sigma) and select wells with the positive control phorbol 
12-myristate 13-acetate (PMA; 25 ng/ml; Sigma) and ionomycin (1 mM; Sigma) for 4 hrs. 
Following this, determination of cytokine gene expression was carried out by separating 
aliquots of the cells and placing them into Trizol (Ambion) to isolate RNA (see below). 
Remaining cells were assayed by flow cytometry for interferon gamma (IFN-γ) and tumor 
necrosis factor alpha (TNF-α) production. Cells were fixed in 2% paraformaldehyde 
(Sigma) and stored overnight at 4oC. After overnight storage, IFN-γ and TNFα intracellular 
staining was carried out as previously described [198]. After the cells were stained, aliquots 
of cells were resuspended in FACS flow and flow cytometric acquisition was performed 
on a FACSCALIBUR™ (Becton Dickinson, San Jose, CA). Determination of the percent 
of IFN-γ and TNFα lymphocytes was accomplished with the use of CELL QUEST™ 
(Becton Dickinson) [42].  
A modified Trizol method was used to extract total RNA from PBMC cultures (see 
above). One µg of RNA was reverse transcribed into cDNA, as previously described [42, 
197].  In brief; 1 µg of each RNA sample and a reverse transcription master mix (Promega, 
Madison, WI) was incubated for 15 min at 42oC and for 5 min at 95oC. Reactions included 
5µl cDNA and 20µl of master mix. Master mix included; 6.25µl nuclease-free water 
(Qiagen), 1.25µl primer/probe 20X assay mix (Applied Biosystems, Foster City, CA), and 
12.5µl TaqManTM (Applied Biosystems). Equine-specific, inventoried, intron-spanning 
primers and probes were used with Applied Biosystems Real-Time PCR (ABI 7900HT) 
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against the following genes: Housekeeping gene beta-glucuronidase (β-gus) and the 
following genes; IFN-γ (catalog number 4331182), interleukin 6 (IL-6; catalog number 
4351372), interleukin 10 (IL-10; catalogue number 4331182), TNF-α (catalog number 
4331182), and transferrin (catalog number 4351372). Samples were processed in duplicate 
and incubated for 95oC for 10 min. They then underwent 40 cycles at 95oC for 15s and 
60oC for 60s. Relative changes in gene expression were determined by the CT method 
[200], with mean CT for week 0 set as the calibrator for all samples. Relative quantity, or 
RQ, was calculated as 2-CT and used to express results. 
8.2.5. Serum Cytokine Analysis 
8.2.5.1. TNF-α ELISA 
Serum concentrations of TNF-α protein were determined using a commercially 
available equine TNF-α ELISA kit (R&D, Minneapolis, MN). This assay is optimized for 
equine serum samples diluted at a minimum of 1:2 [289]. All steps of the ELISA were 
performed according to the manufacturer’s instructions, with the exception of the 
following; coating antibody provided was prepared in carbonate buffer (15 mmol Na2CO3, 
35 mmol NaHCO3, pH 9.6) and the final 2 incubation times were increased from 20 min 
to 30 min. In addition, single absorbance was measured at A450.   
8.2.5.2. IL-6 ELISA  
Serum concentrations of IL-6 were determined using an IL-6 ELISA validated for 
use in the horse with an analytical sensitivity of 780 pg/mL [290]. The ELISA utilizes a 
polyclonal goat anti-horse IL-6 antibody (AF1886, R&D Systems, Inc., Minneapolis, MN) 
to coating ELISA plates (Immunoplate Maxisorp, Nalge Nunc Int., Rochester, NY). The 
antibody was diluted to a final concentration of 1 μg/mL in carbonate buffer (15 mmol 
Na2CO3, 35 mmol NaHCO3, pH 9.6) and incubated overnight at 4 °C. Afterwards, the 
coating solution was discarded and the plates blocked for 30 min at room temperature with 
the addition of phosphate buffered saline (PBS, pH 7.2) containing 0.5% (w/v) bovine 
serum albumin. Plates were washed five times with phosphate buffer (2.5 mmol NaH2PO4, 
7.5 mmol Na2HPO4, 145 mmol NaCl, 0.1% (v/v) Tween 20, pH 7.2). A recombinant 
equine IL-6 (1886-EL, R&D Systems, Inc., Minneapolis, MN) diluted in 2-fold serial 
dilutions ranging from 50 to 0.78 ng/mL was used as standard to determine IL-6 
concentrations in the samples. The serum was diluted in phosphate buffer, added to the 
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plates in triplicate wells and incubated for 90 min at room temperature. After five washes, 
biotinylated goat anti-horse IL-6 (AF1886, R&D Systems, Inc., Minneapolis, MN) diluted 
1:100 in phosphate buffer was added, incubated for 60 min, and washed again. A 
streptavidin–horseradish peroxidase solution (Jackson ImmunoResearch Lab., West 
Grove, PA) was added to the plates for another 30 min. After a final wash, substrate buffer 
(33.3 mmol citric acid, 66.7 mmol NaH2PO4, pH 5.0) was added and incubated for 20 min 
in the dark. The reaction was stopped by adding one volume of 0.5 mol H2SO4. Plates were 
read in an ELISA reader (Bio-Tek, Winooski, VT) at 450 nm absorbance.  
8.2.5.3. CRP ELISA  
A commercially available equine specific kit (Kamiya Biomedical Company, 
Tukwila, WA) was used to measure C - reactive protein (CRP) in the serum according to 
manufacturer’s instructions and as previously described [291]. 
8.2.6. Data Analysis 
Data were analyzed via Sigma Plot 13.0 (Systat Software, San Jose, CA). A two-
way repeated measured ANOVA was used with fixed effects set as treated vs control and 
time point and all possible interactions analyzed. Data not normal were log transformed 
and resulted in normality. Results were considered statistically significant when P < 0.05 
and trends considered at P < 0.10. 
 
8.3. Results 
8.3.1. Lipid, phenotypic, and endocrine measures 
Plasma fatty acid concentrations as a percentage of total circulating fatty acids are 
presented in Table 8.3. DHA-rich microalgae treated horses were higher at time point 2 
compared to all horses at time point 1 and control horses at time point 2 in DHA (P < 
0.001) and C:22 2n6c (P < 0.001) concentrations. However, DHA-rich microalgae treated 
horses at time point 2 were lower compared to all others for C18:1n9c (P = 0.02) and 
C18:3n6c (P = 0.035) plasma concentrations. Control horses at time point 2 had higher 
concentrations of C16:1n7c compared to control horses at time point 1 (P = 0.009), but 
were not different compared to treated horses regardless of time point. In addition, there 
was an overall effect of time point for C20:3n3c (P = 0.011) and C24:1n9c (P = 0.025) 
concentrations, with horses at time point 2 higher compared to horses at time point 1.  
  
1
2
8
 
Table 8.3. Plasma fatty acid results for DHA-rich microalgae treated and control EMS horses both pre (time point 1) and post (time 
point 2) a 46-day supplementation period. 
Plasma Fatty Acid 
Concentrations (% of total fatty acids) 
Control horses  
time point 1 
Control horses  
time point 2 
Treated horses  
time point 1 
Treated horses  
time point 2 
C22:6n3c Docosahexaenoic acid 0.05 + 0.1 a 0.05 + 0.1 a 0.01 + 0.1 a 1.94 + 0.1 b 
C14:0 Myristic Acid 0.86 + 0.1 0.97 + 0.1 0.88 + 0.1 0.89 + 0.1 
C16:0 Palmitic Acid 15.87 + 0.7 16.69 + 0.7 16.31 + 0.6 17.22 + 0.6 
C16:1n7c Palmitoleic Acid 1.10 + 0.2 a 1.49 + 0.2 b 1.13 + 0.1 a, b 1.15 + 0.1 a, b 
C17:0 Margaric Acid 0.36 + 0.03 0.35 + 0.03 0.44 + 0.02 0.39 + 0.02 
C18:0 Steric Acid 15.38 + 0.7 15.40 + 0.7 15.97 + 0.6 15.35 + 0.6 
C18:1n7c Cis-Vaccenic Acid 1.50 + 0.2 1.43 + 0.2 1.55 + 0.1 1.53 + 0.1 
C18:1n9c Oleic Acid 16.10 + 1.5 b 17.67 + 1.5 b 15.74 + 1.2 b 12.64 + 1.2 a 
C18:2n6c Linoleic Acid Methyl Ester 43.76 + 2.0 41.13 + 2.0 43.49 + 1.6 44.89 + 1.6 
C18:3n3c Alpha linolenic Acid 0.23 + 0.04 0.23 + 0.04 0.25 + 0.03 0.18 + 0.03 
C18:3n6c y-Linolenic Acid 3.64 + 0.3 b 3.15 + 0.3 b 3.24 + 0.3 b 1.81 + 0.3 a 
C20:2n6c Eicosadienoic Acid 0.15 + 0.02 0.21 + 0.02 0.14 + 0.01 0.16 + 0.01 
C20:3n3c Eicosatrienoic Acid 0.59 + 0.1 0.75 + 0.1 0.56 + 0.1 0.89 + 0.1 
C20:3n6c Homo-y Linolenic Acid 0.19 + 0.04 0.17 + 0.04 0.12 + 0.03 0.24 + 0.03 
C:22 2n6c Docosadienoic Acid 0.07 + 0.02 a 0.07 + 0.02 a 0.04 + 0.02 a 0.22 + 0.02 b 
C22:4n6c  0.004 + 0.01 a 0.009 + 0.01 a -0.002 + 0.01 a 0.316 + 01 b 
C22:5n3c Docosapentaenoic Acid 0.12 + 0.02 0.15 + 0.02 0.09 + 0.02 0.13 + 0.02 
C24:1n9c Nervonic Acid 0.07 + 0.02 0.10 + 0.02 0.04 + 0.02 0.09 + 0.02 
Plasma fatty acid concentrations as measured by high performance liquid chromatography (HPLC) in EMS control (n=4) versus DHA-
rich microalgae treated (n=6) horses. Data are expressed as the percentage of total fatty acid concentrations. Results are presented as 
least square mean plus or minus standard error of the mean. Within a row, differences (P < 0.05) are represented by differing superscripts.
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OST results and phenotypic data, along with serum leptin and triglycerides are 
presented in Table 8.4. There were no differences in fasting insulin between control and 
treated horses’ both pre and post supplementation (P = 0.568). However, control horses 
had higher insulin concentrations 60 minutes post oral sugar administration at time point 2 
compared to time point 1 (P = 0.012). Similarly, when considering the change in insulin 
concentrations 60 minutes post oral sugar administration compared to baseline insulin 
concentrations (delta change), control horses had an increase (P = 0.009) from time point 
1 to time point 2 whereas DHA-rich microalgae treated horses did not (P = 0.419). In 
addition, control horses did not have greater delta insulin concentrations at time point 1 (P 
= 0.143) compared to treated horses, but they did have a greater delta insulin at time point 
2 (P = 0.027). DHA-rich microalgae treated horses had lower serum triglycerides at time 
point 2 compared control horses (P = 0.017) and compared to treated horses at time point 
1 (P = 0.023). Control horses at time point 1 were not different from control horses at time 
point 2 or from treated horses at any time point. There were no differences between treated 
or control horses for serum leptin, regardless of time point. While there was an overall 
difference in time point for BCS (P < 0.001), with all horses being higher at time point 2 
versus time point 1, there were no differences either pre or post supplementation between 
treated and control horses. Nor were there any differences between treated or control horses 
for CNS or weight.  
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Table 8.4. Endocrine data, phenotypic measures, and serum leptin and triglyceride concentrations for DHA-rich microalgae treated and 
control EMS horses both pre (time point 1) and post (time point 2) a 46-day supplementation period. 
Endocrine and  
phenotypic measures 
Control horses 
time point 1 
Control horses  
time point 2 
Treated horses  
time point 1 
Treated horses  
time point 2 
Basal Insulin (µIU/ml) 21.58 ± 6.89 22.85 ± 6.89 32.61 ± 5.62 29.76 ± 5.62 
Insulin 60 min post oral sugar 
administration (µIU/ml) 
68.90 ± 12.29 a 106.25 ± 12.29 b 78.13 ± 10.04 a, b 82.02 ± 10.04 a, b 
Change in insulin concentrations 
(OST 60 min-basal insulin; µIU/ml) 
47.31 ± 9.69 83.40 ± 9.69 45.53 ± 7.91 52.26 ± 7.91 
Log BCS 0.79 ± 0.01 a 0.84 ± 0.01 b 0.82 ± 0.01 a 0.86 ± 0.01 b 
CNS 2.29 ± 0.44 2.25 ± 0.44 2.97 ± 0.36 3.08 ± 0.36 
Weight (kg) 515.60 ± 34.54 517.19 ± 34.54 562.63 ± 28.03 568.16 ± 28.03 
Leptin (ng/mL) 7.23 ± 1.40 6.72 ± 1.40 7.18 ± 1.14 7.94 ± 1.14 
Triglycerides (mg/dL) 47.75 ± 6.62 a, b 59.00 ± 6.62 b 49.17 ± 5.40 b 35.33 ± 5.40 a 
Phenotypic measures, endocrine data, and serum leptin and triglyceride concentrations in EMS control (n=4) versus DHA-rich 
microalgae treated (n=6) horses. Results are presented as least square mean plus or minus standard error of the mean. Within a row, 
differences (P < 0.05) are represented by differing superscripts. 
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8.3.2. FSIGTT 
As shown in Table 8.5, there were no treatment differences in insulin sensitivity 
(SI), acute insulin response to glucose (AIRg), disposition index (DI), or glucose 
effectiveness (Sg). Nor were there any differences over time in SI, DI, or Sg. While there 
was an increase in acute insulin response to glucose for time point 2 compared to time point 
1 (P = 0.008), there was not a treatment by time point interaction.  
 
Table 8.5. MinMod analysis of FSIGTT data for DHA-rich microalgae treated and control 
EMS horses both pre (time point 1) and post (time point 2) a 46-day supplementation 
period. 
Insulin 
sensitivity 
measures 
Control horses 
time point 1 
Control horses 
time point 2 
Treated horses 
time point 1 
Treated horses 
time point 2 
AIRg (acute 
insulin response 
to glucose) 
158.9 ± 73.8 a 394.4 ± 73.8 b 153.5 ± 60.2 a 335.8 ± 60.2 b 
SI (insulin 
sensitivity) 
0.442 ± 0.215 0.352 ± 0.215 0.324 ± 0.176 0.449 ± 0.176 
DI (disposition 
index) 
73.4 ± 77.8 106.0 ± 77.8 73.5 ± 63.5 185.8 ± 63.5 
Sg (glucose 
effectiveness) 
0.022 ± 0.009 0.025 ± 0.009 0.034 ± 0.007 0.018 ± 0.007 
Measures of insulin resistance in EMS control (n=4) versus DHA-rich microalgae treated 
(n=6) horses from MinMod analysis of FSIGTT data obtained from insulin and glucose 
EDTA plasma concentrations. Results are presented as least square mean plus or minus 
standard error of the mean. Within a row, differences (P < 0.05) are represented by differing 
superscripts. 
 
8.3.3. Peripheral blood mononuclear cell (PBMC) inflammatory cytokine production 
Flow cytometry analysis of TNF-α and IFN-γ intracellular protein (Table 8.6) 
showed no significant differences between DHA-rich microalgae treated and control horses 
for the percent of lymphocytes positive (% gated) for IFN-γ or TNF-α protein, nor for IFN-
γ intensity of fluorescence per lymphocyte (mean fluorescence activity-MFI). There was a 
trend (P = 0.066) for an interaction between treatment and time point for TNF-α MFI, with 
DHA-rich microalgae treated horses having a lower MFI at time point 2 compared to time 
point 1. Control horses were not different between time points or from treated horses, 
regardless of time point. There was an overall time point difference for IFN-γ MFI (P = 
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0.006), with horses at time point 1 higher compared to time point 2, and an overall 
treatment versus control difference with TNF-α % gated higher in treated horses compared 
to controls (P < 0.001). 
 
Table 8.6. PBMC inflammatory cytokine production for DHA-rich microalgae treated and 
control EMS horses both pre (time point 1) and post (time point 2) a 46-day 
supplementation period. 
Inflammatory 
cytokine 
measures 
Control horses 
time point 1 
Control horses 
time point 2 
Treated horses 
time point 1 
Treated horses 
time point 2 
IFN-γ % gated 20.13 ± 2.55 20.22 ± 2.55 24.51 ± 2.08 23.56 ± 2.08 
IFN-γ MFI 126.43 ± 7.98 101.86 ± 7.98 108.45 ± 6.52 94.43 ± 6.52 
TNF-α % gated 39.56 ± 2.76 40.96 ± 2.76 53.10 ± 2.25 58.79 ± 2.25 
TNF-α MFI 57.39 ± 6.12 58.52 ± 6.12 64.11 ± 5.00 54.98 ± 5.00 
IFN-γ RQ 13296 ± 2192 9383 ± 2192 11395 ± 1790 9642 ± 1790 
TNF-α RQ 330.5 ± 136.6 315.4 ± 136.6 619.0 ± 111.6 605.3 ± 111.6 
IL-6 RQ 48.41 ± 8.74 40.75 ± 8.74 42.91 ± 7.14 39.28 ± 7.14 
IL-1β RQ 3.31 ± 0.91 3.36 ± 0.91 1.86 ± 0.74 1.12 ± 0.74 
IL-10 RQ 142.56 ± 34.56 144.06 ± 34.56 221.66 ± 28.22 173.84 ± 28.22 
PBMC inflammatory data in EMS control (n=4) versus DHA-rich microalgae treated (n=6) 
horses. Flow cytometry data is represented by % gated and MFI, which characterize the 
percent of lymphocytes positive for IFN-γ or TNF-α protein (% gated) and the intensity of 
florescence, or mean cytokine activity, per lymphocyte. RT-PCR data is represented by 
relative quantity (RQ) of gene expression. Results are presented as least square mean plus 
or minus standard error of the mean. Within a row, differences (P < 0.05) are represented 
by differing superscripts. 
 
Lymphocyte gene expression of IFN-γ, TNF-α, IL-6, IL-1β, and IL-10 was not 
different between time points, regardless of treatment.  There was an overall treatment 
versus control difference, with IL-1β expression higher in controls compared to treated 
horses (P = 0.009). 
8.3.4. Serum cytokine analysis 
 Circulating concentrations of IL-6, TNF-α, and CRP protein as measured by ELISA 
were not different between DHA-rich microalgae treated or control horses (Table 8.7). 
There were no overall differences between time points 1 or 2, or any overall differences 
between treated or control horses.  
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Table 8.7. Serum inflammatory cytokine and CRP results for DHA-rich microalgae treated 
and control EMS horses both pre (time point 1) and post (time point 2) a 46-day 
supplementation period. 
Serum inflammatory 
cytokines and CRP 
Control horses  
time point 1 
Control horses  
time point 2 
Treated horses  
time point 1 
Treated horses  
time point 2 
TNF-α 18.5 ± 596.6 19.1 ± 596.6 57.0 ± 487.1 1375.1 ± 487.1 
Log IL-6 0.32 ± 0.32 0.34 ± 0.32 1.05 ± 0.26 1.25 ± 0.26 
C-reactive Protein 272.4 ± 837.1 566.9 ± 837.1 278.5 ± 683.5 1636.5 ± 638.5 
Circulating inflammatory cytokines and CRP in EMS control (n=4) versus DHA-rich 
microalgae treated (n=6) horses. Data are expressed as ELISA units. Results are presented 
as least square mean plus or minus standard error of the mean. Within a row, differences 
(P < 0.05) are represented by differing superscripts. 
 
8.4. Discussion 
 As expected, treated horses had increases in circulating DHA as well as other fatty 
acid concentrations post supplementation, similar to what has been observed in other work 
[159, 288, 292]. Also similar to previous studies [177], DHA-rich microalgae treated 
horses in this study had a reduction in serum triglycerides following supplementation. 
Human studies have likewise indicated a positive effect of omega 3 fatty acid 
supplementation on lipids and lipid metabolism [169, 170], including lipids which are 
implicated in insulin resistance and inflammation, such as ceramide [140]. Indeed, linoleic 
and DHA containing phosphatidylcholine and sphingomyelin were found to be increased 
in rats following an exercise regimen, whereas arachidonic acid containing 
phosphatidylcholines, phosphatidylethanolamine, and phosphatidylinositol were increased 
in rats following high fat feeding [125]. In addition, exercised rats were more insulin 
sensitive compared to rats fed a high fat diet. Considering that dietary supplementation 
with omega-3 fatty acids can improve concentrations of these lipids [169, 293], this 
supports their usage in individuals with metabolic dysfunction. Further, these studies 
further indicate a link between circulating fatty acids, insulin sensitivity, and inflammation. 
 Supplementation with omega 3 fatty acids in equines has been proposed as a way 
to improve glucose and insulin dynamics [172], similar to the improved insulin sensitivity 
seen in rats, pigs, and humans following supplementation [164-166].  DHA rich algal 
supplementation has also been shown in horses following dexamethasone administration 
to improve baseline glucose and insulin concentrations, as well as the modified insulin to 
glucose ratio [173]. In this study, there was a positive effect on metabolic parameters in 
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horses fed 16 g/day DHA from an algal source for 46 days. Specifically, treated horses did 
not have the same increase in insulin responses to an OST. These improved insulin 
responses to the OST indicate that supplementation provided a protective effect from 
increases in insulin responses seen in the control group. This increase in insulin measured 
in the control horses may be in part due to seasonal changes, however more work is needed 
to explore possible seasonal effects on insulin and insulin responses to the OST in the EMS 
animal. 
In humans and in mice, metabolic dysfunction has long been associated with 
increases in inflammation [267, 294]. These increases in inflammation have been proposed 
for the EMS horse or pony as well [28, 295, 296]. For this study, treated horses had a trend 
for a decrease in TNF-α MFI post supplementation, indicating immune modulating anti-
inflammatory effect of DHA-rich microalgae supplementation in EMS horses. There were 
no differences in gene expression of PBMC inflammatory markers as measured by RT-
PCR, suggesting modification likely occurs post transcriptionally. Indeed, no differences 
were seen in circulating inflammatory markers as measured by ELISA either pre or post 
supplementation. This is likely due in part to small sample sizes and large variability. 
Results from other work regarding the effect of omega 3 fatty acid supplementation on 
inflammatory parameters in the horse has been mixed. While fish oil supplementation has 
not been shown to lower prostaglandin E2 (PGE2) production in lipopolysaccharide (LPS) 
stimulated PBMCs from yearling horses [292], there has been an effect following 14 weeks 
of fish oil supplementation on PGE2 production in healthy equine LPS stimulated 
bronchoalveolar lavage fluid (BAL) cells compared to those supplemented with corn oil 
[297]. Feeding seal blubber oil as a source of omega 3 fatty acids has also been shown to 
have anti-inflammatory effects in the BAL of horses with recurrent airway obstruction 
[298]. The algal source used for this work largely contained DHA with only minor amounts 
of EPA, and DHA has been shown to be more effective in reducing inflammation compared 
to EPA [299, 300]. This may have been one of the reasons for the observed the trend in 
reduction of TNF-α MFI following supplementation. 
The major limitation of this study was small sample size. Interestingly, treated 
horses had significantly elevated circulating DHA concentrations 263 days following 
cessation of supplementation. Others have reported that 42 days [159] and 56 days [301] 
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post supplementation DHA and EPA concentrations were not different from controls. This 
discrepancy may be explained by the fact that in the current study, horses had increased 
adiposity compared to presumably metabolically normal horses used in other studies. In 
people and in horses, DHA and EPA supplementation appears to be dose responsive [158, 
159]. In addition, it has been shown in humans that DHA can be stored in adipose tissue 
for years [161]. Therefore, treated horses may have stored DHA in large amounts in 
adipose tissue and slowly released it over an extended period of time. An addition 
explanation may be that most other equine studies have utilized a fish oil source of DHA 
and EPA, whereas the current study which utilized an algal source of DHA. Considering 
that DHA has been shown to be more readily incorporated into tissue than EPA [302], 
DHA vs EPA concentrations or the ratio of DHA to EPA may influence DHA incorporation 
into and release from tissue.  
 
8.5. Conclusions 
 DHA-rich microalgae supplementation positively affected metabolic, 
inflammatory, and lipid parameters following 46 days of 16 g/day algal DHA 
supplementation in a group of EMS horses. While supplementation did not normalize 
insulin levels, given long-term it may prove useful as a nutritional therapy in addition to 
diet and exercise for horse with this syndrome. However, more work is needed to 
investigate this further, and to better understand mechanisms responsible for the capacity 
of DHA-rich microalgae to modulate these parameters.  
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CHAPTER 9 DISCUSSION 
 
Given the health concerns associated with insulin dysregulation (ID) in the horse, 
little is known about its underlying mechanisms or the involvement of the immune system 
and inflammation in this endocrine and metabolic dysregulation. Our overall hypothesis 
for this work was that due in part to changes in their gut microbiome and plasma lipidome, 
horses with ID will have changes in circulating proinflammatory markers, in particular in 
response to glycemic challenge, that further drive metabolic dysfunction.  
It has been well established in human and mouse models that metabolic dysfunction 
has an inflammatory component [267, 294]. While this is proposed to be the case in the ID 
horse or pony [28, 295, 296], results have been mixed. There have been reports of increased 
IL-1β and IL-6  gene expression in equine nuchal adipose tissue [41] and increased TNF-
α plasma or serum concentrations in ID horses [28]. Increases in plasma TNF-α 
concentrations have also been observed in ponies with a history of pasture-associated 
laminitis [237]. Correlative analysis has likewise linked insulin insensitivity, obesity, and 
inflammation in horses with ID [8]. Often, differences in inflammatory markers in horses 
with ID are seen at the gene expression level, are limited to adipose tissue, and are not 
observed in circulation [8, 39, 41]. Indeed, others have shown lower peripheral blood 
mononuclear cell (PBMC) cytokine gene expression of IL-1, IL-6, and a trend for lower 
TNF- α in horses with ID compared to normal controls [31]. Similarly, we observed no 
differences in baseline PBMC PMA stimulated cytokine protein concentrations or gene 
expression, although there was a trend for lower IL-6 and TNF- α gene expression in ID 
horses [42]. In fact, in a subsequent study, we further observed that control horses were 
higher at baseline in PBMC PMA stimulated cytokine protein concentration or gene 
expression [47]. However, ID horses then had an opposing inflammatory response to oral 
glycemic challenge wherein they were higher in IFN-γ and TNF-α protein concentrations 
as well as IFN-γ gene expression 60 min following oral administration of a glycemic 
challenge compared to controls.  
There has been evidence in other species that there is an inflammatory response to 
feeding, so called postprandial inflammation, similar to what we have observed. There have 
been reported increases following a high fat or high fat meal combined with glucose in 
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circulating concentrations of intercellular Adhesion Molecule-1 (ICAM-1), a systemic 
soluble adhesion molecule [43, 44]. Soluble adhesion molecules have a role in both the 
inflammatory process and immune response [202] and have been proposed as a biomarker 
of cardiovascular disease in humans [203, 204]. There have also been reports in both 
normal and diabetic individuals of postprandial increases in adhesion molecules or pro-
inflammatory cytokines where diabetic subjects have a greater postprandial response 
compared to normal controls [43, 45]. While others did not see differences in postprandial 
inflammatory markers between diabetic and non-diabetic individuals [205], this may be 
due to differences in meal type or carbohydrate complexity [206]. In horses, the majority 
of data assessing the inflammatory status of ID horses has been in a basal or fasting state 
and examined circulating or tissue levels of inflammation. Postprandial inflammatory 
responses in the horse are not well studied. In metabolically normal horses, IL-1β was 
shown to increase in response to a high sugar high starch meal [46]. Differences in 
postprandial inflammation in individuals with metabolic dysfunction has several proposed 
explanations. One of which may be difference in circulating endotoxin concentrations 
similar to what is seen in humans with type 2 diabetes [303]. Endotoxin concentrations 
have also increased in response to a meal in humans, particularly one high in fat [59, 60]. 
These increases in endotoxin may stem from differences in the gut microbiota, especially 
considering the proposed interactions between the gut microbiota, metabolic, and 
inflammatory processes  [62, 63]. We were able to show that horses with ID have 
differences in their gut microbiota compared to metabolically normal controls. Specifically 
changes in community structure, suggesting overgrowth or undergrowth of different 
community members. A member of the Verrucomicrobia phylum was the most abundant 
in ID horses. This phyla has been shown to be increased in diet-induced obese minipigs 
[78]. One of the genus in this phyla, Akkermansia, is inversely associated in humans with 
fasting glucose, waist-to-hip ratio, and subcutaneous adipose measures [221]. Further, the 
abundance of Verrucomicrobia is proposed as a method to monitor the progression of 
glucose intolerance in people [222]. ID horses also had a decreased representation of 
Fibrobacter as compared to controls. Fibrobacter has been shown to decrease, along with 
increases in lactic acid producing bacteria, in response to both intestinal disease and 
changes in diet [225]. Increases in Verrucomicrobia and under representation of 
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Fibrobacter in ID horses may indicate that horses with metabolic dysfunction have adapted 
protective mechanisms, perhaps due in part to an acidic environment, however this has yet 
to be established in the ID horse. 
While alterations in the gut microbiota of horses with ID possibly contributed to 
the differences in postprandial inflammatory responses we observed, we did not see any 
differences between ID and control horses in circulating lipopolysaccharide (LPS) 
concentrations either prior to or following supplementation with a mannan rich fraction of 
the yeast cell wall or in response to glycemic challenge. Nor did supplementation have an 
appreciable effect on metabolic or inflammatory parameters. However, there was an effect 
of date (pre vs post supplementation period) and glycemic challenge on serum insulin and 
glucose, as well as many inflammatory markers. In horses there have been some indications 
that metabolic parameters are influenced by season. Horses with PPID are reportedly 
higher in serum insulin in the fall months [256] and healthy horses had a higher area under 
the curve for glucose concentrations in response to the combined glucose-insulin tolerance 
test in February compared to August and November and June compared to November 
[257]. This was not observed by others who saw no differences in serum glucose or insulin 
concentrations in respect to season in a group of healthy or ID horses [258]. For our work, 
serum glucose and insulin had an apparent effect of season wherein the ID horses had an 
even greater increase from July to September as compared to controls.  
Inflammation and the immune response have in other species been shown to be 
affected by season [259-261]. In baboons and Siberian hamsters the immune response 
appears to be suppressed in the fall and into the winter seasons [259, 260]. This may be the 
case in the horse as well [262-264], with a reported increase in IFN-γ and decrease in IL-4 
in the winter as opposed to the summer months [265]. However, PBMC IFN-γ gene 
expression was conversely shown to be increased in the summer as opposed to winter 
months in another group of horses [266]. We observed an increase in gene expression of 
the proinflammatory cytokines IFN-γ and TNF-α as well as TLR-4 from the summer (July) 
to the fall (September) and a decrease in anti-inflammatory gene expression of IL-10 as 
well as IL-6, and protein concentrations of IFN-γ and TNF-α from lymphocytes. This 
supports the hypothesis that seasonal variations in inflammatory cytokines are present in 
both ID and metabolically normal horses. In fact, our results indicate that ID horses may 
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be particularly sensitive to seasonal changes in inflammation, as they had differences or 
trends to differ from controls dependent upon date for gene expression of TLR-4, IL-6, and 
TNF-α as well as lymphocyte protein concentrations of TNF-α and IFN-γ.  
Not only have we observed differences between ID and metabolically normal 
horses’ inflammatory responses and gut microbiota with this work, but we have also seen 
changes in circulating plasma lipid concentrations. ID horses had increases in serum 
triglycerides and leptin, as well as plasma diacylglycerides, triacylglycerides, 
monoacylglyceride, and ceramide. They also had decreases in plasma sphingomyelins, 
sulfatide, and choline plasmalogens as compared to controls. Lipids have been shown in 
humans and mice to be able to influence multiple biological functions, including; cell 
signaling, gene expression, and activation of inflammatory pathways in multiple cell types 
[112-114]. Changing lipid concentrations has also been shown to impact insulin resistance 
[114, 228, 240]. Bioactive lipids (including ceramide and sulfatides) are also able to serve 
as chemoattractant and intracellular messengers [118, 119]. One of the lipid moieties we 
observed to be increased in ID horses, ceramide, has received attention in human research 
as it is increased in skeletal muscle of obese individuals with metabolic dysfunction [208]. 
Further, it appears to have a prominent role in both cell signaling and metabolism [113, 
115, 116]. ID horses also had decreased levels of critical membrane lipids, sphingomyelins 
and plasmalogens, indicating possible changes in membrane fluidity and permeability 
[109-111]. These differences, along with increased levels of tri-, di-, and 
monoacylglycerides, may point to changes in cell signaling and add to existing metabolic 
dysfunction in ID horses. However, the full impact of changes in plasma lipid 
concentrations in ID horses as it relates to cell signaling and metabolism is unclear. 
Considering that lipids can influence inflammatory signaling, including acting as 
chemoattractants for lymphocytes [118], and the fact that inflammation has a role in the 
immune response, it is perhaps not surprising that the immune system can recognize both 
foreign [126] and self-lipids [127-129] as antigens. In addition, a reduced cell mediated 
immune response (CMI) has been observed in obese humans and mice [134-137]. Data 
generated from stimulated PBMCs, as in our results, more strongly reflects cellular 
responses opposed to systemic responses. Indeed, we show that at fasting in PBMC 
stimulated lymphocytes, ID horses often are lower in proinflammatory cytokine protein or 
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gene expression compared to controls. This indicates a reduced CMI response in these 
animals.  In response to a Hepatitis B vaccine, a reduced hepatitis specific antibody and T 
cell activation but increased levels of IFN-γ and TNF-α as well as T and B cell proliferation 
have been observed in diet-induced obese mice [135]. In influenza vaccinated obese 
humans, PBMCs had a lower functional protein expression in response to viral challenge 
[138]. When we vaccinated a group of ID and non-ID controls, we observed a normal 
humoral response to vaccination, regardless of metabolic status, compared to non-
vaccinated saline controls. This is similar to what is seen in humans where body mass 
index, but not diabetes status, was positively correlated with a greater decline in influenza 
antibody titers 12 months following influenza vaccination [138]. While we did not observe 
an effect of metabolic status on humoral immune responses to vaccination, there was some 
evidence that CMI responses were different in ID compared to control horses. Flu 
stimulated PBMC IL-2 gene expression was lower in ID horses and TNF-α gene expression 
did not change over time in ID horses whereas control horses had differences between pre 
and post vaccination time points. ID horses also had lower PMA stimulated PBMC gene 
expression of IFN-γ and IL-2 compared to controls, dependent upon time point. As TNF-
α and IFN-γ play important roles in CMI immune responses [248, 249] and IL-2 is 
associated with lymphocyte proliferation [247], it lends further evidence for a reduced CMI 
response in horses with ID. However, it is important to note that while this work observed 
differences in immune responses of horses with ID, the physiological impact of these 
differences, in particular in the face of challenge, remains to be seen.  
To better understand mechanisms behind alterations is inflammatory signaling 
pathways, we also examined gene expression of inflammatory cytokines and markers 
involved in TLR-4 inflammatory signaling pathways in equine whole blood both 
unstimulated and stimulated with endotoxin. For all horses and all inflammatory markers 
(with the exception of CCL2; chemokine (C-C motif) ligand 2), LPS was able to stimulate 
gene expression. However, stimulation was minimal or nonexistent for chemokine (C-C 
motif) ligand 5 (CCL5, or RANTES) and CCL2 (or MCP-1, monocyte chemoattractant 
protein-1), which are associated with the MyD88 independent signaling pathway. Others 
have similarly demonstrated this in LPS stimulated monocytes from metabolically normal 
horses [274]. Interesting, there was an effect of metabolic status on two chemokines, 
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interleukin 8 (IL-8) and CCL2, with ID horses having lower gene expression compared to 
controls. Conversely, healthy elderly humans LPS  stimulated whole blood gene expression 
[283], obese humans or those with metabolic dysfunction circulating levels [279-282] and 
LPS stimulated leukocytes in elderly horses or those with PPID [284] have all shown an 
increased IL-8 gene expression as compared to controls. However, others have shown no 
difference in lymphocyte gene expression of IL-8 in obese hyperinsulinemic horses 
compared to non-obese normoinsulinemic controls [31], although neutrophil oxidative 
activity was increased in the obese hyperinsulinemic group. Our horses did not differ in 
age and were all classified as adults. Lower IL-8 and CCL2 concentrations therefore 
indicate that ID horses may have decreased innate immune function.  
Treatment strategies for both humans and animals with metabolic dysfunction have 
been varied. One of the proposed dietary strategies in humans and horses has been 
supplementation with omega-3 fatty acids, specifically docosahexaenoic acid (DHA) and 
eicosapentaenoic acid (EPA) [157]. We observed, similar to others [159, 288, 292], that 
following supplementation with a DHA rich algae, ID horses had significant increases in 
serum DHA concentrations, among other fatty acids. Also similar to others [177], we 
observed a significant decrease in serum triglycerides in response to supplementation. 
There was also a trend for a decrease in lymphocyte TNF-α protein production. Others 
have not seen an effect of omega 3 fatty acid supplementation on prostaglandin E2 (PGE2) 
as an inflammatory marker in PBMCs of yearling horses [292], although it did impact 
PGE2 production and other markers of inflammation in adult horses bronchoalveolar 
lavage fluid (BAL) in other studies [297, 298]. These differences in results are possibly 
due to different sources of omega 3 fatty acids as well as the resulting differences in DHA 
to EPA ratio, especially considering that DHA appears to have a more potent anti-
inflammatory effect compared to EPA [299, 300]. Importantly for this work, 
supplementation with a DHA rich algae in ID horses also resulted in an improved 
insulinemic response to an oral sugar challenge. Others have shown that following 
dexamethasone administration in horses, DHA rich algae reduced both glucose and insulin 
concentrations and improved their modified insulin to glucose ratio [173]. However, we 
are the first to demonstrate a positive metabolic effect of DHA rich microalgae 
supplementation in the ID horse.  
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With these results we have been able to show that compared to metabolically 
normal controls, horses with ID have differences in their gut microbiota, specifically a 
decrease in microbial diversity and overall community structure. Horses with ID also have 
differences in their plasma lipidome, with increased tri-, di- and mono-acylglycerides as 
well as ceramide but lower levels of sphingomyelins, sulfatide, and choline plasmalogens.  
In addition, ID horses demonstrated an abnormal inflammatory response to glycemic 
challenge, having an inverse, often proinflammatory response, compared to controls. ID 
horses were able to mount a normal humoral response to routine vaccination, however 
lower IFN-γ and IL-2 gene expression indicated a possible reduced cell mediated immune 
(CMI) responses to vaccination. Circulating endotoxin concentrations did not appear to be 
influenced by metabolic status or glycemic challenge. While there was a minor effect of 
yeast cell wall supplementation on inflammatory markers, it did not influence serum 
glucose of insulin concentrations. However, there appeared to be a seasonal effect as well 
as an effect of glycemic challenge on both metabolic and inflammatory markers, indicating 
that ID horses may be particularly sensitive to changes in either diet or season. Endotoxin 
stimulation of whole blood was able to induce inflammatory gene expression primarily in 
MyD88 dependent associated genes for all horses. In ID horses, a reduced whole blood 
gene expression of the chemokines IL-8 and CCL2 may further point to a suppressed innate 
immune response in these horses. Finally, we were able to show that supplementation with 
DHA rich algae can improve insulin responses and may potentially improve inflammatory 
parameters in ID horses. Overall this work has indicated differences in inflammation in the 
ID horse, primarily in a TLR-4 MyD88 dependent associated gene and particularly in 
response to oral glycemic challenge. It also demonstrated changes in their circulating lipid 
concentrations and gut microbiota as well as a possible reduced innate immune or cell 
mediated immune responses in these animals. 
 
 
 
 
 
Copyright © Sarah E. Elzinga 2017
  143 
REFERENCES 
[1]  Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in 
the distribution of body mass index among US adults, 1999-2010. Jama. 
2012;307:491-7. 
[2]  Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult 
obesity in the United States, 2011-2012. Jama. 2014;311:806-14. 
[3]  Geor R, Thatcher C, Pleasant R, Elvinger F, Gay L, Werre S. Prevalence of 
hyperinsulinemia in mature horses: Relationship to adiposity.  Journal of 
Veterinary Internal Medicine: AMER COLL VETERINARY INTERNAL 
MEDICINE 1997 WADSWORTH BOULEVARD, STE A, LAKEWOOD, CO 
80214-5293 USA; 2007. p. 601-. 
[4]  Thatcher C, Pleasant R, Geor R, Elvinger F, Negrin K, Franklin J, et al. 
Prevalence of obesity in mature horses: an equine body condition study. Journal 
of Animal Physiology and Animal Nutrition. 2008;92:222-. 
[5]  Robin C, Ireland J, Wylie C, Collins S, Verheyen K, Newton J. Prevalence of and 
risk factors for equine obesity in Great Britain based on owner‐reported body 
condition scores. Equine veterinary journal. 2015;47:196-201. 
[6]  Potter S, Bamford N, Harris P, Bailey S. Prevalence of obesity and owners’ 
perceptions of body condition in pleasure horses and ponies in south‐eastern 
Australia. Australian Veterinary Journal. 2016;94:427-32. 
[7]  Wyse C, McNie K, Tannahil V, Murray J, Love S. Prevalence of obesity in riding 
horses in Scotland. Veterinary Record. 2008;162:590. 
[8]  Vick M, Adams A, Murphy B, Sessions D, Horohov D, Cook R, et al. 
Relationships among inflammatory cytokines, obesity, and insulin sensitivity in 
the horse. Journal of animal science. 2007;85:1144-55. 
[9]  Vick M, Sessions D, Murphy B, Kennedy E, Reedy S, Fitzgerald B. Obesity is 
associated with altered metabolic and reproductive activity in the mare: effects of 
metformin on insulin sensitivity and reproductive cyclicity. Reproduction, 
Fertility and Development. 2006;18:609-17. 
[10]  McGowan T, Pinchbeck G, McGowan C. Prevalence, risk factors and clinical 
signs predictive for equine pituitary pars intermedia dysfunction in aged horses. 
Equine veterinary journal. 2013;45:74-9. 
[11]  Klinkhamer K, Menheere PP, van der Kolk JH. Basal glucose metabolism and 
peripheral insulin sensitivity in equine pituitary pars intermedia dysfunction. 
Veterinary Quarterly. 2011;31:19-28. 
[12]  Frank N, Tadros E. Insulin dysregulation. Equine veterinary journal. 
2014;46:103-12. 
[13]  Schuver A, Frank N, Chameroy KA, Elliott SB. Assessment of insulin and 
glucose dynamics by using an oral sugar test in horses. Journal of Equine 
Veterinary Science. 2014;34:465-70. 
[14]  de Laat MA. Metabolic dysfunction and laminitis. Australian Equine 
Veterinarian. 2014;33:44-52. 
[15]  Menzies‐Gow N, Harris P, Elliott J. Prospective cohort study evaluating risk 
factors for the development of pasture‐associated laminitis in the United 
Kingdom. Equine veterinary journal. 2016. 
  144 
[16]  Lane H, Burns T, Hegedus O, Watts M, Weber P, Woltman K, et al. Lamellar 
events related to insulin‐like growth factor‐1 receptor signaling in two models 
relevant to endocrinopathic laminitis. Equine Veterinary Journal. 2017. 
[17]  Geor RJ, Belknap JK. Equine Laminitis: John Wiley & Sons; 2016. 
[18]  Belknap J, Giguere S, Pettigrew A, Cochran A, Eps A, Pollitt C. Lamellar pro‐
inflammatory cytokine expression patterns in laminitis at the developmental stage 
and at the onset of lameness: innate vs. adaptive immune response. Equine 
veterinary journal. 2007;39:42-7. 
[19]  Asplin KE, Sillence MN, Pollitt CC, McGowan CM. Induction of laminitis by 
prolonged hyperinsulinaemia in clinically normal ponies. The Veterinary Journal. 
2007;174:530-5. 
[20]  Karikoski NP, Patterson-Kane JC, Asplin KE, McGowan TW, McNutt M, Singer 
ER, et al. Morphological and cellular changes in secondary epidermal laminae of 
horses with insulin-induced laminitis. American journal of veterinary research. 
2014;75:161-8. 
[21]  Wylie CE, Collins SN, Verheyen KL, Newton JR. Frequency of equine laminitis: 
a systematic review with quality appraisal of published evidence. The Veterinary 
Journal. 2011;189:248-56. 
[22]  Karikoski N, Horn I, McGowan T, McGowan C. The prevalence of 
endocrinopathic laminitis among horses presented for laminitis at a first-
opinion/referral equine hospital. Domestic animal endocrinology. 2011;41:111-7. 
[23]  Frank N, Geor R, Bailey S, Durham A, Johnson P. Equine metabolic syndrome. 
Journal of Veterinary Internal Medicine. 2010;24:467-75. 
[24]  Kaur J. A comprehensive review on metabolic syndrome. Cardiology research 
and practice. 2014;2014. 
[25]  Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 
Harmonizing the metabolic syndrome. Circulation. 2009;120:1640-5. 
[26]  Ertelt A, Barton A-K, Schmitz RR, Gehlen H. Metabolic syndrome: is equine 
disease comparable to what we know in humans? Endocrine connections. 
2014;3:R81-R93. 
[27]  Bremer AA, Devaraj S, Afify A, Jialal I. Adipose tissue dysregulation in patients 
with metabolic syndrome. The Journal of Clinical Endocrinology & Metabolism. 
2011;96:E1782-E8. 
[28]  Marycz K, Basinska K, TOKER NY. The Activity of IL-6 and TNF-α in Adipose 
Tissue and Peripheral Blood in horses Suffering from Equine Metabolic 
Syndrome (EMS). Kafkas Üniversitesi Veteriner Fakültesi Dergisi. 2014;20:493-
9. 
[29]  McGowan C, Dugdale A, Pinchbeck G, Argo CM. Dietary restriction in 
combination with a nutraceutical supplement for the management of equine 
metabolic syndrome in horses. The Veterinary Journal. 2013;196:153-9. 
[30]  Tadros EM, Frank N, Donnell RL. Effects of equine metabolic syndrome on 
inflammatory responses of horses to intravenous lipopolysaccharide infusion. 
American journal of veterinary research. 2013;74:1010-9. 
[31]  Holbrook TC, Tipton T, McFarlane D. Neutrophil and cytokine dysregulation in 
hyperinsulinemic obese horses. Veterinary immunology and immunopathology. 
2012;145:283-9. 
  145 
[32]  Tiley HA, Geor RJ, McCutcheon LJ. Effects of dexamethasone administration on 
insulin resistance and components of insulin signaling and glucose metabolism in 
equine skeletal muscle. American journal of veterinary research. 2008;69:51-8. 
[33]  Carter RA, McCutcheon LJ, George LA, Smith TL, Frank N, Geor RJ. Effects of 
diet-induced weight gain on insulin sensitivity and plasma hormone and lipid 
concentrations in horses. American journal of veterinary research. 2009;70:1250-
8. 
[34]  Banse HE, McCann J, Yang F, Wagg C, McFarlane D. Comparison of two 
methods for measurement of equine insulin. Journal of Veterinary Diagnostic 
Investigation. 2014;26:527-30. 
[35]  Carslake H, Pinchbeck G, McGowan C. Evaluation of a Chemiluminescent 
Immunoassay for Measurement of Equine Insulin. Journal of Veterinary Internal 
Medicine. 2017. 
[36]  Warnken T, Huber K, Feige K. Comparison of three different methods for the 
quantification of equine insulin. BMC Veterinary Research. 2016;12:196. 
[37]  Bertin F, Taylor S, Bianco A, Sojka‐Kritchevsky J. The Effect of Fasting 
Duration on Baseline Blood Glucose Concentration, Blood Insulin Concentration, 
Glucose/Insulin Ratio, Oral Sugar Test, and Insulin Response Test Results in 
Horses. Journal of veterinary internal medicine. 2016;30:1726-31. 
[38]  Knowles E, Harris P, Elliott J, Menzies‐Gow N. Use of the oral sugar test in 
ponies when performed with or without prior fasting. Equine veterinary journal. 
2016. 
[39]  Vick MM, Murphy BA, Sessions DR, Reedy SE, Kennedy EL, Horohov DW, et 
al. Effects of systemic inflammation on insulin sensitivity in horses and 
inflammatory cytokine expression in adipose tissue. American journal of 
veterinary research. 2008;69:130-9. 
[40]  Suagee J, Corl B, Crisman M, Pleasant R, Thatcher C, Geor R. Relationships 
between Body Condition Score and Plasma Inflammatory Cytokines, Insulin, and 
Lipids in a Mixed Population of Light‐Breed Horses. Journal of Veterinary 
Internal Medicine. 2013;27:157-63. 
[41]  Burns T, Geor R, Mudge M, McCutcheon L, Hinchcliff K, Belknap J. 
Proinflammatory Cytokine and Chemokine Gene Expression Profiles in 
Subcutaneous and Visceral Adipose Tissue Depots of Insulin‐Resistant and 
Insulin‐Sensitive Light Breed Horses. Journal of Veterinary Internal Medicine. 
2010;24:932-9. 
[42]  Elzinga S, Wood P, Adams AA. Plasma Lipidomic and Inflammatory Cytokine 
Profiles of Horses With Equine Metabolic Syndrome. Journal of Equine 
Veterinary Science. 2016;40:49-55. 
[43]  Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. 
Postprandial endothelial activation in healthy subjects and in type 2 diabetic 
patients: role of fat and carbohydrate meals. Journal of the American College of 
Cardiology. 2002;39:1145-50. 
[44]  Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, et al. Effect of 
postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion 
molecules and oxidative stress generation and the possible role of simvastatin 
treatment. Diabetes. 2004;53:701-10. 
  146 
[45]  Esposito K, Nappo F, Giugliano F, Giugliano G, Marfella R, Giugliano D. Effect 
of dietary antioxidants on postprandial endothelial dysfunction induced by a high-
fat meal in healthy subjects. The American journal of clinical nutrition. 
2003;77:139-43. 
[46]  Suagee JK, Splan RK, Swyers KL, Geor RJ, Corl BA. Effects of High-Sugar and 
High-Starch Diets on Postprandial Inflammatory Protein Concentrations in 
Horses. Journal of Equine Veterinary Science. 2015;35:191-7. 
[47]  Elzinga S, Rohleder B, Schanbacher B, McQuerry K, Barker V, Adams A. 
Metabolic and inflammatory responses to the common sweetener stevioside and a 
glycemic challenge in horses with equine metabolic syndrome. Domestic Animal 
Endocrinology. 2017. 
[48]  Council NR. Nutrient Requirements of Horses: Sixth Revised Edition. 
Washington D.C.: The National Academies Press; 2007. 
[49]  Shepherd M, Pleasant R, Crisman M, Werre S, Milton S, Swecker Jr W. Effects 
of high and moderate non‐structural carbohydrate hay on insulin, glucose, 
triglyceride, and leptin concentrations in overweight Arabian geldings. Journal of 
animal physiology and animal nutrition. 2012;96:428-35. 
[50]  Eps Av, Pollitt C. Equine laminitis induced with oligofructose. Equine veterinary 
journal. 2006;38:203-8. 
[51]  Tadros EM, Frank N, Horohov DW. Inflammatory cytokine gene expression in 
blood during the development of oligofructose-induced laminitis in horses. 
Journal of Equine Veterinary Science. 2013;33:802-8. 
[52]  Bonnard C, Durand A, Peyrol S, Chanseaume E, Chauvin M-A, Morio B, et al. 
Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of 
diet-induced insulin-resistant mice. The Journal of clinical investigation. 
2008;118:789-800. 
[53]  Marycz K, Kornicka K, Basinska K, Czyrek A. Equine metabolic syndrome 
affects viability, senescence, and stress factors of equine adipose-derived 
mesenchymal stromal stem cells: new insight into EqASCs isolated from ems 
horses in the context of their aging. Oxidative medicine and cellular longevity. 
2015;2016. 
[54]  Meigs JB, Larson MG, Fox CS, Keaney JF, Vasan RS, Benjamin EJ. Association 
of oxidative stress, insulin resistance, and diabetes risk phenotypes. Diabetes care. 
2007;30:2529-35. 
[55]  Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morioka K, et al. 
Oxidative stress is associated with adiposity and insulin resistance in men. The 
Journal of Clinical Endocrinology & Metabolism. 2003;88:4673-6. 
[56]  Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence 
for an independent and cumulative effect of postprandial hypertriglyceridemia 
and hyperglycemia on endothelial dysfunction and oxidative stress generation. 
Circulation. 2002;106:1211-8. 
[57]  Annuzzi G, Bozzetto L, Costabile G, Giacco R, Mangione A, Anniballi G, et al. 
Diets naturally rich in polyphenols improve fasting and postprandial dyslipidemia 
and reduce oxidative stress: a randomized controlled trial. The American journal 
of clinical nutrition. 2014;99:463-71. 
  147 
[58]  Sottero B, Gargiulo S, Russo I, Barale C, Poli G, Cavalot F. Postprandial 
dysmetabolism and oxidative stress in type 2 diabetes: pathogenetic mechanisms 
and therapeutic strategies. Medicinal research reviews. 2015;35:968-1031. 
[59]  Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade 
endotoxemia: evidence of a novel mechanism of postprandial inflammation. The 
American journal of clinical nutrition. 2007;86:1286-92. 
[60]  Lyte JM, Gabler NK, Hollis JH. Postprandial serum endotoxin in healthy humans 
is modulated by dietary fat in a randomized, controlled, cross-over study. Lipids 
in Health and Disease. 2016;15:186. 
[61]  Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic 
endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-72. 
[62]  Laugerette F, Vors C, Peretti N, Michalski M-C. Complex links between dietary 
lipids, endogenous endotoxins and metabolic inflammation. Biochimie. 
2011;93:39-45. 
[63]  Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. 
Changes in gut microbiota control metabolic endotoxemia-induced inflammation 
in high-fat diet–induced obesity and diabetes in mice. Diabetes. 2008;57:1470-81. 
[64]  Costa MC, Weese JS. The equine intestinal microbiome. Animal Health Research 
Reviews. 2012;13:121-8. 
[65]  Dougal K, de la Fuente G, Harris PA, Girdwood SE, Pinloche E, Geor RJ, et al. 
Characterisation of the faecal bacterial community in adult and elderly horses fed 
a high fibre, high oil or high starch diet using 454 pyrosequencing. PloS one. 
2014;9:e87424. 
[66]  Fernandes KA, Kittelmann S, Rogers CW, Gee EK, Bolwell CF, Bermingham 
EN, et al. Faecal microbiota of forage-fed horses in New Zealand and the 
population dynamics of microbial communities following dietary change. PloS 
one. 2014;9:e112846. 
[67]  Shepherd ML, Swecker Jr WS, Jensen RV, Ponder MA. Characterization of the 
fecal bacteria communities of forage-fed horses by pyrosequencing of 16S rRNA 
V4 gene amplicons. FEMS microbiology letters. 2012;326:62-8. 
[68]  Costa M, Silva G, Ramos R, Staempfli H, Arroyo L, Kim P, et al. 
Characterization and comparison of the bacterial microbiota in different 
gastrointestinal tract compartments in horses. The Veterinary Journal. 2015. 
[69]  Fernandes KA, Kittelmann S, Rogers CW, Gee EK, Bolwell CF, Bermingham 
EN, et al. Faecal Microbiota of Forage-Fed Horses in New Zealand and the 
Population Dynamics of Microbial Communities following Dietary Change. 2014. 
[70]  Biddle AS, Black SJ, Blanchard JL. An in vitro model of the horse gut 
microbiome enables identification of lactate-utilizing bacteria that differentially 
respond to starch induction. PloS one. 2013;8:e77599. 
[71]  Lecomte V, Kaakoush NO, Maloney CA, Raipuria M, Huinao KD, Mitchell HM, 
et al. Changes in gut microbiota in rats fed a high fat diet correlate with obesity-
associated metabolic parameters. PloS one. 2015;10:e0126931. 
[72]  Steelman SM, Chowdhary BP, Dowd S, Suchodolski J, Janečka JE. 
Pyrosequencing of 16S rRNA genes in fecal samples reveals high diversity of 
hindgut microflora in horses and potential links to chronic laminitis. BMC 
veterinary research. 2012;8:231. 
  148 
[73]  Milinovich GJ, Trott DJ, Burrell PC, Croser EL, Al Jassim RA, Morton JM, et al. 
Fluorescence in situ hybridization analysis of hindgut bacteria associated with the 
development of equine laminitis. Environmental microbiology. 2007;9:2090-100. 
[74]  Milinovich G, Trott D, Burrell P, Van Eps A, Thoefner M, Blackall L, et al. 
Changes in equine hindgut bacterial populations during oligofructose‐induced 
laminitis. Environmental Microbiology. 2006;8:885-98. 
[75]  Costa MC, Arroyo LG, Allen-Vercoe E, Stampfli HR, Kim PT, Sturgeon A, et al. 
Comparison of the fecal microbiota of healthy horses and horses with colitis by 
high throughput sequencing of the V3-V5 region of the 16S rRNA gene. PLoS 
One. 2012;7:e41484. 
[76]  Weese J, Holcombe S, Embertson R, Kurtz K, Roessner H, Jalali M, et al. 
Changes in the faecal microbiota of mares precede the development of post 
partum colic. Equine veterinary journal. 2015. 
[77]  Fava F, Gitau R, Griffin B, Gibson G, Tuohy K, Lovegrove J. The type and 
quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain 
fatty acid excretion in a metabolic syndrome ‘at-risk’population. International 
Journal of Obesity. 2013;37:216-23. 
[78]  Pedersen R, Ingerslev H-C, Sturek M, Alloosh M, Cirera S, Christoffersen BØ, et 
al. Characterisation of gut microbiota in Ossabaw and Göttingen minipigs as 
models of obesity and metabolic syndrome. PloS one. 2013;8:e56612. 
[79]  Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. 
A core gut microbiome in obese and lean twins. nature. 2009;457:480-4. 
[80]  Park HJ, Lee SE, Kim HB, Isaacson R, Seo KW, Song KH. Association of 
Obesity with Serum Leptin, Adiponectin, and Serotonin and Gut Microflora in 
Beagle Dogs. Journal of Veterinary Internal Medicine. 2015;29:43-50. 
[81]  Costa MC, Stämpfli HR, Arroyo LG, Allen-Vercoe E, Gomes RG, Weese JS. 
Changes in the equine fecal microbiota associated with the use of systemic 
antimicrobial drugs. BMC veterinary research. 2015;11:19. 
[82]  Elzinga SE, Weese JS, Adams AA. Comparison of the Fecal Microbiota in Horses 
With Equine Metabolic Syndrome and Metabolically Normal Controls Fed a 
Similar All-Forage Diet. Journal of Equine Veterinary Science. 2016;44:9-16. 
[83]  Kim K-A, Jeong J-J, Yoo S-Y, Kim D-H. Gut microbiota lipopolysaccharide 
accelerates inflamm-aging in mice. BMC Microbiology. 2016;16:1. 
[84]  Haro C, Garcia-Carpintero S, Alcala-Diaz JF, Gomez-Delgado F, Delgado-Lista 
J, Perez-Martinez P, et al. The gut microbial community in metabolic syndrome 
patients is modified by diet. The Journal of nutritional biochemistry. 2016;27:27-
31. 
[85]  Isabel M-I, Lidia S-A, Pablo P-M, Cristina A-L, Fernando C, Francisco T, et al. 
Red wine polyphenols modulate fecal microbiota and reduce markers of the 
metabolic syndrome in obese patients. Food & function. 2016. 
[86]  Han SH, Suk KT, Kim DJ, Kim MY, Baik SK, Kim YD, et al. Effects of 
probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment 
of alcoholic hepatitis: randomized-controlled multicenter study. European journal 
of gastroenterology & hepatology. 2015;27:1300-6. 
  149 
[87]  Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for 
modulating the microbial ecology of the gut. The American Journal of Clinical 
Nutrition. 1999;69:1052s-7s. 
[88]  Berg E, Fu C, Porter J, Kerley M. Fructooligosaccharide supplementation in the 
yearling horse: effects on fecal pH, microbial content, and volatile fatty acid 
concentrations. Journal of animal science. 2005;83:1549-53. 
[89]  Respondek F, Goachet A, Julliand V. Effects of dietary short-chain 
fructooligosaccharides on the intestinal microflora of horses subjected to a sudden 
change in diet. Journal of animal science. 2008;86:316-23. 
[90]  Bornet F, Brouns F, Tashiro Y, Duvillier V. Nutritional aspects of short-chain 
fructooligosaccharides: natural occurrence, chemistry, physiology and health 
implications. Digestive and Liver Disease. 2002;34:S111-S20. 
[91]  Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body 
weight and insulin sensitivity. Nature reviews Endocrinology. 2015;11:577. 
[92]  Puertollano E, Kolida S, Yaqoob P. Biological significance of short-chain fatty 
acid metabolism by the intestinal microbiome. Current Opinion in Clinical 
Nutrition & Metabolic Care. 2014;17:139-44. 
[93]  Respondek F, Myers K, Smith T, Wagner A, Geor R. Dietary supplementation 
with short-chain fructo-oligosaccharides improves insulin sensitivity in obese 
horses. Journal of animal science. 2011;89:77-83. 
[94]  Respondek F, Swanson KS, Belsito KR, Vester BM, Wagner A, Istasse L, et al. 
Short-chain fructooligosaccharides influence insulin sensitivity and gene 
expression of fat tissue in obese dogs. The Journal of nutrition. 2008;138:1712-8. 
[95]  Yuan K, Mendonça L, Hulbert L, Mamedova L, Muckey M, Shen Y, et al. Yeast 
product supplementation modulated humoral and mucosal immunity and uterine 
inflammatory signals in transition dairy cows. Journal of dairy science. 
2015;98:3236-46. 
[96]  Świątkiewicz S, Arczewska-Włosek A, Jozefiak D. Immunomodulatory efficacy 
of yeast cell products in poultry: a current review. World's Poultry Science 
Journal. 2014;70:57-68. 
[97]  Smith IM, Christensen JE, Arneborg N, Jespersen L. Yeast modulation of human 
dendritic cell cytokine secretion: an in vitro study. PloS one. 2014;9:e96595. 
[98]  Stier H, Ebbeskotte V, Gruenwald J. Immune-modulatory effects of dietary Yeast 
Beta-1, 3/1, 6-D-glucan. Nutrition journal. 2014;13:38. 
[99]  Spatuzza C, Postiglione L, Covelli B, Ricciardone M, Benvenuti C, Mondola P, et 
al. Effects of berberine and red yeast on proinflammatory cytokines IL-6 and 
TNF-α in peripheral blood mononuclear cells (PBMCs) of human subjects. 
Frontiers in pharmacology. 2014;5:230. 
[100]  Koke K. Effects of dietary yeast supplementation on serum immunoglobulin 
concentrations in quarter horse mares: The Ohio State University; 2014. 
[101]  Schoster A, Weese J, Guardabassi L. Probiotic Use in Horses–What is the 
Evidence for Their Clinical Efficacy? Journal of veterinary internal medicine. 
2014;28:1640-52. 
[102]  Sanchez NCB, Young TR, Carroll JA, Corley JR, Rathmann RJ, Johnson BJ. 
Yeast cell wall supplementation alters the metabolic responses of crossbred 
heifers to an endotoxin challenge. Innate immunity. 2014;20:104-12. 
  150 
[103]  Kannan M, Karunakaran R, Balakrishnan V, Prabhakar T. Influence of prebiotics 
supplementation on lipid profile of broilers. Int J Poult Sci. 2005;4:994-7. 
[104]  Huff G, Huff W, Farnell M, Rath N, de Los Santos FS, Donoghue A. Bacterial 
clearance, heterophil function, and hematological parameters of transport-stressed 
turkey poults supplemented with dietary yeast extract. Poultry science. 
2010;89:447-56. 
[105]  Jin L, Dong G, Lei C, Zhou J, Zhang S. Effects of dietary supplementation of 
glutamine and mannan oligosaccharides on plasma endotoxin and acute phase 
protein concentrations and nutrient digestibility in finishing steers. Journal of 
Applied Animal Research. 2014;42:160-5. 
[106]  Hansen ME, Simmons KJ, Tippetts TS, Thatcher MO, Saito RR, Hubbard ST, et 
al. Lipopolysaccharide disrupts mitochondrial physiology in skeletal muscle via 
disparate effects on sphingolipid metabolism. Shock (Augusta, Ga). 2015;44:585. 
[107]  Frank N, Elliott SB, Brandt LE, Keisler DH. Physical characteristics, blood 
hormone concentrations, and plasma lipid concentrations in obese horses with 
insulin resistance. Journal of the American Veterinary Medical Association. 
2006;228:1383-90. 
[108]  Gross RW, Han X. Lipidomics in diabetes and the metabolic syndrome. Methods 
in enzymology. 2007;433:73-90. 
[109]  Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, 
Kaprio J, et al. Acquired obesity is associated with changes in the serum 
lipidomic profile independent of genetic effects–a monozygotic twin study. 2007. 
[110]  Hunte C, Richers S. Lipids and membrane protein structures. Current opinion in 
structural biology. 2008;18:406-11. 
[111]  Kasimova MA, Tarek M, Shaytan AK, Shaitan KV, Delemotte L. Voltage-gated 
ion channel modulation by lipids: Insights from molecular dynamics simulations. 
Biochimica et Biophysica Acta (BBA)-Biomembranes. 2014;1838:1322-31. 
[112]  Dennis EA, Deems RA, Harkewicz R, Quehenberger O, Brown HA, Milne SB, et 
al. A mouse macrophage lipidome. Journal of Biological Chemistry. 
2010;285:39976-85. 
[113]  Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central 
role of ceramide biosynthesis in body weight regulation, energy metabolism, and 
the metabolic syndrome. American Journal of Physiology-Endocrinology and 
Metabolism. 2009;297:E211-E24. 
[114]  Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin 
resistance. Cell metabolism. 2012;15:635-45. 
[115]  Meikle PJ, Christopher MJ. Lipidomics is providing new insight into the 
metabolic syndrome and its sequelae. Current opinion in lipidology. 2011;22:210-
5. 
[116]  Turpin SM, Lancaster GI, Darby I, Febbraio MA, Watt MJ. Apoptosis in skeletal 
muscle myotubes is induced by ceramides and is positively related to insulin 
resistance. American Journal of Physiology-Endocrinology and Metabolism. 
2006;291:E1341-E50. 
[117]  Chavez JA, Siddique MM, Wang ST, Ching J, Shayman JA, Summers SA. 
Ceramides and glucosylceramides are independent antagonists of insulin 
signaling. Journal of Biological Chemistry. 2014;289:723-34. 
  151 
[118]  Kihara A, Mitsutake S, Mizutani Y, Igarashi Y. Metabolism and biological 
functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and 
ceramide 1-phosphate. Progress in lipid research. 2007;46:126-44. 
[119]  Samad F, Hester KD, Yang G, Hannun YA, Bielawski J. Altered Adipose and 
Plasma Sphingolipid Metabolism in Obesity A Potential Mechanism for 
Cardiovascular and Metabolic Risk. Diabetes. 2006;55:2579-87. 
[120]  Katz S, Ernst O, Avni D, Athamna M, Philosoph A, Arana L, et al. Exogenous 
ceramide-1-phosphate (C1P) and phospho-ceramide analogue-1 (PCERA-1) 
regulate key macrophage activities via distinct receptors. Immunology letters. 
2016;169:73-81. 
[121]  Lankinen M, Schwab U, Erkkila A, Seppanen-Laakso T, Hannila M-L, Mussalo 
H, et al. Fatty fish intake decreases lipids related to inflammation and insulin 
signaling–a lipidomics approach. PLoS one. 2009;4:e5258. 
[122]  Browning L, Krebs J, Moore C, Mishra G, O’Connell M, Jebb S. The impact of 
long chain n‐3 polyunsaturated fatty acid supplementation on inflammation, 
insulin sensitivity and CVD risk in a group of overweight women with an 
inflammatory phenotype. Diabetes, Obesity and Metabolism. 2007;9:70-80. 
[123]  Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-
inflammatory potential of long-chain omega-3 fatty acids. Nutrition reviews. 
2010;68:280-9. 
[124]  Davies P, Bailey PJ, Goldenberg MM, Ford-Hutchinson AW. The role of 
arachidonic acid oxygenation products in pain and inflammation. Annual review 
of immunology. 1984;2:335-57. 
[125]  Goto-Inoue N, Yamada K, Inagaki A, Furuichi Y, Ogino S, Manabe Y, et al. 
Lipidomics analysis revealed the phospholipid compositional changes in muscle 
by chronic exercise and high-fat diet. Scientific reports. 2013;3. 
[126]  Raetz CR, Reynolds CM, Trent MS, Bishop RE. Lipid A modification systems in 
gram-negative bacteria. Annual review of biochemistry. 2007;76:295. 
[127]  De Libero G, Mori L. How the immune system detects lipid antigens. Progress in 
lipid research. 2010;49:120-7. 
[128]  Kain L, Webb B, Anderson BL, Deng S, Holt M, Costanzo A, et al. The 
identification of the endogenous ligands of natural killer t cells reveals the 
presence of mammalian α-linked glycosylceramides. Immunity. 2014;41:543-54. 
[129]  Kim J, Kim JH, Winau F. Thinking inside the box: endogenous α-anomeric lipid 
antigens. Immunity. 2014;41:505-6. 
[130]  Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate 
immunity and fatty acid–induced insulin resistance. Journal of Clinical 
Investigation. 2006;116:3015. 
[131]  Balasubramanyam A. The role of the immune system in obesity and insulin 
resistance. Journal of obesity. 2013;2013. 
[132]  Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with 
improved vaccine adjuvants. Nature medicine. 2005;11:S63-S8. 
[133]  Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune 
system. science. 2010;327:291-5. 
  152 
[134]  Kim Y-H, Kim J-K, Kim D-J, Nam J-H, Shim S-M, Choi Y-K, et al. Diet-induced 
obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a 
mouse model. Journal of Infectious Diseases. 2011:jir731. 
[135]  Chen S, Akbar SMF, Miyake T, Abe M, Al-Mahtab M, Furukawa S, et al. 
Diminished immune response to vaccinations in obesity: Role of myeloid-derived 
suppressor and other myeloid cells. Obesity research & clinical practice. 
2015;9:35-44. 
[136]  Diepersloot R, Bouter K, Beyer W, Hoekstra J, Masurel N. Humoral immune 
response and delayed type hypersensitivity to influenza vaccine in patients with 
diabetes mellitus. Diabetologia. 1987;30:397-401. 
[137]  Horowitz MM, ERSHLER WB, MCKINNEY WP, BATTIOLA RJ. Duration of 
immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. 
Annals of internal medicine. 1988;108:185-9. 
[138]  Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, et al. 
Obesity is associated with impaired immune response to influenza vaccination in 
humans. International journal of obesity. 2012;36:1072-7. 
[139]  Kotronen A, Seppänen‐Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepää 
AL, et al. Comparison of Lipid and Fatty Acid Composition of the Liver, 
Subcutaneous and Intra‐abdominal Adipose Tissue, and Serum. Obesity. 
2010;18:937-44. 
[140]  Hla T, Kolesnick R. C16: 0-Ceramide Signals Insulin Resistance. Cell 
metabolism. 2014;20:703-5. 
[141]  Bamford N, Potter S, Baskerville C, Harris P, Bailey S. Effect of increased 
adiposity on insulin sensitivity and adipokine concentrations in different equine 
breeds adapted to cereal-rich or fat-rich meals. The Veterinary Journal. 
2016;214:14-20. 
[142]  McCue ME, Geor RJ, Schultz N. Equine metabolic syndrome: a complex disease 
influenced by genetics and the environment. Journal of Equine Veterinary 
Science. 2015;35:367-75. 
[143]  McGowan C, Cooper D, Ireland J. No evidence that therapeutic systemic 
corticosteroid administration is associated with laminitis in adult horses without 
underlying endocrine or severe systemic disease. Veterinary Evidence. 2016;1. 
[144]  Welsh CE, Duz M, Parkin TD, Marshall JF. Disease and pharmacologic risk 
factors for first and subsequent episodes of equine laminitis: A cohort study of 
free-text electronic medical records. Preventive Veterinary Medicine. 
2017;136:11-8. 
[145]  Spencer M, Yang L, Adu A, Finlin BS, Zhu B, Shipp LR, et al. Pioglitazone 
treatment reduces adipose tissue inflammation through reduction of mast cell and 
macrophage number and by improving vascularity. 2014. 
[146]  Ebke LA, Nestor‐Kalinoski AL, Slotterbeck BD, Al‐Dieri AG, Ghosh‐Lester S, 
Russo L, et al. Tight association between macrophages and adipocytes in obesity: 
Implications for adipocyte preparation. Obesity. 2014;22:1246-55. 
[147]  Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling 
by IL-6 promotes alternative activation of macrophages to limit endotoxemia and 
obesity-associated resistance to insulin. Nature immunology. 2014;15:423-30. 
  153 
[148]  Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate 
immunity and fatty acid–induced insulin resistance. The Journal of clinical 
investigation. 2006;116:3015-25. 
[149]  Vaure C, Liu Y. A comparative review of toll-like receptor 4 expression and 
functionality in different animal species. Frontiers in immunology. 2014;5:316. 
[150]  Schaeffler A, Gross P, Buettner R, Bollheimer C, Buechler C, Neumeier M, et al. 
Fatty acid‐induced induction of Toll‐like receptor‐4/nuclear factor‐κB pathway in 
adipocytes links nutritional signalling with innate immunity. Immunology. 
2009;126:233-45. 
[151]  Zhang Z, Amorosa LF, Coyle SM, Macor MA, Birnbaum MJ, Lee LY, et al. 
Insulin-dependent regulation of mTORC2-Akt-FoxO suppresses TLR4 signaling 
in human leukocytes: Relevance to type 2 diabetes. Diabetes. 2016;65:2224-34. 
[152]  Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. 
Mechanism by which metformin reduces glucose production in type 2 diabetes. 
Diabetes. 2000;49:2063-9. 
[153]  Visser T. Pathways of thyroid hormone metabolism. Acta Medica Austriaca. 
1995;23:10-6. 
[154]  Durham A, Rendle D, Newton J. The effect of metformin on measurements of 
insulin sensitivity and β cell response in 18 horses and ponies with insulin 
resistance. Equine veterinary journal. 2008;40:493-500. 
[155]  Frank N, Elliott SB, Boston RC. Effects of long-term oral administration of 
levothyroxine sodium on glucose dynamics in healthy adult horses. American 
journal of veterinary research. 2008;69:76-81. 
[156]  Frank N, Sommardahl CS, Eiler H, Webb LL, Denhart JW, Boston RC. Effects of 
oral administration of levothyroxine sodium on concentrations of plasma lipids, 
concentration and composition of very-low-density lipoproteins, and glucose 
dynamics in healthy adult mares. American journal of veterinary research. 
2005;66:1032-8. 
[157]  Spencer M, Finlin BS, Unal R, Zhu B, Morris AJ, Shipp LR, et al. Omega-3 fatty 
acids reduce adipose tissue macrophages in human subjects with insulin 
resistance. Diabetes. 2013;62:1709-17. 
[158]  Skulas-Ray AC, Kris-Etherton PM, Harris WS, Heuvel JPV, Wagner PR, West 
SG. Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, 
and endothelial function in healthy persons with moderate hypertriglyceridemia. 
The American journal of clinical nutrition. 2011;93:243-52. 
[159]  King S, AbuGhazaleh A, Webel S, Jones K. Circulating fatty acid profiles in 
response to three levels of dietary omega-3 fatty acid supplementation in horses. 
Journal of animal science. 2008;86:1114-23. 
[160]  Hess T, Rexford J, Hansen D, Harris M, Schauermann N, Ross T, et al. Effects of 
two different dietary sources of long chain omega-3, highly unsaturated fatty 
acids on incorporation into the plasma, red blood cell, and skeletal muscle in 
horses. Journal of animal science. 2012;90:3023-31. 
[161]  Katan MB, Deslypere J, Van Birgelen A, Penders M, Zegwaard M. Kinetics of 
the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte 
membranes, and adipose tissue: an 18-month controlled study. Journal of lipid 
research. 1997;38:2012-22. 
  154 
[162]  Tsitouras P, Gucciardo F, Salbe A, Heward C, Harman S. High omega-3 fat 
intake improves insulin sensitivity and reduces CRP and IL6, but does not affect 
other endocrine axes in healthy older adults. Hormone and metabolic research. 
2008;40:199-205. 
[163]  Lombardo YB, Hein G, Chicco A. Metabolic syndrome: effects of n-3 PUFAs on 
a model of dyslipidemia, insulin resistance and adiposity. Lipids. 2007;42:427-37. 
[164]  Behme MT. Dietary fish oil enhances insulin sensitivity in miniature pigs. The 
Journal of nutrition. 1996;126:1549. 
[165]  Lou J, Rizkalla S, Boillot J, Alamowitch C. Dietary (n-3) polyunsaturated fatty 
acids improve adipocyte insulin action and glucose metabolism in insulin-
resistance rats: relation to membrane fatty acids. J Nutr. 1996;126:1951-8. 
[166]  Rasic-Milutinovic Z, Perunicic G, Pljesa S, Gluvic Z, Sobajic S, Djuric I, et al. 
Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory 
biomarkers in hemodialysis patients. Renal failure. 2007;29:321-9. 
[167]  Baillie R, Takada R, Nakamura M, Clarke S. Coordinate induction of peroxisomal 
acyl-CoA oxidase and UCP-3 by dietary fish oil: a mechanism for decreased body 
fat deposition. Prostaglandins, leukotrienes and essential fatty acids. 1999;60:351-
6. 
[168]  Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation 
of gene expression. Current opinion in lipidology. 2000;11:3-7. 
[169]  Lankinen M, Schwab U, Erkkilä A, Seppänen-Laakso T, Hannila M-L, Mussalo 
H, et al. Fatty fish intake decreases lipids related to inflammation and insulin 
signaling—a lipidomics approach. PLoS one. 2009;4:e5258. 
[170]  Ottestad I, Hassani S, Borge GI, Kohler A, Vogt G, Hyötyläinen T, et al. Fish oil 
supplementation alters the plasma lipidomic profile and increases long-chain 
PUFAs of phospholipids and triglycerides in healthy subjects. PLoS One. 
2012;7:e42550. 
[171]  O’Connor C, Lawrence L, St Lawrence A, Janicki K, Warren L, Hayes S. The 
effect of dietary fish oil supplementation on exercising horses. Journal of animal 
science. 2004;82:2978-84. 
[172]  Hess TM, Rexford J, Hansen DK, Ahrens NS, Harris M, Engle T, et al. Effects of 
Ω-3 (n-3) fatty acid supplementation on insulin sensitivity in horses. Journal of 
Equine Veterinary Science. 2013;33:446-53. 
[173]  Brennan KM, Graugnard DE, Spry ML, Brewster-Barnes T, Smith AC, Schaeffer 
RE, et al. Effects of a docosahexaenoic acid–rich microalgae nutritional product 
on insulin sensitivity after prolonged dexamethasone treatment in healthy mature 
horses. American journal of veterinary research. 2015;76:889-96. 
[174]  McCann ME, Moore JN, Carrick JB, Barton MH. Effect of intravenous infusion 
of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid 
composition and inflammatory mediator production in vitro. Shock. 2000;14:222-
8. 
[175]  Dinnetz JM, Furtney SR, Pendergraft JS, Davis EG, Epp TS, Minton JE. Omega-3 
fatty acid supplementation reduces basal TNFα but not toll-like receptor-
stimulated TNFα in full-sized and miniature mares. Journal of Equine Veterinary 
Science. 2013;33:523-9. 
  155 
[176]  Morris DD, Henry M, Moore J, Fischer J. Effect of dietary alpha-linolenic acid on 
endotoxin-induced production of tumor necrosis factor by peritoneal macrophages 
in horses. American journal of veterinary research. 1991;52:528-32. 
[177]  O’Connor C, Lawrence L, Hayes S. Dietary fish oil supplementation affects 
serum fatty acid concentrations in horses. Journal of animal science. 
2007;85:2183-9. 
[178]  McHaney AM, Welti R, Roth MR, Dinnetz JM, Furtney SR, Pendergraft JS, et al. 
Omega-3 Fatty Acid Supplementation Affects Selected Phospholipids in 
Peripheral White Blood Cells and in Plasma of Full-Sized and Miniature Mares. 
Journal of Equine Veterinary Science. 2013;33:779-86. 
[179]  Goyal S, Goyal R. Stevia (Stevia rebaudiana) a bio-sweetener: a review. 
International Journal of Food Sciences and Nutrition. 2010. 
[180]  Barriocanal LA, Palacios M, Benitez G, Benitez S, Jimenez JT, Jimenez N, et al. 
Apparent lack of pharmacological effect of steviol glycosides used as sweeteners 
in humans. A pilot study of repeated exposures in some normotensive and 
hypotensive individuals and in Type 1 and Type 2 diabetics. Regulatory 
toxicology and pharmacology. 2008;51:37-41. 
[181]  Chang J, Wu M, Liu I, Cheng J. Increase of insulin sensitivity by stevioside in 
fructose-rich chow-fed rats. Hormone and metabolic research= Hormon-und 
Stoffwechselforschung= Hormones et metabolisme. 2005;37:610-6. 
[182]  Chen T-H, Chen S-C, Chan P, Chu Y-L, Yang H-Y, Cheng J-T. Mechanism of 
the hypoglycemic effect of stevioside, a glycoside of Stevia rebaudiana. Planta 
medica. 2005;71:108-13. 
[183]  Anton SD, Martin CK, Han H, Coulon S, Cefalu WT, Geiselman P, et al. Effects 
of stevia, aspartame, and sucrose on food intake, satiety, and postprandial glucose 
and insulin levels. Appetite. 2010;55:37-43. 
[184]  Jeppesen PB, Gregersen S, Poulsen C, Hermansen K. Stevioside acts directly on 
pancreatic β cells to secrete insulin: Actions independent of cyclic adenosine 
monophosphate and adenosine triphosphate—sensitivie K+-channel activity. 
Metabolism. 2000;49:208-14. 
[185]  Williams O, Pharm B. Botanicals in diabetes treatment: A look at stevia. 2014. 
[186]  Henneke D, Potter G, Kreider J, Yeates B. Relationship between condition score, 
physical measurements and body fat percentage in mares. Equine veterinary 
journal. 1983;15:371-2. 
[187]  Carter RA, Geor RJ, Staniar WB, Cubitt TA, Harris PA. Apparent adiposity 
assessed by standardised scoring systems and morphometric measurements in 
horses and ponies. The Veterinary Journal. 2009;179:204-10. 
[188]  Herieka M, Erridge C. High‐fat meal induced postprandial inflammation. 
Molecular nutrition & food research. 2014;58:136-46. 
[189]  Abraham G, Allersmeier M, Schusser GF, Ungemach FR. Serum thyroid 
hormone, insulin, glucose, triglycerides and protein concentrations in normal 
horses: Association with topical dexamethasone usage. The Veterinary Journal. 
2011;188:307-12. 
[190]  Brennan K, Urschel K. Recovery of insulin sensitivity in mature horses after a 3 
week course of dexamethasone therapy. Equine veterinary journal. 2014;46:718-
21. 
  156 
[191]  Beech J, Boston R, Lindborg S, Russell GE. Adrenocorticotropin concentration 
following administration of thyrotropin-releasing hormone in healthy horses and 
those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia. 
Journal of the American Veterinary Medical Association. 2007;231:417-26. 
[192]  McFarlane D, Beech J, Cribb A. Alpha-melanocyte stimulating hormone release 
in response to thyrotropin releasing hormone in healthy horses, horses with 
pituitary pars intermedia dysfunction and equine pars intermedia explants. 
Domestic animal endocrinology. 2006;30:276-88. 
[193]  de Castro ED, Lopez I, Cortes B, Pineda C, Garfia B, Aguilera-Tejero E. 
Influence of feeding status, time of the day, and season on baseline 
adrenocorticotropic hormone and the response to thyrotropin releasing hormone-
stimulation test in healthy horses. Domestic animal endocrinology. 2014;48:77-
83. 
[194]  Donaldson MT, McDonnell SM, Schanbacher BJ, Lamb SV, McFarlane D, Beech 
J. Variation in plasma adrenocorticotropic hormone concentration and 
dexamethasone suppression test results with season, age, and sex in healthy 
ponies and horses. Journal of veterinary internal medicine. 2005;19:217-22. 
[195]  Perkins G, Lamb S, Erb H, Schanbacher B, Nydam D, Divers T. Plasma 
adrenocorticotropin (ACTH) concentrations and clinical response in horses 
treated for equine Cushing's disease with cyproheptadine or pergolide. Equine 
veterinary journal. 2002;34:679-85. 
[196]  Reimers T, Salerno V, Lamb S. Validation and application of solid-phase 
chemiluminescent immunoassays for diagnosis of endocrine diseases in animals. 
Comparative Haematology International. 1996;6:170-5. 
[197]  Adams AA, Sturgill TL, Breathnach CC, Chambers TM, Siger L, Minke JM, et al. 
Humoral and cell-mediated immune responses of old horses following 
recombinant canarypox virus vaccination and subsequent challenge infection. 
Veterinary immunology and immunopathology. 2011;139:128-40. 
[198]  Adams AA, Katepalli MP, Kohler K, Reedy SE, Stilz J, Vick MM, et al. Effect of 
body condition, body weight and adiposity on inflammatory cytokine responses in 
old horses. Veterinary immunology and immunopathology. 2009;127:286-94. 
[199]  Adams AA, Betancourt A, Barker VD, Siard MH, Elzinga S, Bellaw JL, et al. 
Comparison of the Immunologic Response to Anthelmintic Treatment in Old 
Versus Middle-Aged Horses. Journal of Equine Veterinary Science. 2015;35:873-
81. e3. 
[200]  Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2− ΔΔCT method. methods. 2001;25:402-8. 
[201]  FDA U. Agency Response Letter GRAS Notice No. GRN 000348 [Stevioside 
purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni (stevioside)]. 
Center for Food Safety and Applied Nutrition (CFSAN). 2011. 
[202]  Albelda SM, Buck CA. Integrins and other cell adhesion molecules. The FASEB 
Journal. 1990;4:2868-80. 
[203]  Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. 
Circulating cell adhesion molecules and death in patients with coronary artery 
disease. Circulation. 2001;104:1336-42. 
  157 
[204]  Park M, Vittinghoff E, Ganz P, Peralta CA, Whooley M, Shlipak MG. Role of 
Soluble Endothelial Cell–Selective Adhesion Molecule Biomarker in 
Albuminuria and Kidney Function Changes in Patients With Coronary Artery 
Disease The Heart and Soul Study. Arteriosclerosis, thrombosis, and vascular 
biology. 2014;34:231-6. 
[205]  Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M, et al. Meal 
modulation of circulating interleukin 18 and adiponectin concentrations in healthy 
subjects and in patients with type 2 diabetes mellitus. The American journal of 
clinical nutrition. 2003;78:1135-40. 
[206]  Burdge GC, Calder PC. Plasma cytokine response during the postprandial period: 
a potential causal process in vascular disease? British journal of nutrition. 
2005;93:3-9. 
[207]  Consultation W. Definition, diagnosis and classification of diabetes mellitus and 
its complications. Part; 1999. 
[208]  Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic 
syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. 
Circulation. 2005;112:3066-72. 
[209]  Geor R, Frank N. Metabolic syndrome—from human organ disease to laminar 
failure in equids. Veterinary Immunology and immunopathology. 2009;129:151-
4. 
[210]  Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent 
metabolic syndrome via nutritional modulation. FEMS microbiology ecology. 
2014;87:303-14. 
[211]  Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, 
et al. QIIME allows analysis of high-throughput community sequencing data. 
Nature methods. 2010;7:335-6. 
[212]  Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. 
Introducing mothur: open-source, platform-independent, community-supported 
software for describing and comparing microbial communities. Applied and 
environmental microbiology. 2009;75:7537-41. 
[213]  Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves 
sensitivity and speed of chimera detection. Bioinformatics. 2011;27:2194-200. 
[214]  Gihring TM, Green SJ, Schadt CW. Massively parallel rRNA gene sequencing 
exacerbates the potential for biased community diversity comparisons due to 
variable library sizes. Environmental microbiology. 2012;14:285-90. 
[215]  Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. 
Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60. 
[216]  Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: generative models 
for microbial metagenomics. PloS one. 2012;7:e30126. 
[217]  Knights D, Costello EK, Knight R. Supervised classification of human 
microbiota. FEMS microbiology reviews. 2011;35:343-59. 
[218]  Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, et al. 
Predictive functional profiling of microbial communities using 16S rRNA marker 
gene sequences. Nature biotechnology. 2013;31:814-21. 
[219]  Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-
talk between Akkermansia muciniphila and intestinal epithelium controls diet-
  158 
induced obesity. Proceedings of the National Academy of Sciences. 
2013;110:9066-71. 
[220]  Shin N-R, Lee J-C, Lee H-Y, Kim M-S, Whon TW, Lee M-S, et al. An increase 
in the Akkermansia spp. population induced by metformin treatment improves 
glucose homeostasis in diet-induced obese mice. Gut. 2013:gutjnl-2012-303839. 
[221]  Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, et 
al. Akkermansia muciniphila and improved metabolic health during a dietary 
intervention in obesity: relationship with gut microbiome richness and ecology. 
Gut. 2015. 
[222]  Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C, et al. Human gut microbiota 
changes reveal the progression of glucose intolerance. PLoS One. 2013;8:e71108. 
[223]  O'Donnell M, Harris H, Jeffery I, Claesson M, Younge B, O'Toole P, et al. The 
core faecal bacterial microbiome of Irish Thoroughbred racehorses. Letters in 
applied microbiology. 2013;57:492-501. 
[224]  Faubladier C, Julliand V, Danel J, Philippeau C. Bacterial carbohydrate-degrading 
capacity in foal faeces: changes from birth to pre-weaning and the impact of 
maternal supplementation with fermented feed products. British Journal of 
Nutrition. 2013;110:1040-52. 
[225]  Daly K, Proudman CJ, Duncan SH, Flint HJ, Dyer J, Shirazi-Beechey SP. 
Alterations in microbiota and fermentation products in equine large intestine in 
response to dietary variation and intestinal disease. British Journal of Nutrition. 
2012;107:989-95. 
[226]  Bagi Z, Broskova Z, Feher A. Obesity and Coronary Microvascular Disease–
Implications for Adipose Tissue-Mediated Remote Inflammatory Response. 
Current vascular pharmacology. 2014;12:453. 
[227]  Yao L, Herlea-Pana O, Heuser-Baker J, Chen Y, Barlic-Dicen J. Roles of the 
chemokine system in development of obesity, insulin resistance, and 
cardiovascular disease. Journal of immunology research. 2014;2014. 
[228]  Borkman M, Storlien LH, Pan DA, Jenkins AB, Chisholm DJ, Campbell LV. The 
relation between insulin sensitivity and the fatty-acid composition of skeletal-
muscle phospholipids. New England Journal of Medicine. 1993;328:238-44. 
[229]  Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, et 
al. Lipidomics reveals a remarkable diversity of lipids in human plasma. Journal 
of lipid research. 2010;51:3299-305. 
[230]  Jové M, Naudí A, Portero-Otin M, Cabré R, Rovira-Llopis S, Bañuls C, et al. 
Plasma lipidomics discloses metabolic syndrome with a specific HDL phenotype. 
The FASEB Journal. 2014;28:5163-71. 
[231]  Graessler J, Schwudke D, Schwarz P, Herzog R, Shevchenko A, Bornstein SR. 
Top-down lipidomics reveals ether lipid deficiency in blood plasma of 
hypertensive patients. PloS one. 2009;4:e6261. 
[232]  Maeba R, Hara H. Serum choline plasmalogen is a reliable biomarker for 
atherogenic status. Coronary artery disease–new insights and novel approaches. 
2012:243. 
[233]  Hellmann J, Zhang MJ, Tang Y, Rane M, Bhatnagar A, Spite M. Increased 
saturated fatty acids in obesity alter resolution of inflammation in part by 
  159 
stimulating prostaglandin production. The Journal of Immunology. 
2013;191:1383-92. 
[234]  Wu D, Ren Z, Pae M, Guo W, Cui X, Merrill AH, et al. Aging up-regulates 
expression of inflammatory mediators in mouse adipose tissue. The Journal of 
Immunology. 2007;179:4829-39. 
[235]  Ren H, Zhang C, Su L, Bi X, Wang C, Wang L, et al. Type II anti-CD20 mAb-
induced lysosome mediated cell death is mediated through a ceramide-dependent 
pathway. Biochemical and biophysical research communications. 2015;457:572-
7. 
[236]  Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. International 
journal of molecular sciences. 2015;16:924-49. 
[237]  Treiber K, Carter R, Gay L, Williams C, Geor R. Inflammatory and redox status 
of ponies with a history of pasture-associated laminitis. Veterinary immunology 
and immunopathology. 2009;129:216-20. 
[238]  Wood PL. Mass spectrometry strategies for clinical metabolomics and lipidomics 
in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology. 
2014;39:24-33. 
[239]  Breathnach C, Sturgill-Wright T, Stiltner J, Adams A, Lunn D, Horohov D. Foals 
are interferon gamma-deficient at birth. Veterinary Immunology and 
immunopathology. 2006;112:199-209. 
[240]  Park E, Wong V, Guan X, Oprescu AI, Giacca A. Salicylate prevents hepatic 
insulin resistance caused by short-term elevation of free fatty acids in vivo. 
Journal of Endocrinology. 2007;195:323-31. 
[241]  Frasca D, Ferracci F, Diaz A, Romero M, Lechner S, Blomberg BB. Obesity 
decreases B cell responses in young and elderly individuals. Obesity. 
2016;24:615-25. 
[242]  Costanzo AE, Taylor KR, Dutt S, Han PP, Fujioka K, Jameson JM. Obesity 
impairs γδ T cell homeostasis and antiviral function in humans. PloS one. 
2015;10:e0120918. 
[243]  Chambers TM, Reedy SE. Equine Influenza Serological Methods.  Animal 
Influenza Virus: Springer; 2014. p. 411-22. 
[244]  Liu C, Betancourt A, Cohen D, Adams A, Sun L, Horohov D. Granzyme B-
mRNA expression by equine lymphokine activated killer (LAK) cells is 
associated with the induction of apoptosis in target cells. Veterinary immunology 
and immunopathology. 2011;143:108-15. 
[245]  Young KM, Gray CM, Bekker L-G. Is obesity a risk factor for vaccine non-
responsiveness? PloS one. 2013;8:e82779. 
[246]  He X-S, Holmes TH, Zhang C, Mahmood K, Kemble GW, Lewis DB, et al. 
Cellular immune responses in children and adults receiving inactivated or live 
attenuated influenza vaccines. Journal of virology. 2006;80:11756-66. 
[247]  Lord JD, McIntosh BC, Greenberg PD, Nelson BH. The IL-2 receptor promotes 
lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes 
through the trans-activation domain of Stat5. The Journal of Immunology. 
2000;164:2533-41. 
[248]  O'Garra A. Cytokines induce the development of functionally heterogeneous T 
helper cell subsets. Immunity. 1998;8:275-83. 
  160 
[249]  Li Q, Verma IM. NF-κB regulation in the immune system. Nature Reviews 
Immunology. 2002;2:725-34. 
[250]  de Laat MA, McGree JM, Sillence MN. Equine hyperinsulinemia: investigation 
of the enteroinsular axis during insulin dysregulation. American Journal of 
Physiology-Endocrinology and Metabolism. 2016;310:E61-E72. 
[251]  Bamford N, Baskerville C, Harris P, Bailey S. Postprandial glucose, insulin, and 
glucagon-like peptide-1 responses of different equine breeds adapted to meals 
containing micronized maize. Journal of animal science. 2015;93:3377-83. 
[252]  Ofek I, Beachey EH. Mannose binding and epithelial cell adherence of 
Escherichia coli. Infection and Immunity. 1978;22:247-54. 
[253]  Baurhoo B, Letellier A, Zhao X, Ruiz-Feria C. Cecal populations of lactobacilli 
and bifidobacteria and Escherichia coli populations after in vivo Escherichia coli 
challenge in birds fed diets with purified lignin or mannanoligosaccharides. 
Poultry Science. 2007;86:2509-16. 
[254]  Baurhoo B, Ferket P, Ashwell CM, de Oliviera J, Zhao X. Cell walls of 
Saccharomyces cerevisiae differentially modulated innate immunity and glucose 
metabolism during late systemic inflammation. PloS one. 2012;7:e30323. 
[255]  Guan X, Matte JJ, Ku PK, Snow JL, Burton JL, Trottier NL. High chromium 
yeast supplementation improves glucose tolerance in pigs by decreasing hepatic 
extraction of insulin. The Journal of nutrition. 2000;130:1274-9. 
[256]  Frank N, Elliott SB, Chameroy K, Toth F, Chumbler N, McClamroch R. 
Association of season and pasture grazing with blood hormone and metabolite 
concentrations in horses with presumed pituitary pars intermedia dysfunction. 
Journal of veterinary internal medicine. 2010;24:1167-75. 
[257]  Funk RA, Wooldridge A, Stewart A, Behrend E, Kemppainen R, Zhong Q, et al. 
Seasonal changes in the combined glucose‐insulin tolerance test in normal aged 
horses. Journal of veterinary internal medicine. 2012;26:1035-41. 
[258]  Place N, McGowan C, Lamb S, Schanbacher B, McGowan T, Walsh D. Seasonal 
variation in serum concentrations of selected metabolic hormones in horses. 
Journal of veterinary internal medicine. 2010;24:650-4. 
[259]  McFarlane D, Wolf RF, McDaniel KA, White GL. The effect of season on 
inflammatory response in captive baboons. J Med Primatol. 2012;41:341-8. 
[260]  Bilbo SD, Drazen DL, Quan N, He L, Nelson RJ. Short day lengths attenuate the 
symptoms of infection in Siberian hamsters. Proc Biol Sci. 2002;269:447-54. 
[261]  Bowden TJ, Thompson KD, Morgan AL, Gratacap RM, Nikoskelainen S. 
Seasonal variation and the immune response: a fish perspective. Fish Shellfish 
Immunol. 2007;22:695-706. 
[262]  Riihimaki M, Raine A, Elfman L, Pringle J. Markers of respiratory inflammation 
in horses in relation to seasonal changes in air quality in a conventional racing 
stable. Can J Vet Res. 2008;72:432-9. 
[263]  Secombe CJ, Lester GD, Robertson ID, Cullimore AM. Retrospective survey of 
bronchoalveolar lavage fluid cytology in Western Australian horses presented for 
evaluation of the respiratory tract: effect of season on relative cell percentages. 
Aust Vet J. 2015;93:152-6. 
  161 
[264]  Wray H, Elliott J, Bailey SR, Harris PA, Menzies-Gow NJ. Plasma concentrations 
of inflammatory markers in previously laminitic ponies. Equine Vet J. 
2013;45:546-51. 
[265]  Hamza E, Doherr MG, Bertoni G, Jungi TW, Marti E. Modulation of allergy 
incidence in icelandic horses is associated with a change in IL-4-producing T 
cells. Int Arch Allergy Immunol. 2007;144:325-37. 
[266]  Beadle RE, Horohov DW, Gaunt SD. Interleukin-4 and interferon-gamma gene 
expression in summer pasture-associated obstructive pulmonary disease affected 
horses. Equine Vet J. 2002;34:389-94. 
[267]  Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of 
adipokines and the relationship between obesity, inflammation, insulin resistance, 
dyslipidemia and nonalcoholic fatty liver disease. International journal of 
molecular sciences. 2014;15:6184-223. 
[268]  Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. The Journal of 
Clinical Endocrinology & Metabolism. 2004;89:2548-56. 
[269]  Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS. Differential 
induction of the toll-like receptor 4-MyD88-dependent and-independent signaling 
pathways by endotoxins. Infection and immunity. 2005;73:2940-50. 
[270]  Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of 
adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. 
Science. 2003;301:640-3. 
[271]  Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is 
associated with insulin resistance in adipocytes. Biochemical and biophysical 
research communications. 2006;346:739-45. 
[272]  Reyna SM, Ghosh S, Tantiwong P, Meka CR, Eagan P, Jenkinson CP, et al. 
Elevated toll-like receptor 4 expression and signaling in muscle from insulin-
resistant subjects. Diabetes. 2008;57:2595-602. 
[273]  Kuhel DG, Konaniah ES, Basford JE, McVey C, Goodin CT, Chatterjee TK, et al. 
Apolipoprotein E2 accentuates postprandial inflammation and diet-induced 
obesity to promote hyperinsulinemia in mice. Diabetes. 2013;62:382-91. 
[274]  Figueiredo MD, Vandenplas ML, Hurley DJ, Moore JN. Differential induction of 
MyD88-and TRIF-dependent pathways in equine monocytes by Toll-like receptor 
agonists. Veterinary immunology and immunopathology. 2009;127:125-34. 
[275]  Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, Kantarci A, et al. TLR 
cross-talk specifically regulates cytokine production by B cells from chronic 
inflammatory disease patients. The Journal of Immunology. 2009;183:7461-70. 
[276]  Niebuhr M, Baumert K, Werfel T. TLR‐2‐mediated cytokine and chemokine 
secretion in human keratinocytes. Experimental dermatology. 2010;19:873-7. 
[277]  Kobayashi M, Saitoh S-i, Tanimura N, Takahashi K, Kawasaki K, Nishijima M, 
et al. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. 
The Journal of Immunology. 2006;176:6211-8. 
[278]  Klein DC, Skjesol A, Kers‐Rebel ED, Sherstova T, Sporsheim B, Egeberg KW, et 
al. CD14, TLR4 and TRAM show different trafficking dynamics during LPS 
stimulation. Traffic. 2015;16:677-90. 
[279]  Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A, et 
al. Raised Interleukin‐6 Levels in Obese Patients. Obesity research. 2000;8:673-5. 
  162 
[280]  Straczkowski M, Dzienis-Straczkowska S, Stêpieñ A, Kowalska I, Szelachowska 
M, Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects 
and related to fat mass and tumor necrosis factor-α system. The Journal of 
Clinical Endocrinology & Metabolism. 2002;87:4602-6. 
[281]  Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of 
the obesity-diabetes link. Diabetes. 1994;43:1271-8. 
[282]  Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and 
insulin resistance. Proceedings of the National Academy of Sciences. 
2003;100:7265-70. 
[283]  Gabriel P, Cakman I, Rink L. Overproduction of monokines by leukocytes after 
stimulation with lipopolysaccharide in the elderly. Experimental gerontology. 
2002;37:235-47. 
[284]  McFarlane D, Holbrook T. Cytokine dysregulation in aged horses and horses with 
pituitary pars intermedia dysfunction. Journal of veterinary internal medicine. 
2008;22:436-42. 
[285]  McFarlane D, Hill K, Anton J. Neutrophil function in healthy aged horses and 
horses with pituitary dysfunction. Veterinary immunology and immunopathology. 
2015;165:99-106. 
[286]  Haghiac M, Yang X-h, Presley L, Smith S, Dettelback S, Minium J, et al. Dietary 
omega-3 fatty acid supplementation reduces inflammation in obese pregnant 
women: a randomized double-blind controlled clinical trial. PloS one. 
2015;10:e0137309. 
[287]  Toth F, Frank N, Elliott SB, Perdue K, Geor R, Boston R. Optimisation of the 
frequently sampled intravenous glucose tolerance test to reduce urinary glucose 
spilling in horses. Equine veterinary journal. 2009;41:844-51. 
[288]  Woodward A, Nielsen B, O'Connor C, Skelly C, Webel S, Orth M. 
Supplementation of dietary long-chain polyunsaturated omega-3 fatty acids high 
in docosahexaenoic acid (DHA) increases plasma DHA concentration and may 
increase trot stride lengths in horses. Equine and Comparative Exercise 
Physiology. 2007;4:71-8. 
[289]  Lavoie-Lamoureux A, Maghni K, Lavoie J-P. Optimization of a procedure to 
accurately detect equine TNFα in serum samples. Veterinary immunology and 
immunopathology. 2010;138:118-23. 
[290]  Burton A, Wagner B, Erb H, Ainsworth D. Serum interleukin-6 (IL-6) and IL-10 
concentrations in normal and septic neonatal foals. Veterinary immunology and 
immunopathology. 2009;132:122-8. 
[291]  Leclere M, Lavoie‐Lamoureux A, Lavoie JP. Acute phase proteins in racehorses 
with inflammatory airway disease. Journal of Veterinary Internal Medicine. 
2015;29:940-5. 
[292]  Vineyard K, Warren L, Kivipelto J. Effect of dietary omega-3 fatty acid source on 
plasma and red blood cell membrane composition and immune function in 
yearling horses. Journal of animal science. 2010;88:248-57. 
[293]  Blank ML, Smith ZL, Cress EA, Snyder F. Molecular species of ethanolamine 
plasmalogens and transacylase activity in rat tissues are altered by fish oil diets. 
Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism. 
1994;1214:295-302. 
  163 
[294]  Jia L, Vianna CR, Fukuda M, Berglund ED, Liu C, Tao C, et al. Hepatocyte Toll-
like receptor 4 regulates obesity-induced inflammation and insulin resistance. 
Nature communications. 2014;5. 
[295]  de Laat M, Clement C, McGowan C, Sillence M, Pollitt C, Lacombe V. Toll-like 
receptor and pro-inflammatory cytokine expression during prolonged 
hyperinsulinaemia in horses: implications for laminitis. Veterinary immunology 
and immunopathology. 2014;157:78-86. 
[296]  Basinska K, Marycz K, Smieszek A, Nicpoń J. The production and distribution of 
IL-6 and TNF-α in subcutaneous adipose tissue and their correlation with serum 
concentration in Welsh Ponies with EMS. Journal of veterinary science. 2014. 
[297]  Hall JA, Saun RJ, Tornquist SJ, Gradin JL, Pearson EG, Wander RC. Effect of 
type of dietary polyunsaturated fatty acid supplement (corn oil or fish oil) on 
immune responses in healthy horses. Journal of veterinary internal medicine. 
2004;18:880-6. 
[298]  Khol-Parisini A, van den Hoven R, Leinker S, Hulan HW, Zentek J. Effects of 
feeding sunflower oil or seal blubber oil to horses with recurrent airway 
obstruction. Canadian journal of veterinary research. 2007;71:59. 
[299]  Weldon SM, Mullen AC, Loscher CE, Hurley LA, Roche HM. Docosahexaenoic 
acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human 
THP-1 macrophages more effectively than eicosapentaenoic acid. The Journal of 
nutritional biochemistry. 2007;18:250-8. 
[300]  Mullen A, Loscher CE, Roche HM. Anti-inflammatory effects of EPA and DHA 
are dependent upon time and dose-response elements associated with LPS 
stimulation in THP-1-derived macrophages. The Journal of nutritional 
biochemistry. 2010;21:444-50. 
[301]  Vineyard K, Warren L, Webel S, Kivipelto J. Effect of fish oil supplementation 
on neutrophil function and antibody production in yearling horses. Proceedings of 
the 20th Equine Science Society Hunt Valley, MD: Equine Science Society, 
Champaign, Illinois. 2007:13-4. 
[302]  Kaur G, Begg DP, Barr D, Garg M, Cameron-Smith D, Sinclair AJ. Short-term 
docosapentaenoic acid (22: 5 n-3) supplementation increases tissue 
docosapentaenoic acid, DHA and EPA concentrations in rats. British journal of 
nutrition. 2010;103:32-7. 
[303]  Creely SJ, McTernan PG, Kusminski CM, Da Silva N, Khanolkar M, Evans M, et 
al. Lipopolysaccharide activates an innate immune system response in human 
adipose tissue in obesity and type 2 diabetes. American Journal of Physiology-
Endocrinology And Metabolism. 2007;292:E740-E7. 
 
  
  164 
VITA 
Sarah Elzinga 
EDUCATION  
2009-2011 Michigan State University East Lansing, MI 
 MS Degree in Animal Science 
2002-2005 Saint Mary-of-the-Woods College Saint Mary-of-the-Woods, IN 
 BS Degree in Equine Science 
WORK EXPERIENCE 
2013-present University of Kentucky Lexington, KY 
 Graduate Research Assistant, Veterinary Science 
Department, Gluck Equine Research Center 
2011-2013 Chemical Bank Grand Rapids, MI 
 Teller 
2009-2011 Michigan State University East Lansing, MI 
 Research Assistant, Equine Nutrition Lab 
2008-2009 Schmitt’s Animal Hospital Grand Rapids, MI 
 Veterinary Assistant 
2007 Melissa Sexton Performance Horses Okanogan, WA 
 Assistant Trainer 
2006-2007 Rivendell Stables Lowell, MI 
 Assistant Manager, Riding Instructor/trainer 
HONORS AND AWARDS 
 Veterinary Science Annual 3MT Graduate Student Competition Winner (2017) 
 AQHF Young Investigator Award for Equine Research (2015) 
 Deans Scholarship Recipient (2002-2005) 
 Equestrian Scholarship Recipient (2002-2005) 
 Saint Mary-of-the-Woods college Outstanding Academic Achievement (2003-2005) 
 Saint Mary-of-the-Woods college Honors List and National Dean’s List (2003) 
 Saint Mary-of-the-Woods college Knoerle Honors Forum for Academic Scholarship 
Award (2002 & 2003) 
 Saint Mary-of-the-Woods College Graduate with Honors (2005) 
 Michigan Merit Award Recipient (May 2002) 
 Michigan Competitive Scholarship Recognition (May 2002) 
  
  165 
GRANT PARTICIPATION 
 Neogen Pony: Characterization of cell-mediated and humoral immune 
responses and stress to an immunostimulant in ponies, utilizing weaning as a 
model of stress.  
 BI PPID: Compare immune response to multi-path vaccination of PPID 
(Pituitary Pars Intermedia Dysfunction) vs non-PPID controls 
 Seasonal Cytokines: Comparison of adult and old horse inflammatory markers 
and assessment of lymphocyte proliferation monthly over the course of a year 
 Buckeye:  Relationship between circulating vitamin and fatty acid levels as well 
as systemic inflammation and muscle mass in aged horses to determine if a rating 
balancer pellet can modulate these factors 
 Zoetis Dewormer: Comparison of immunologic responses to anthelmintic 
treatment in old versus middle-aged adult horses 
 Alltech Omega 3 Fatty Acids: Metabolic and inflammatory responses of EMS 
horses to algal DHA supplementation 
 Lipidomic and inflammatory profiling: Characterization of the lipidomic and 
inflammatory status of a group of Equine Metabolic Syndrome (EMS) and non-
EMS controls 
 Microbiota profiling: Characterization of the fecal microbiota of a group of 
EMS and non-EMS control horses 
 AHQA vaccine: Humoral and cell-mediated immune responses to an influenza 
vaccine in EMS and non-EMS controls 
 Lincoln Memorial: Inflammatory responses to an oral sugar challenge utilizing 
a common sweetener as well as a glucose and maltose syrup in a group of EMS 
and non-EMS controls 
 Alltech yeast cell wall: Metabolic and inflammatory responses of EMS and non-
EMS control horses to yeast cell wall supplementation 
PEER REVIEWED PUBLICATIONS 
Elzinga, S. E., et al. "Metabolic and inflammatory responses to the common 
sweetener stevioside and a glycemic challenge in horses with equine 
metabolic syndrome." Domestic Animal Endocrinology 60 (2017): 1-8. 
Elzinga, Sarah E., J. Scott Weese, and Amanda A. Adams. "Comparison of the 
Fecal Microbiota in Horses With Equine Metabolic Syndrome and 
Metabolically Normal Controls Fed a Similar All-Forage Diet." Journal of 
Equine Veterinary Science 44 (2016): 9-16. 
Elzinga, Sarah, Paul Wood, and Amanda A. Adams. "Plasma Lipidomic and 
Inflammatory Cytokine Profiles of Horses With Equine Metabolic 
Syndrome." Journal of Equine Veterinary Science 40 (2016): 49-55. 
  166 
Adams, Amanda A., et al. "Effects of an immunostimulant containing 
Propionibacterium acnes (EqStim TM) on cell-mediated immunity and 
nasal shedding of respiratory pathogens using a model of ‘weaning’ stress 
in foals." Journal of Equine Veterinary Science (2016). 
Adams, Amanda A., et al. "Comparison of the Immunologic Response to 
Anthelmintic Treatment in Old Versus Middle-Aged Horses." Journal of 
Equine Veterinary Science 35.11 (2015): 873-881. 
Elzinga, Sarah, et al. "Comparison of Nutrient Digestibility Between Adult and 
Aged Horses." Journal of Equine Veterinary Science 34.10 (2014): 1164-
1169. 
Dougal, Kirsty, et al. "Characterisation of the faecal bacterial community in adult 
and elderly horses fed a high fibre, high oil or high starch diet using 454 
pyrosequencing." PloS one 9.2 (2014): e87424. 
